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a p p e n d i x  I
THE PREPARATION OF REAGENTS
1. Acetic acid
1 2 %  and 5 %  (v/v) solutions of Glacial acetic acid A.R.
(Sp.G. 1.060) are made in distilled water.
2. Acetone A.R. (B.D.H.)
3. Adsorbing agents
A- Alumina (Aluminium hydroxide gel) (Method of Bertho and 
Grassman, 1938).
Solution 1 : Ammonia (Sp.G. 0.880) 25 mis.
Distilled water 25 mis.
Solution 2 : Ammonium sulphate 11 gms.
Distilled water 300 mis. (in a litre flask)
Solution 3 : 38.35 gms. of ammonium alum (Aluminium ammonium
sulphate) are dissolved in 500 mis. distilled water. The solution 
is then heated to 58°C., at which temperature it is maintained over 
a pilot flame.
Solution 1 is added to solution 2, the mixture shaken 
thoroughly and heated to 58°C. Solution 3 is then added while 
stirring and the mixture kept at 58 C. for 10 minutes. The 
following washings are then carried out on the precipitate
- 3 - (Appendix I)
obtained by centrifugation of the preparation at 2,500 r.p.m. for
10 minutes, the washings similarly separated :-
a) 750 mis. distilled water + 0.22 ml of solution 1
b) 750 mis. distilled water + 0.44 ml of solution 1
c) 750 mis. distilled water,
d) 750 mis. distilled water,
e) 750 mis. distilled water.
The supernatant should be clear after each spinning. The 
precipitate is then suspended in the least amount of water that
is required to make a gelatinous suspension that can be pipetted
without undue difficulty. The volume of water usually used in
this work varied from 85 to 100 mis. The preparation keeps for 
about six weeks.
B- Barium sulphate (Biggs and Macfarlane, 1957).
1 lb. of x-ray BaSO^ is suspended in about 4 litres of
0.005 M trisodium citrate and allowed to stand overnight. The 
milky supernatant is drawn off and discarded. The sediment is 
resuspended in a further 4 litres of citrate solution and again 
allowed to settle. The sediment is then collected on a large 
filter paper and dried in a hot air oven at 100 C. The dried 
material is then powdered. This washing is required because
the BaSO contains some very fine material which is not removed
4
from the plasma by centrifugation at 2000 r.p.m.
- 4 - (Appendix I)
C- Tricalcium phosphate
i. 0.2 M stock solution : 6.66 gms. of anhydrous CaCl^
are dissolved in 100 mis. of water and added to a solution 
containing 15.8 gms. trisodium phosphate in 100 mis. water, while 
thoroughly stirring. The pH is adjusted to 7 and the precipitated 
Ca3(P04)2 is washed repeatedly by decantation till the NaCl is 
removed. The volume is made up to 200 mis. with water.
ii. 0.016 M working solution : dilute 8 mis. of the stock
solution up to 100 mis. with water. Each ml. of this suspension 
contains 50 mg. tricalcium phosphate. For use, 1 ml. of this 
0.016 M suspension is centrifuged, the supernatant discarded, the 
tube drained, and 1 ml. of the plasma added and mixed with it.
4. Alizarin red indicator (Alizarin mono-sodium sulfonate)
0.1 gm is dissolved in 100 mis. of water and a trace of thymol 
added to inhibit moulds.
5. Ammonium chloride standard
0.771 gm KH.C1 is dissolved in 1 litre of water. (0.2 mg N/ml).
6. Ammonium sulphate saturated solution
100 gms. (MEL) .SO are dissolved in 130 mis. of water with
4  ^  T
the aid of heat, leave to cool and decant.
7. Anticoagulants
A— Ammonium and potassium oxalate mixture
1.2 gms. of ammonium oxalate and 0.8 gm. of potassium oxalate 
are dissolved in 100 mis. water. Half millilitre volumes (each
- 5 - (Appendix I)
containing 10 mgms. of the mixed salts) are delivered into small 
tubes marked at the 5 ml level, which are then dried in an oven 
at a temperature not exceeding 60 C. Smaller and larger volumes 
can be used, adjusting the volume of blood so that 2 mgms. of the 
dry salts are used for each 1 ml of blood.
B- Potassium oxalate
i. 1.85 gm <fo (w/v) in water,
ii. 2.5 gm fo (w/v) in water.
Seguestrene (di-sodium ethylenediamine tetra-acetic acid)
A 10 $ (w/v) solution is made in distilled water. 0.1 ml 
volumes are delivered by pipette into small bottles or tubes marked 
at the 5 ml level. The solution is then allowed to dry at room 
temperature.
D- Sodium citrate
3.8 gms. of trisodium citrate (Na^ C^ H^ O^ .. 2 *1,0) are <&ssolve(l 
in 100 mis. of distilled water.
E- Sodium oxalate (0.1 M)
1.34 gms. are dissolved in 100 mis. of distilled water.
8. Barbitone buffer for electrophoresis (Flynn and DeMayo, 1951)
1.84 gms. barbitone, and 10.3 gms. sodium diethyl barbitone 
are dissolved in distilled water and the volume made up to one litre. 
This buffer has an ionic strength (p) of 0.05 and a pH of 8.6
- 6 - (Appendix I)
9. Barium chloride standard solution (Shank and Hoagland, 1946)
0.0962 N solution is made by dissolving 1.175 gms of barium 
chloride (BaCl^ 2 1^0) in 100 mis of distilled water. Three 
millilitres of this suspension when diluted up to 100 mis with 
0.2 N - ^SO^ give a turbidity equivalent to 20 units.
10. Calcium chloride solution
A) 0.1 M solution is made by dissolving 11.099 gms of anhydrous 
CaC^ in 1 litre of distilled water. The solution is standardised 
by titrating it against standard potassium thiocyanate solution. 
From this stock solution, 0.05 M (M/20) and 0.025 M (M/40) solutions 
are made by dilution with water.
B) 0.25 M solution is made by dilution from a stock 1 M solution 
prepared by dissolving 11.099 gms of anhydrous CaCl2 in 100 mis of 
distilled water.
C) 3 io solution is made by dissolving 3 gms anhydrous CaCl2 in 
100 mis distilled water.
11. Chloroform A.R. (B.D.H.)
12. Citrate - saline solution
30.6 gms NaCl and 15.2 gms trisodium citrate are dissolved in 
4 litres of distilled water.
13. De-ionised water (called distilled water throughout this work) 
Water de—ionised in an Elgastat portable Deioniser, Type B 102
(Elga Products Ltd.) was used throughout this work instead of 
distilled water. It had a resistance of more than 4,000,000 ohms,
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which means it is purer than water that has passed three distill­
ations in glass whose resistance is usually about 800,000 ohms.
14. Folin and Ciocalteu's reagent (B.D.H.).
15. Formaldehyde solution (37 %, pH 8)
The pH is adjusted by adding NaOH solution till phenolphthalein 
indicator (0.04 ^  in 95 °fo alcohol) becomes faintly pink.
16. Formol - citrate solution
3 gms trisodium citrate are dissolved in water, and 1 ml of 40 fo
formalin is added, and the final volume made up to 100 mis. Filter
before use.
17. Glass powder
Pyrex glass powder of porosity 3, mesh 200, is vigorously 
stirred with distilled water (1.5 litres/100 gms powder). Stand 
for 12 hours, and decant the turbid supernatant. Repeat till the 
supernatant is clear, and dry the powder on filter paper in the 
hot air oven.
18. Glycerol A.R. (B.D.H.)
19. Heparin
Pularin vials (Evans Medical Ltd., Liverpool) containing 
5,000 units/ml were used.
20. Imidazole (Glvoxaline) buffer (Mertz and Owen, 1940)
Base solution ; 680 mg imidazole dissolved in 50 mis water.
Buffer at pH 7.3 : 2.5 parts of base solution + 1.86 parts
N/lO HC1 + 5.64 parts of distilled water.
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21. Hydrochloric acid
Normal solution : 86 mis of concentrated HC1 (Sp.G. 1.18) are
made up to 1 litre with water.
N/6 and N/lO solutions : are made from the above by dilution.
22. Kjeldahl catalyst tablets (B.D.H.)
Each tablet contains 1 gm Na^SO^ and the equivalent of 0.1 gm 
of mercury.
23. Leishmanfs stain
0.15 gm of Leishman powder is dissolved in 100 mis of methyl 
alcohol by grinding in a mortar. The stain is left to mature in 
a clear glass bottle for few months. Filter before use.
24. Phenol red indicator (B.D.H.)
0.01 gm of phenol red powder is dissolved in 100 mis distilled 
water to make a 0.01 fo solution.
25. Phosphate buffers
A) For ^ iJbrJjiogen^ £e£^ a£a_ti£n (Biggs and Mac far lane, 1957, 
as modified from Jaques, 1943). A 2 molar phosphate buffer at 
pH 6.6 is made by dissolving 817 gms of anhydrous in one
litre of distilled water to which has been added 750 mis of 4 N 
KOH solution (containing 168 gms KOH). After warming to dissolve, 
the volume is made up to 3 litres and the solution filtered.
Molar and M/4 solutions are made from this stock solution by 
dilution.
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B) E P L  JilntjLon ^ f^rojthrombin (Biggs and Macfarlane, 1957) 
Solution 1 : 11.88 gms Na2HP04.2 H20 are dissolved in 1 litre
of distilled water to make an M/15 solution.
Solution 2 : 9.1 gms KH^O^ are dissolved in 1 litre of
distilled water to make an M/15 solution.
To make a buffer at pH 8, 9.7 parts of solution 1 are added
to 0.3 parts of solution 2.
26. Polybrene (Hexadimethrine bromide)
Polybrene is the brand name of hexadimethrine bromide which 
is manufactured by Abbott Laboratories, North Chicago, Illinois. 
The contents of one ampoule (100 mg dissolved in 10 mis isotonic 
aqueous solution) were used as such.
27. Ponceau S stain
0.2 gm °/o solution of the powder is made in 3 $ aqueous 
trichloracetic acid solution.
28. Pyrocatechol solution
1 gm of o-dihydroxy-benzene (B.D.H.) is dissolved in 100 mis 
of saline.
29. Saline solution
A sterile solution containing 0.877 gms NaOl/lOO mis distilled 
water was used.
30. Siliconed glassware (Dacie, 1956)
A 10 ^  (v/v) solution of silicone M 441 (I.C.I.) is made in 
petroleum ether. The clean glassware is immersed in it for five
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minutes, allowed to drain dry, then soaked overnight in distilled 
water, rinsed in a change of distilled water, and finally dried 
in an incubator.
31. Sodium carbonate
0.5 fo, 2 io, and 20 °/o solutions are made by dissolving the 
respective weights of anhydrous Na2C03 in 100 ml amounts of water. 
Filter the concentrated solution before use.
32. Sodium citrate in saline (as eluate)
5 gms of trisodium citrate §,re dissolved in 100 mis of saline.
33. Sodium chloride
A 1 io (w/v) solution in distilled water was used in the 
turbidimetric method of fibrinogen estimation.
34. Sodium hydroxide
A) Noraal_so_lution : 40 gms of NaOH are dissolved in 1 litre
of freshly boiled distilled water (CO^ - free).
B) N/2 j _  N/6 N/_20_,_N/70 j _  and N/lOO ^ ojUrfcions : these are
made by dilution from the above normal solution, the N/70 solution
is standardised by titration against N/50 sulphuric acid before 
using it in the miero-Kjeldahl method for protein estimation.
C) 10j£_and_40 £ £oluti_ons : dissolve the respective weights
of NaOH in 100 ml volumes of distilled water. Filter before use.
35. Sterimats (T.B.Ford Ltd., High Wycombe, Bucks.)
Two kinds of Sterimat asbestos filter pads of 14 cm. diameter
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were used, one containing 20 c/o asbestos (FCB), and the other 30 % 
asbestos (S/FC/2).
36. Sulphuric acid
A) £onc£njbra,ted_A_Jii_: Sp.Or. 1.84
B) Normal_solution : 27.8 mis of the A.R. acid are added
slowly to water and the volume made up to 1 litre.
C) N/5 and N/50__s_o lu_ti_ons_: are made from the above by dilution.
37. TAMe substrate (L.Light & Co. Ltd., Colnbrook, England.)
0.746 gm of TAMe powder (p-toluene sulphonyl-L-arginine methyl 
ester) is thoroughly dissolved in 10 mis of distilled water to make 
a 0.2 molar solution.
38. Toluidine blue
1. 25 mg toluidine blue powder dissolved in 100 mis saline,
ii. 50 mg toluidine blue powder dissolved in 100 mis saline.
39. Tris buffer
60.57 gms of Tris powder (2-amino-2-(hydroxy--methyl)-l:3- 
propanediol) Tris-(hydroxy-methyl)-amino-methane, (B.D.H.) are 
dissolved in about 800 mis of distilled water to make a 0.5 molar 
solution. The pH is adjusted to 9 by adding 2 N- HC1, finally 
the volume is made up to one litre with water.
40. Tyrosine
A) Stock standard solution : 100 mg of DL-Tyrosine (B.D.H.) 
are dissolved in 100 mis of N/lO HC1.
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B) Working standard solution : dilute the stock solution
1 in 10 in water to make a solution containing 0.1 mg/ml.
41. Veronal buffer (Owren, 1949).
5.878 gms of sodium diethyl barbiturate, and 7.335 gms of 
sodium chloride are dissolved in a mixture of 500 mis water and 
215 mis of N/lO HC1. After complete solution, the volume is 
made up to 1 litre with water and the pH checked. This buffer 
has an ionic strength (|i) of 0.15 and its pH should be 7.33
42. Zinc powder A.R. (B.D.H.)
This powder is virtually NH^-free. The maximum limit of 
impurity for nitrogen is 0.02 fo.
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The following specifications of general technique have been 
applied throughout this work.
1. Collection of blood specimens
Blood was obtained by the use of siliconed syringes and needles 
(appendix I, 30) by applying the least suction possible to avoid 
frothing. The blood was immediately delivered into siliconed 
tubes containing the anticoagulant and the contents mixed by gentle 
inversion of the tube twice. Samples suspect of frothing or 
incipient clotting were abandoned. All specimens were used fresh 
as soon after collection as possible, keeping them meanwhile at 4°C.
The various sites for withdrawal of the blood varied according 
to the species concerned as follows :-
Species 
i. Human 
ii. Chicken 
iii. Lobster 
iv. Horse 
v. Rabbit
Site of withdrawal
antecubital veins 
wing veins 
claw joints 
external jugular vein 
ear marginal veins 
vi. Cattle : bovine blood was obtained from the slaughter-house
Needle (S.W.G.) Amount
2 5 - 10 ml.
12 2 - 5  ml.
1 2 - 5 ml.
1 10 - 20 ml.
cut by sharp razor 5 - 10 ml.
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where the cows were killed by the captive bolt, and while the 
animal was bled from the neck the midstream blood was collected 
in a siliconed plastic beaker and immediately delivered in the 
appropriate siliconed tubes. The time between the slaughter of 
the animal and blood mixing with the anticoagulant was about one 
minute. The plasma was separated within half an hour of the 
collection of the blood.
2. Centrifugation
All centrifugations were carried out in a refrigerated M.S.E. 
Magnum centrifuge (model S 51) set at 4°C., unless otherwise 
indicated. The following are the relative centrifugal forces 
(RCF) or g values for the various speeds used with each particular 
head ;—
Speed 
(r.p.m.)
16-place head for tubes 6-place head for cups
(up to 50 ml.) (50 - 250 ml. each)
1,000
1.500 
2,000
2.500 
2,800
500 72 g 
290 g 
651 g
1,160 g
65 g 
257 g 
578 g
1,810 g
1,029 g
1,610 g
2,270 g — -
Super speed 6-place angle head (up to 7 ml.)
5,000
10,000
15,000
20,000
25,000
1,930 g 
7,724 g 
17,380 g 
30,900 g 
48,280 g
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3. Clotting experiments
These were carried out in glass tubes of uniform diameter 
(10 x 75 mms.), which were placed shortly before use in an electric 
water-bath, type S.B.2 (Grant Instruments (Cambridge) Ltd.) which 
was thermostatically controlled at 37°C. ^ 0.25 (unless otherwise 
stated) and fitted with a propeller circulator which ensures 
virtually no temperature gradient throughout the bath, even when 
fully loaded with test-tubes.
Samples were delivered using blood pipettes of 0.1 ml and
0.2 ml - 0.002 ml, (Elliott Ltd., E-Mil Works, Treforest, Glam.)
4. Dialysis
Dialysis was performed at 4°C. in Visking casings, (H.M.C.).
5. pH measurements
During the first year of this work (1961) the pH was measured 
by the E.I.L. direct reading pH meter, model 23 A (Electronic 
Instruments Ltd.). Thereafter by a Beckman 9600-9602 Zeromatic 
direct reading pH meter.
6. Spectrophotometric measurements
Were performed using a Unicam S.P.500 spectrophotometer,
(Unicam Instuments Ltd.) using cuvettes of 1 cm. diameter.
7. Electrophoresis
Electrophoretic runs were performed in a horizontal Shandon 
tank, using cellulose acetate strips (Oxoid) measuring 5 x 20 cms. 
The current was supplied through a constant voltage power supply
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unit, type 2523 (bhandon Scientific Co. Ltd., London) giving a 
volt gradient of 7.5 V/cm., and 0.7m.amp./cm. width of the strip. 
Duration of the run was 2 hours. A barbitone buffer of pH 8.6 
was used (appendix I, 8). The strips were stained with Ponceau 
S stain (appendix I, 27) for 5 - 1 0  minutes, and washed in three 
successive trays containing 5 rfo aqueous acetic acid. Finally, 
they were cleared in paraffin oil.
Densitometric scanning of the electrophoresis strips was 
carried out in an electric double-beam recording and integrating 
reflectance densitometer, Chromoscan J 118 (Joyce, Loebl, and Co. 
Ltd., England) using the blue filter, and the slit aperture.
With the gain control set at 5, the gear ratio 1 : 1 was selected 
to allow direct matching between the strips and their tracings.
Cam 5-034/B was used for all the tracings.
8. Phase contrast microscopy and photomicrography
An Ortholux microscope (Leitz) was used, fitted with built-in 
illumination, Heine condenser, using the oculars x8 and xl2 in 
combination with the objectives Pv achromatic 20/0.45 and Pv n apo 
40/0.70 The photomicrographs were taken with a Leica 35 mm camera 
(Leitz Instruments Ltd., London) fitted with a visoflex attachement, 
on Ektachroine high-speed artificial light film. Prints from the 
transparencies were made commercially by Kodak Ltd., London.
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9. Micro-titration
This was carried out using the syringe type microburette 
(model SB2) fitted with ST buret tip, (Micro-Metric Instruments 
Co., Cleveland, Ohio.). This outfit delivers accurately volumes 
of 0.001 ml which registers as one division on the counter dial.
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1.Preparation of citrated platelet-rich plasma 
Whole blood is collected in a graduated centrifuge tube and 
mixed with 3.8 fo trisodium citrate in the proportion of 9 parts 
blood to 1 part citrate. The mixture is centrifuged for 51 at 
1,500 r.p.m., and the supernatant plasma pipetted off into a 
clean lusteroid tube.
N.B. i. Chicken plasma treated as above contains virtually no 
platelets, as they are nucleated cells and rapidly sediment with 
the other cells. To obtain platelet-rich chicken plasma it was 
necessary to spin the blood at 500 r.p.m.; the plasma in such 
circumstances contains also some white blood cells, mainly the 
lymphocytes which are of about the same size as chicken thrombocytes.
ii. Bovine blood had to be spun at 2,500 r.p.m. (at least) to 
effect as good a separation as with human blood. Such plasma 
was used for all assays except those necessitating the presence 
of the platelets. To obtain platelet-rich bovine plasma the 
blood was spun several times (for 5 minutes each) starting with
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very slow speeds, and after pipetting off the supernatant few 
millimitres, the blood is spun again at a higher speed, and so on. 
The first two thirds only of the plasma is used as the j>latelet- 
rich fraction.
2. Preparation of citrated platelet-poor plasma
(High-spun plasma)
The platelet-rich plasma prepared as above is centrifuged at 
15,000 r.p.m. for 5 minutes, the supernatant decanted into lusteroid 
tubes and kept at -20°C. The plug of sedimented platelets is 
used for the preparation of platelet suspensions.
3. Preparation of oxalated plasma
Nine parts of blood were mixed with one part of 1.34 fo sodium 
oxalate (unless otherwise mentioned) and centrifuged for 5 minutes 
at 1,500 r.p.m.
N.B. Crustacean blood (haemolymph) was constantly obtained over 
2.5 fa potassium oxalate in the proportion of 9 to 1, and immediately 
centrifuged for 5 minutes at 2,000 r.p.m.
4. Preparation of adsorbed plasma
A) Alumnn-^^oi^b^djl^a^ma (Alumina plasma)
1 ml citrated plasma is mixed with 0.1 ml alumina (appendix I, 3A),
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and the mixture allowed to stand at 37 0. for 3*, then centrifuged 
for 5' at 1,500 r.p.m. to remove the alumina. For use, such 
treated plasma is usually diluted 1 in 5 with saline. Through­
out the text, by "adsorbed plasma" is meant alumina-treated plasma.
B) Bar^im^sulphate^ - adsorbed plasma
1 ml oxalated plasma is mixed with 100 mg BaSC>4( appendix I, 3B), 
the mixture incubated at room temperature for 15* with occasional 
stirring, then centrifuged at 2,000 r.p.m. for 15' to remove the 
BaSO^. Other variations are indicated where necessary.
C) Ga^ (PO^)^- adsorbed piasma
1 ml oxalated plasma is mixed with 50 mg tricalcium phosphate 
(appendix I, 3C), the mixture allowed to stand at room temperature 
for 10* with occasional stirring, and the deposit removed by 
centrifuging.
5. Preparation of serum 
Whole blood is collected in a dry tube and allowed to stand 
for 4 hours at 37°C., the serum is then separated by centrifugation. 
Such serum when prepared from human blood has been shown not to 
contain any appreciable amounts of prothrombin, factor V, or 
A.H.G. (Douglas and Biggs, 1953). For lobster serum, whole 
lobster blood was allowed to clot spontaneously in ordinary glass 
tubes, then shaken with ballotini glass beads, centrifuged, and
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the supernatant separated for use.
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6. Preparation of fibrinogen
A) Phosj}hat£ jd> r ecipitaMon method (Biggs and Macfarlane, 1957)
To 1 litre of fresh citrated bank plasma is added 20 ml alumina 
(appendix I, 3A), and the mixture placed at 37°C. for 15', then 
centrifuged at 2,000 r.p.m. for 15*. The supernatant is tested 
by Quick’s one-stage test; the clotting time should be more than 
90" to ensure proper adsorption, or else the plasma will need 
readsorption. The supernatant is poured into a measuring cylinder, 
cooled to 4°C., and the volume noted, volume X. The following 
steps are then carried out s-
- To X mis plasma are added X mis 2M phosphate buffer previously 
cooled to 4°C. (appendix I, 25A). The mixture is stood for 15' 
then centrifuged at 2,000 r.p.m. for 15' at 4°C. Discard the 
supernatant.
- The precipitate is washed in 300 mis M phosphate buffer, and 
centrifuged at 2,000 r.p.m. for 15'.
- Dissolve the precipitate in 250 mis M/4 phosphate buffer ...: 
volume X.
- Y mis precipitate solution + T mis 2M phosphate buffer, centrifuge 
for 15’.
- Wash ppt. in 200 mis M phosphate buffer and centrifuge for 15'.
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- Dissolve ppt. in 130 mis M/4 phosphate buffer : volume Z.
- Z mis ppt. solution + Z mis 2M phosphate buffer, centrifuge.
- Wash ppt. in 120 mis M phosphate buffer, and centrifuge.
The final precipitate is dissolved in 100 mis citrate-saline 
solution (appendix I, 12) then dialysed against 4 litres of 
citrate—saline solution in the cold, overnight. The solution is 
then centrifuged at 4°C. for 15' at 2,000 r.p.m. to make it free 
from pro—fibrin (Apitz, 1938; Owren, 1947), then delivered in 
5 ml amounts in screw-capped bijou bottles, and stored at -20°C.
For use, this fibrinogen solution was diluted 1 in 2 in saline. 
Fibrinogen prepared by this method is known to be free from other 
known coagulation factors except A.H.G. and possibly plasminogen. 
The relative purity of the different batches was also ascertained 
by clotting doublefolding dilutions of the fibrinogen in saline 
with a standard amount of thrombin, and plotting the clotting times 
in seconds against the fibrinogen concentrations, which should 
give a straight line relationship. Also by clotting the same 
amount of fibrinogen with doublefolding dilutions of thrombin, 
when a pure preparation should give a straight line on plotting 
the clotting times in seconds against the reciprocal of the thrombin
concentrations (Astrup and Darling, 1941).
Before using a newly prepared fibrinogen solution, a thrombin- 
-fibrinogen dilution curve was constucted for it using the stock
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standard thrombin, as described in appendix IV, 7, and illustrated 
in figure 1. If this curve was found to conform to the original 
thrombin-fibrinogen dilution curve, the fibrinogen is suitable for 
use, otherwise it was discarded.
Fibrinogen prepared and tested as above was used as substrate 
in all test systems whenever required, unless otherwise stated.
Fibrinogen solutions of other species were prepared by the 
same method and under the same conditions as the human control, 
only using proportionately smaller quantities all through the 
method.
B) A^ oiiiiM_sulpiia.te jQr^ cijuta.ti^ on. method (modified from 
Duchateau and Florkin, 1954). This method was used only to 
prepare crustacean fibrinogen.
- The lobster haemolymph was obtained (as described in appendix 
II, 1-iii) over 2.5 %  potassium oxalate monohydrate, in the
proportion of 9 to 1 respectively, and immediately centrifuged 
at 1,500 r.p.m. for 51.
_ The pH of the haemolymph is adjusted to 6.8 by the addition of
1 $ acetic acid.
- To a volume of the supernatant "plasma" is added drop by drop
a half volume of saturated ammonium sulphate solution while the 
mixture is stirred by a magnetic stirrer.
- Leave the mixture to precipitate for 12 hours (at least), then
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centrifuge at 3,000 r.p.m. for 15’. Discard the supernatant 
and drain the tubes well, then dissolve the rose—orange ppt. in 
a volume of saline equal to three quarters the original plasma 
volume ...... : ppt.l solution.
- To ppt. 1 solution is added dropwise saturated ammonium sulphate 
solution till its concentration attains 31 f>, stand for 2 hours, 
then centrifuge. The ppt. is dissolved in saline equal to one 
quarter the original plasma volume .....: ppt. 2 solution.
The supernatant is kept.
- To the supernatant which is slightly opalescent is added more 
ammonium sulphate saturated solution to attain a concentration 
of 45 f, stand for 12 hours at least, then centrifuge at 3,000 
r.p.m. for 15’, and dissolve the ppt. in a volume of saline equal
to one quarter the original plasma volume : ppt. 3 solution.
Filter to eliminate the insoluble residue.
- The different precipitate solutions (1, 2, and 3) were dialysed 
against saline in the cold, overnight, as soon as each preparation 
was made. The fibrinogen solutions were kept in 5 ml amounts
at -20°C.
In the original authors' method, the blood was left after the 
spinning down of the cells in the second step, in the cold for 
12 - 24 hours. This step was dispensed with, as in most instances 
the blood was found to have clotted during that period.
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Again, they dissolved the precipitates obtained in distilled 
water, and no dialysis was done. Solution in saline was thought 
to be more physiological, and the dialysis introduced to get rid 
of the excess sulphate ions.
In their hands ppt.3 was the purest form, being electrophoretic- 
ally homogeneous, while ppt.l was of moderate purity (contaminated 
with haemocyanin) and ppt.2 of no importance at all as it clotted 
in 12 minutes. As explained in the text in more detail, using 
the above modifications, ppt.l was obtained as of moderate purity, 
while ppt.2 was the purest, most reactive, and electrophoretically 
homogeneous fibrinogen preparation (figure 74), while ppt.3 was 
very minimal and contained no fibrinogen at all, being non-clottable.
7. Preparation of thrombin
A) l&£ombinJfopical__ (Parke, Davis & Co.)
This is a bovine thrombin preparation, commercially processed 
from bovine plasma by the addition of traces of tissue thrombo­
plastin and calcium chloride to activate the prothrombin. It was 
used throughout this study for the various assays, unless otherwise 
stated, as in the species specificity tests of the thrombin and 
fibrinogen solutions. The contents of 1 vial were dissolved in 
5 mis of glycerol-saline mixture (equal parts) giving a concentration 
of 1,000 N.I.H.units/ml. This is kept at -20°C., and before use
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dilutions were made in saline. Each batch was cross-matched 
against the standardised fibrinogen by the thrombin-fibrinogen 
dilution curve procedure. If it was found to conform to the 
original dilution curve, which invariably occured except in one 
batch that was discarded, denoting an identical concentration as 
the original thrombin solution, it was released for use in the 
various assays, and also kept as reference standard for standardising 
future fibrinogen preparations, within one month of its preparation.
Such concentrated thrombin solutions kept at -20°C. for one 
month were found to have the same potency as when fresh, as judged 
by the similar thrombin-fibrinogen dilution curves obtained with 
the same batch of fibrinogen.
B) j^rombins o_f_ojther_sj3e_ci_es (Biggs and Macfarlane, 1957)
400 mis of citrated fresh plasma is made up to 4 litres with 
distilled water, and the pH adjusted to 5.3 with 2 f> acetic acid. 
Centrifuge and discard the supernatant. Dissolve the ppt. in 
100 mis saline and readjust the pH to 7 with 2 fo sodium carbonate.
To this solution is added 12 mis M/4 CaCl2 and the coagulated 
fibrin removed as it forms, this is performed using one’s hand 
and squeezing the fibrin tightly before its removal. Stand the 
solution for 2 hours to allow for maximum thrombin generation.
Add an equal amount of acetone to the remaining solution, and 
centrifuge. The thrombin is extracted from the precipitate by 
adding saline (100 mis) and stirring with a glass rod to break
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up the precipitate. Centrifuge and discard the precipitate.
The thrombin solution is dialysed against distilled water in the 
cold, overnight, then stored in 2 ml amounts in the deep-freeze.
Usually the various thrombins were prepared from proportionately 
smaller amounts alongside the human control, under the same 
experimental conditions.
8. Preparation of prothrombin 
(method of Biggs and Macfarlane, 1957)
To 1 litre of fresh normal citrated platelet-poor plasma is 
added 25 mis alumina and the mixture incubated for 15* at 37°C., 
then centrifuged and the supernatant tested by Quick's one-stage 
prothrombin time. The clotting time should be longer than 90", 
else the plasma is to be readsorbed. The supernatant is either 
discarded or used for the preparation of A.H.G. or fibrinogen if 
required. The precipitate is washed twice with cold distilled 
water. The prothrombin is then eluted from the ppt. by mixing 
it with 25 mis of phosphate buffer at pH 8 (appendix I, 25,B) 
and standing the mixture at 37 C. for 20 — 60 minutes, then 
centrifuged. The supernatant which contains the prothrombin is 
retained, and the ppt. is again eluted with a further 25 mis of 
phosphate buffer, the second supernatant is then added to the 
first, and the pH adjusted to 7 by adding 2 fo acetic acid. This
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final solution is dialysed against 4 litres of citrate—saline in 
the cold, overnight, then stored in 5 ml amounts in the deep­
freeze. Such prothrombin preparations were free from A.I-I.G., 
factor V, fibrinogen, antithrombin, and plasmin.
For preparing prothrombin of other species proportionately 
smaller amounts of reagents were used, depending on the quantity 
of plasma available.
9. Preparation of factor Y 
(method of Douglas and Biggs, 1953)
Two mis. of fresh citrated plasma are treated with 0.2 ml of 
alumina for 3' at 37°G. and the alumina removed by centrifuging.
To the supernatant in a high-spinning tube is added 1 ml of 
saturated ammonium sulphate solution, mixed well, then centrifuged 
at 15,000 r.p.m. for 51. The supernatant is poured into another 
clean high-spinning tube, 1 ml of saturated ammonium sulphate 
solution is added with thorough mixing, the mixture centrifuged 
again at 15,000 r.p.m. for 5' and the supernatant discarded.
The precipitate which contains the factor V is dissolved in 2 mis 
citrate—saline and dialysed against 4 litres of citrate—saline in 
the cold, overnight. The solution is then diluted to 10 mis with
saline and tested as follows
0.3 ml amounts of prothrombin (appendix III, 8), factor V
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solution under test (different dilutions), and brain thromboplastin 
(appendix III, 13) are delivered into a clotting tube placed in 
a water-bath at 37°C. and the mixture recalcified with 0.3 ml M/40 
calcium chloride solution, simultaneously starting a stop watch. 
After 5 and 6 minute intervals, 0.1 ml amounts of the incubation 
mixture are pipetted off onto 0.4 ml amounts of fibrinogen solution 
previously warmed to 37°C. and the clotting times noted. The 
highest dilution giving a reasonably short clotting time is noted 
and the factor V preparation diluted accordingly, as it may be very 
potent, then stored in 2 ml amounts at -20°C. Such a factor Y 
preparation has been shown to be free from prothrombin, factor VII, 
Christmas factor, Stuart-Prower factor, and most of the A . H . G . , 
fibrinogen, and antithrombin, (Douglas, 1957). When prepared 
from bovine plasma, the factor V substance usually contains some 
prothrombin (Biggs and Macfarlane, 1962).
10. Preparation of factor VII 
(Biggs and Macfarlane, 1957)
Ten mis. of serum (appendix III, 5) are adsorbed with barium 
sulphate powder (100 mg/ml) at 37°C. for 15'. The mixture is 
centrifuged at 2,000 r.p.m. for 10' and the ppt. washed twice 
with cold distilled water. The deposit is treated with 5 mis of 
5 f  trisodium citrate in saline (appendix I, 32) for 15' at 37 C.
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The inactive BaSO^ is removed by centrifugation, and the eluate 
dialysed against 5 litres citrate-saline in the cold overnight, 
finally the volume is made up to 10 mis with saline.
This preparation contains factors VII, IX, and X.
11. Preparation of anti-haemophilic globulin (factor VIII) 
(Biggs and Macfarlane, 1957)
The alumina adsorbed plasma which remains after step 2 for 
prothrombin preparation is used. The supernatant which contains 
little prothrombin, factor VII, or factor IX, is precipitated with 
33 f  saturation of ammonium sulphate, i.e. to each 10 mis adsorbed 
plasma is added 5 mis saturated ammonium sulphate solution.
The mixture is centrifuged and the ppt. dissolved in a volume of 
saline equal to half the original plasma volume, i.e. 5 mis.
This solution is dialysed against 5 litres of citrate-saline in 
the cold, overnight, and the final volume is made up with saline 
to 10 mis (the original adsorbed plasma volume).
This A.H.G. preparation was always used fresh for the various 
tests.
12. Preparation of Christmas factor (factor IX) 
(White, Aggeler, and Glendening, 1953)
Whole blood is allowed to clot and stand for 24 hours at room
- 33 - (Appendix III)
temperature. The serum is separated after centrifuging, and to 
9 mis of serum is added 1 ml of 3.2 °/o trisodium citrate and the 
mixture stood for 30' at 37°C. to allow for the neutralization 
of any remaining thrombin. The pH is adjusted to 2.9 by the 
dropwise addition of N-HC1, and allow to stand for 2 hours at 
37°C., to destroy factor VII activity. The pH is readjusted to 
7.3 with N-NaOH. The serum is then adsorbed with BaSO^ (100 mg 
per ml) for 15' at 37°(J. The mixture is centrifuged at 2,000 
r.p.ra. for 30', and the ppt. washed twice with cold distilled 
water. The ppt. is then eluted with 5 mis of 5 fo trisodium 
citrate in saline for 15' at 37°C., and the eluate dialysed against 
5 litres of citrate-saline, in the cold overnight. The volume 
of the Christmas factor solution is then made up with saline to 
the original serum volume.
13. Preparation of tissue extracts
I. Preparation of brain thromboplastin extract (Owren, 1949)
A fresh whole normal brain is freed from all blood vessels 
and membranes and washed well with water. The brain matter is 
emulsified in an equal volume of saline warmed to 37 C. for one 
minute in an electric homogeniser. The emulsion is centrifuged 
at 2,000 r.p.m. for 30’, the supernatant separated and the deposit 
discarded. Doublefolding dilutions of the supernatant are made
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in saline and tested by the one-stage prothrombin time using 
normal homologous plasma and M/40 CaCfl^ - The dilution which 
gives the shortest clotting time (13 - 16 seconds) is noted, and 
the whole supernatant diluted accordingly. To this extract is 
added a one tenth volume of Owren’s buffer (appendix I, 41).
The final extract is distributed in 5 ml amounts in small bijou 
bottles and stored at -20°C. A fresh bottle is opened at a time, 
and once used should not be re-frozen for later use.
For the preparation of chicken brain extract it was necessary 
to use from 6 to 10 whole chicken brains for one preparation, so 
as to supply enough material of the same potency for as large a 
battery of tests as possible.
II. Preparation of crustacean muscle extract
A) By the method of Loeb, 1903
One part of fresh lobster muscle is washed well with water, 
then ground with one part sand and one part distilled water in a 
mortar. The homogeneate is stood overnight in the refrigerator, 
then centrifuged at 3,000 r.p.m. for 10 minutes. The supernatant 
is delivered into small bottles and kept at -20°C.
B) By the method of Qwren, 1949
The same procedure is used as for the preparation of the brain 
thromboplastin extract, except for substituting the lobster muscle 
instead of the brain substance.
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14. Preparation of crude cephalin 
(Bell and Alton, 1954)
Preparation of acetone dried brain (Biggs and Macfarlane, 1957)
A fresh human brain is obtained, freed from all blood vessels 
and meninges, then macerated with 3 - 4  times its volume of acetone 
in a mortar. The acetone is changed 4 times and the granular 
powder is dried on a suction filter (200 gms wet weight of brain 
yield about 30 gms dry powder).
Extraction of the cephalin
The acetone dried brain is further washed with acetone (20 mis 
per gm of brain powder) till the washings are cholesterol-free as 
judged by a negative Liebermann-Burchard reaction. After removal 
of the supernatant acetone, the brain powder is again dried on a 
suction filter. This powder is extracted with chloroform A.R.
(50 mls/gm powder) at room temperature for 2 hours with occasional 
shakings. Filter to remove the ppt. which is discarded, and the 
filtrate evaporated under vacuum. This usually yields about 300 
mg of gummy active material for every gram of dried brain used.
The residue is finely homogenised in saline (50 mls/gm dried brain) 
to give a concentration of about 0.6 gm cephalin per cent, then 
stored in small amounts at -20°C. ’When frozen, this stock solution 
is stable for 12 months at least and can be thawed and refrozen
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repeatedly without loss of activity. The exact dilution of each
batch for maximal potency should be determined.
For use, the stock solution is diluted 1 in 100 in saline or 
in veronal buffer. This preparation would contain about 0.006 gm 
cephalin per cent and is designated as Cephalin 1/100 throughout 
this study. Other dilutions were sometimes used and are mentioned 
where appropriate.
This cephalin preparation has proved relatively pure as the 
clotting times of recalcified plasma with various dilutions of 
cephalin increased with higher dilutions (i.e. decreased activity); 
had it been a crude preparation the clotting times should have been 
shorter with the initial dilutions due to dilution of inhibitors. 
Also it has been shown to possess no thromboplastic lipoprotein 
contaminants i.e. no free thromboplastic activity.
15. Preparation of platelet suspensions
A) Human platelet suspension (Biggs and Macfarlane, 1957)
Fresh platelet-rich human plasma is spun at 15,000 r.p.m. for 
51 and the clear supernatant removed (used as high-spun plasma).
The button of platelets is washed twice in saline after thoroughly 
resuspending the platelets in it. The final plug of platelets is 
suspended in saline in a volume equal to half that of the original 
plasma. The suspension is stored at —20°C. in small amounts,
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each sufficient for one day's use. For use in the T.G.T. the 
suspension is diluted in saline (1 : 2).
The same procedure was used for the preparation of horse and 
rabbit platelet suspensions.
B) Chicken thrombocyte suspension
Fresh platelet-rich chicken plasma prepared as described in 
appendix III, 1, i, is treated as above. This preparation also 
contains some lymphocytes.
C) Bovine platelet suspension
Fresh citrated platelet-rich bovine plasma obtained by the 
stepwise centrifugation method described in appendix III, 1, ii, 
is treated as above.
16. Preparation of crustacean blood cells1 extract
Crustacean blood (haemolymph) is obtained from a joint space 
by the use of siliconed needles and syringes. Nine parts of the 
blood are mixed with one part of 2.5 $ potassium oxalate solution 
in a siliconed centrifuge tube and is immediately spun at 4°C. for 
five minutes at 2,000 r.p.m. The supernatant blue plasma is 
decanted and the tube drained well and rinsed with saline without 
dislodging the precipitate. This cell sediment is suspended in 
a volume of saline equal to one third the original blood volume, 
and is thoroughly broken up using wooden applicator sticks, for
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one to two minutes. The suspension is centrifuged again for five 
minutes at 2,000 r.p.m., the clear supernatant is decanted into a 
clean lusteroid tube and used as fresh as possible.
A potent preparation should clot an aliquot of oxalated lobster 
plasma in the presence of calcium chloride solution (3fo) in about 
six seconds. It also should clot an aliquot of the purified 
lobster fibrinogen in the presence of calcium chloride solution 
in about the same time.
On keeping, this preparation was found to lose all activity 
even if kept frozen at -20°C. for several hours only.
17. Preparation of Russell's viper venom reagent
A) R.V.V. in saline
The contents of each vial of Stypven (Burroughs Wellcome & Co.) 
are dissolved in 1 ml saline solution and stored frozen at -20°C. 
The concentration of this solution is 0.1 mg/ml and usually 
expressed as 1/10,000 (i.e. 1 gm/10,000 mis). Further dilutions 
in saline are made before use as required.
B) R.V.V. in cephalin
The contents of each vial of Stypven (0.1 mg) are dissolved 
in 1 ml of 1/10 cephalin suspension. The latter is made by 
dilution of the stock cephalin suspension (appendix III, 14) 1 : 10 
in veronal buffer (appendix I, 41). The concentration of R.V.V.
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in this solution is 1/10,000, and the concentration of cephalin 
is 0.06 gm *fo approximately. This is kept frozen at -20°C. in
0.5 ml volumes. Before use, further dilutions are made in cephalin 
suspension (l/lO) to give final concentrations of R.V.V. of 
1/40,000, 1/80,000, and 1/200,000 as required.
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ASSAY METHODS AND SPECIAL TECHNIQUES
Throughout this work fresh blood or reagents prepared there­
from, obtained from the same subject (the author) were used to 
represent the normal human control materials. They were ascribed 
100 per cent values so that the results obtained for the various 
species can be assessed on a relatively uniform basis.
Fresh test samples of plasma or serum from each species were 
pooled from at least three animals each time to obviate individual 
variations in the coagulation factors' levels from affecting the 
results as much as possible.
1. Platelet and thrombocyte counts
A) Platelet count (Dacie, 1956)
The following method was used for counting human, bovine, 
equine, and rabbit platelets.
Ten mis. of filtered formol-citrate solution (appendix I, 16) 
are delivered into a clean screw—capped bottle. A small volume 
of freshly withdrawn blood is delivered into a waxed watch-glass 
(after removal of the syringe needle) and the blood immediately
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diluted 1 in 100 in the formo1-citrate solution by using a 0.1 and
0.2 ml blood pipette, first drawing the diluting fluid up to the
0.1 mark, then the blood is taken up into the pipette till the upper 
level of the fluid reaches the 0.2 mark. The contents of the 
pipette are washed into the 9.9 mis of diluting fluid remaining in 
the bottle. The suspension of blood is well mixed by inversion 
several times. The platelets are well preserved in this fluid 
for several hours. The contents of the bottle are again well 
shaken for 2 minutes before a Neubauer counting chamber is filled 
with the suspension, which is placed in a moist chamber and left 
undisturbed for 20 minutes to allow the platelets to settle.
The preparation is then examined under the microscope. Racking 
down the condenser renders the platelets easily distinguished, 
appearing as highly refractile particles. They should be well 
separated from each other, the presence of many platelet clumps 
invalidates the count in which case it should be repeated.
The number of platelets in one square millimetre are counted, and 
the procedure repeated on the other side of the chamber, taking 
the average of the total counts.
Calculation Total platelet count /c.mm. whole blood = 
average count/sq.mm. x 10 x 100 (dilution factor).
N.B. i. For human platelet counts, fresh venous blood was obtained 
by a clean venepuncture using siliconed syringes.
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ii. For bovine platelet counts, blood was collected at the 
slaughter house in siliconed plastic containers as described in 
appendix II, 1, vi, and immediately delivered into a 5 ml bijou 
bottle containing the appropriate amount of dried sequestrene 
(appendix I, 7, C), well shaken, and the count carried out within 
1 hour of collection.
B) Chicken thrombocyte counts
Since chicken platelets are nucleated cells it was necessary 
to count the total white blood corpuscles first, then make a 
differential white cell count from a blood film in which is 
included the thrombocytes. From these data the total thrombocyte 
counts were calculated.
i. Preparation and staining of the blood film: a drop of
fresh blood is obtained by pricking the wing vein and immediately 
spread on a glass slide and allowed to dry in the air. The slide 
is flooded with Leishman’s stain (appendix I, 23) for 2-3', then 
double the volume of distilled water is added and well mixed by 
blowing through a pasteur pipette. A shiny scale forms if the 
dilution is properly done. After 5 - 71 the slide is washed in 
a stream of distilled water till the film differentiates into a 
rose-pink colour. The film is then allowed to dry in the air.
ii. Differential counts thrombocytes are apt to be mistaken 
for lymphocytes unless great care is paid to detail. The former
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are of similar size as the small lymphocytes, occur either singly 
or in groups of two or three, have a rather abundant light violet 
cytoplasm which may contain few azurophilic granules and may 
appear vacuolated, while their nuclei are small, usually oval, and 
concentric.
iii. Total leucocyte count: using a bulb diluting pipette the
blood is diluted 1 in 20 in 2 ^ acetic acid solution. After 
thorough mixing a counting chamber is filled (both sides) and the 
white cells contained in 1 square mm. area are counted on each 
side and the average calculated. It should be noted that the 
red cells of the chicken are also nucleated and are not haemolysed 
by the acetic acid solution, but it is very easy to distinguish 
them from the white cells because of their oval shape and haemo­
globin content.
Calculation Total leucocyte count/c.mm. whole blood = 
average count/sq.rmn. x 10 x 20 (dilution factor).
C) Lobster blood cells1 count
i. Total cell count ; is carried out as an ordinary total 
leucocyte count as described above.
ii. Differential cell count : since lobster cells concerned
with the coagulation process cannot be differentiated easily by 
cytology because of their rapid disintegration, they were counted 
by phase contrast microscopy immediately after withdrawal of the 
blood from the animal. Thus visualised, the "explosive cells"
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can be seen to produce rounded vacuoles which explode, clotting 
the surrounding plasma film which then appears as a finely 
granular area of higher density. Such cells were counted in 
each field as compared to the total cells in the same field. 
Several fields are thus examined covering at least 1000 cells for 
each individual count. The percentage of the explosive cells is 
then easily calculated, and from the total count their absolute 
number is derived accordingly.
2* Fibrinogen estimation 
I♦ micro-Kneldahl method (Cullen and van Slyke, 1920)
The fibrinogen after being converted into fibrin is digested 
with concentrated sulphuric acid, the protein nitrogen is driven 
off by the action of excess concentrated sodium hydroxide in the 
form of ammonia which is collected volumetrically in standard 
sulphuric acid solution. The excess sulphuric acid is back 
titrated with sodium hydroxide to calculate the amount neutralized 
by the ammonia. The amount of protein present is thus calculated 
on the assumption that 16 °/o of the dry weight of protein is 
nitrogen. This is quite arbitrary since each protein has a 
different nitrogen concentration. If this factor is used, the 
weight of nitrogen found as ammonia is multiplied by the factor 
6.25 to obtain the amount of protein present in milligrams.
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Apparatus
- Digestion tubes and rack.
- Glass beads, these should be boiled in concentrated sodium 
hydroxide before use to drive off any ammonia in the dust 
which may contaminate them.
- micro-Kjeldahl distillation apparatus.
- Na^SO^ catalyst tablets, (appendix I, 22)
- Zinc dust, (appendix 1,42)
- h2so4,a .r ., (appendix I, 36A)
- NaOH 40 (appendix I, 34C)
- N/50 H SO.
2 4 (appendix I, 36C)
- N/70 NaOH (appendix I, 34B)
- Alizarin red indicator, (appendix I, 4)
- Standard NH^Cl solution, (appendix I, 5).
Method
1. Preparation of standard : 5 mis standard NH^Cl solution are
delivered in a digestion tube + 1 catalyst tablet + 1 ml conc.
+ 3 glass beads.
2. Preparation of the blank : 5 mis of water are substituted for
the standard solution.
3. Preparation of the test specimen : should not contain more
than 2 mg nitrogen. In case of fibrinogen, that from 1 to 2 mis
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of fresh plasma would be an adequate sample. One ml of the 
plasma is added to 9 mis saline and after mixing 1 ml of thrombin 
is added and the tube placed for 15' at 37°C. The formed clot 
is collected on a glass rod and washed in two changes of saline 
then squeezed down the rod into the digestion tube. One 
catalyst tablet is added together with 5 mis water, 1 ml conc. 
H2S04, and 3 glass beads.
N.B. a) For chicken fibrinogen 1 ml M/40 CaCl2 solution had to 
be added to the diluted plasma thrombin mixture to 
bring about fibrinogen conversion, 
b) For lobster fibrinogen; as this was very difficult 
to collect on the glass rod, after clotting the diluted 
plasma with 0*5 ml lobster cell extract in the presence 
of 1 ml of 3 fo CaCl^ solution, the fibrin is collected 
on ballotini glass beads, washed twice with saline with 
centrifuging after each wash. The glass beads with 
the adsorbed fibrin are transferred into the digestion 
tube to which is added the rest of the reagents as above. 
Boil the tubes very gently till the excess water is boiled off, 
then as the solutions turn brown the flame is increased and the 
mixtures boiled vigorously till they become clear, and thereafter 
gently for 30 minutes.
While the digestion is in progress the N/70 NaOH solution is
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standardised against N/50 solution.
6. Prepare several 250 ml conical flasks each containing 10 mis 
of N/50 ^SO^ and 0.8 ml alizarin red indicator.
7. Dilute the digested samples with distilled water to not more 
than 4 mis total volume. This is dangerous and should be done 
over a sink as the tubes may explode if the water is added too 
quickly.
8. Transfer the contents of one digestion tube to the distillation 
flask, the apparatus having been first steamed up for about 
one hour. Place one of the conical flasks under the delivery 
tube of the distillation plant. Rinse the distillation flask 
three times with 2 ml volumes of distilled water, adding about
0.2 gm zinc dust before the last rinse.
9. Add at least 5 mis conc. NaOH solution and immediately clip the 
funnel to prevent any escape of ammonia to the outside.
10.Distill off about 50 mis into the conical flask.
11.The distillation flask is then washed with distilled water twice 
and the procedure repeated for the next digestion tube and so on
12.Back titrate the contents of each flask against standardised 
N/70 NaOH.
„ i i + • / i 10 x °*28 x 6*25 ( B “ T )Calculation mg protem/c.c.plasma = ------------------------
A
B = mis N/70 NaOH required in titration of the blank.
T = mis N/70 NaOH required in titration of test specimen.
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A = mis N/70 NaOH required in titration of 10 mis N/50 H SO .
eL
N.B. If the blood was obtained with a fluid anticoagulant, 
correction for the dilution of the plasma is made taking the 
haematocrit value in consideration for each particular sample.
II. Modified Greenberg method (Tyrosine method)
Reagents
- NaOH 1CY/o (appendix I, 34, C).
- (appendix I, 31).
- Folin and Ciocalteu's phenol reagent.
- Standard tyrosine (appendix I, 40, A & B).
- Thrombin Topical (Parke, Davis & Co.).
Method
1. Preparation of test specimen: 0.5 ml plasma is added to 9 ml
saline in a test-tube containing 0.5 ml ballotini glass beads.
The solution is mixed gently and 0.2 ml thrombin solution 
(50 units/ml) is added and the tube mixed raixldly and left at 
37°C. for 10-15', after which time the fibrin is collected on 
the beads by brisk shaking without inversion, finally centrifuging. 
The deposit is washed twice with saline which should almost 
fill the test-tube to wash off all soluble proteins, and the 
washing removed after centrifugation. One ml of NaOH IQ P/o 
solution is delivered down the sides of the tube and heated 
in a boiling water-bath for approximately 2 minutes, then
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cooled under the tap. To the mixture is added 6 mis of water, 
together with 3 mis of 20$ Na^CO^ and 1 ml of Folin phenol 
reagent. Stand for 30 minutes, then add 1 ml to 3 mis of 
distilled water and mix well. The extinction reading of the 
mixture is measured at 650 mp.
2. Preparation of the blank: substitute water for the plasma
and proceed as above.
3. Preparation of the standard calibration curve: amounts of
the working standard tyrosine solution (appendix I, 40, B) 
ranging from 0.05 to 4 mis are made up to 6 mis with water, 
then add to each tube 1 ml of 10$ NaOH + 3 mis 20$ Na^CO^ +
1 ml Folin phenol reagent. Stand for 30 minutes for maximum 
colour development, dilute an aliquot of each 1 in 4 with 
water and read at 650 mp then draw the curve relating the 
extinction readings to the equivalent tyrosine concentration 
in milligrams.
Calculation
The tyrosine content of the test plasma is read off from the 
calibration curve and converted into fibrinogen as follows:- 
mg fibrinogen/100 mis plasma = mg tyrosine x 11.7 (conversion 
factor) x 200 (dilution factor).
N.B. For the lobster fibrinogen estimation, lobster cell extract 
and 3$ CaCl^ solutions were used instead of the thrombin solution
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which does not clot lobster plasma. The final result was 
corrected for the plasma dilution as it was collected over fluid 
potassium oxalate in the ratio of 9 to 1.
III. Turbidimetric method (Stirland, 1956)
Blood is obtained over dry oxalate or sequestrene (2 mg/ml) 
and the plasma separated. 0.2 ml plasma is mixed thoroughly 
with 3 mis of 1$ NaCl solution in each of two half inch diameter 
test-tubes, (dilution 1 in 16). One of the tubes is placed in 
a hot water bath at 56°C. for 15 minutes. The extinction reading 
at 650 mp is taken using the unheated tube as the blank. 
Preparation of the standard curve: (Shank and Hoagland, 1946,
and Kunkel, 1947). A solution of 3 mis of 0.0962 N-BaCl .2H 0 
(appendix I, 9) is diluted up to 100 mis with 0.2 N-ELjSO^  at 10°C. 
This solution is equivalent to 20 Kunkel units. Dilutions are 
made from this with distilled water to represent 5, 10, and 15 
Kunkel units, and the solutions read at 650 mp immediately. The 
curve is drawn relating the extinction readings to the equivalent 
turbidity units. One Kunkel unit equals 42.8 mg fibrinogen per 
100 mis plasma (or 26.8 pgm fibrinogen/ml diluted plasma solution). 
N.B. If the fibrinogen is higher than 850 mg $ it requires 
further dilution of the test plasma, e.g. 0.1 ml plasma diluted 
in 3.1 ml NaCl solution (dilution l/32); while if the fibrinogen 
is very low (faint turbidity) use a dilution of 1 in 8.
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3. Whole blood clotting time 
(method of Lee and White, 1913)
Whole venous blood obtained by a clean venepuncture (appendix 
II, 1) is delivered in 1 ml volumes in each of four small test- 
tubes (10 x 75 mm) placed in a water ba.th at 37°C. The tubes are 
tilted in turn at half minute intervals till each tube can be 
inverted without spilling the blood. A stop watch is started as 
the blood enters the syringe, and the clotting time recorded when 
the blood has solidified. The average of the four clotting tubes 
is calculated. Whole blood clotting times were estimated in 
ordinary glass tubes and in siliconed glass tubes.
For lobster haemolymph clotting time, the test was carried out 
both at 37°C. and at 15°C. which is nearer their normal habitat 
temperature.
4. Clot retraction 
(method of Macfarlane, 1938, as modified by Aggeler, Lucia, and 
Hamlin, 1942).
Apparatus - siliconed centrifuge tubes graduated in 0.1 ml 
divisions.
- spiral made of wire whose diameter is 1-1.5 mm. 
Method Freshly withdrawn venous blood is immediately placed
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into the siliconed tube up to the 5 ml mark exactly. The wire 
spiral is then placed in the tube which is put in a water bath at 
37°C. The tube is examined from time to time until the blood has 
clotted. It is then left undisturbed in the water bath for a 
further hour at the end of which the wire around which the clot 
should have retracted is carefully lifted up and allowed to drain 
for about one minute and then is removed. The volume of the 
expressed serum and red cells is read off directly from the tube 
graduations. This volume is expressed as a percentage of the 
5 mis of blood, thus giving the percentage retraction of the clot 
in one hour.
5. Plasma recalcification time 
Into a tube in a water bath is delivered 0.1 ml of citrated 
platelet-rich plasma and 0*1 ml of saline. Simultaneously with 
the addition of 0.1 ml Vi/40 CaC^ solution a stop watch is started 
and the clotting time recorded.
6. Quick1s one-stage prothrombin time 
0.1 ml of citrated plasma and 0.1 ml of tissue extract 
(appendix III, 13) are mixed in a clotting tube placed in a water 
bath at 37°C. for 30”, and a stop watch is started at the moment 
of the addition of 0.1 ml kj/40 CaCl2 and the tube tilted almost
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horizontally every few seconds until a firm clot is observed, and 
the time recorded. The test is done in duplicate and the average 
reported.
7. Thrombin-fibrinogen dilution curve 
(Biggs and Macfarlane, 1957)
Thrombin Topical (Parke, Davis & Co.) solution containing 
1000 N.I.H. units/ml (appendix III, 7) is diluted with saline to 
contain 50, 40, 30, 20, 15, 10, 8, 5, 4, 3, 2, and 1 units of 
thrombin per ml. (occasionally double-folding dilutions were made 
to contain 50, 25, 12.5, 6.2, 3.1, and 1.5 units/ml for the sake 
of simplicity). Dilutions were always made in siliconed tubes 
to obviate the adsorption of the thrombin on the glass surface 
(Waugh and Livingstone, 1951, Seegers et al, 1952) especially in 
solutions of low concentration.
A series of tubes containing 0.4 ml amounts of fibrinogen are 
placed in the water bath at 37°C. and to each is added 0.1 ml of 
each of the thrombin solutions and the clotting times recorded.
The clotting times are plotted against the thrombin concentrations 
on double logarithmic paper when a straight line should be obtained 
(figure 1). Prom this curve the clotting times of 0.4 ml amounts 
of fibrinogen can be read in terms of thrombin units. These units 
have no absolute significance but are used for comparing the
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relative amounts of thrombin formed in the various test systems.
Plotting the clotting times in seconds against the reciprocal 
of the thrombin concentrations gives a straight line which almost 
passes through the origin, because however strong the concentration 
of thrombin is the fibrinogen still takes some time to clot.
New batches of fibrinogen or thrombin were always assayed by 
this method, only those conforming to the original curve shown in 
figure 1 were used.
T H R O M B I N - F I B R I N O G E N  DILUTION CURVE.
200 r
100
60 80 1000.2 0.5
T h ro m b in  Units  /ml.
Pig. 1 Reference thrombin-fibrinogen dilution curve.
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8. Thrombin-fibrinogen reaction of the plasma 
Serial dilutions of thrombin are made ranging from l/l to 1/32 
in saline in siliconed tubes. Six clotting tubes are placed in 
the water bath, each containing 0.1 ml of the citrated plasma 
together with 0.1 ml of saline. 0.1 ml of each thrombin dilution 
is added to each and the clotting times recorded. A curve is 
drawn by plotting the clotting times in seconds against the 
thrombin concentrations in units. Usually the most concentrated 
solution of thrombin (l/l) contained 50 units/ml.
Sometimes, double the amounts were used so as to be able to 
test the effect of other reagents on the reaction by substituting 
them for the saline, as described in the next test.
9. Effect of various reagents on the thrombin-fibrinogen reaction 
Essentially the same procedure as in the thrombin-fibrinogen 
reaction of the plasma except for using 0.2 ml amounts of each 
constituent. The effect of adding toluidine blue (appendix I, 38), 
pyrocatechol (appendix I, 28), heparin (appendix I, 19), hexa- 
dimethrine bromide (appendix I, 26), and M/40 CaCl^ solutions 
either singly or in combination, was tested by substituting 0.1 ml 
of the required reagent instead of 0.1 of the saline solution or 
0.1 ml of each reagent instead of the 0.2 ml of saline.
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10. Testing for the species specificity of the thrombin-fibrinogen
reaction in a purified system 
Purified thrombin (appendix III, 7, B) and purified fibrinogen 
(appendix III, 6, A) prepared from the various species were used.
0.4 ml of each fibrinogen solution mixed with 0.1 ml saline was 
clotted with 0.1 ml of each thrombin solution at 37°C. and the 
clotting time recorded. The results are compared with that of 
a homologous human system. The effect of pyroeatechol was tested 
by adding 0.1 ml of the pyroeatechol solution (appendix I, 28) 
instead of the 0.1 ml of saline, to the fibrinogen solution under 
investigation, then clotting the mixture with the thrombin solutions. 
N.B. Both thrombin and fibrinogen preparations were processed 
at the same time under identical conditions and tested immediately 
after processing. Stored batches were not used for this test.
11. Measurement of antithrombin
A. Method of Douglas and Biggs. 1953
To 0.5 ml fresh citrated plasma is added 0.5 ml thrombin 
solution (50 units/ml) and the clot immediately removed by winding 
it on a wooden swab stick. At intervals of {, 1, 2, 3, 4, 5, and 
6 minutes from the addition of the thrombin, 0.1 ml amounts are 
removed from this incubation mixture and added to 0.4 ml amounts
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of fibrinogen previously prepared in clotting tubes placed in the 
water bath at 37°C., and the clotting times recorded. The 
equivalent thrombin units are read from the thrombin-fibrinogen 
dilution curve (figure 1) and a curve relating the logarithm of 
the thrombin in units to the incubation time in minutes is drawn.
The test plasma is similaxly treated as the control plasma.
The distance from the zero point at which the curve crosses the
abscissa is a measure of the antithrombin activity.
CCalculation Antithrombin activity per cent = —— - x 100 
where C = distance of control human plasma (considered 100 fo)
and T = distance of test plasma.
B. Modified method of Astrup and Darling (1942d) (Biggs and Macfarlane, 1957) 
Citrated plasma is diluted 1 in 5 in saline and mixtures of 
this diluted plasma and saline are made as follows 
Diluted plasma in ml. 0.0 0.05 0.10 0.15 0.2 0.3
Saline in ml. 0.3 0.25 0.20 0.15 0.1 0.0
To each of these mixtures is added 1 ml of thrombin solution, 
and the mixtures incubated for 15 minutes at 37°C. after which time 
the tubes are removed and placed in water at the temperature of 
melting ice to stop the neutralization of the thrombin. From 
each tube 0.1 ml volume of solution is delivered onto 1 ml amounts 
of fibrinogen previously distributed in clotting tubes kept at 
37°C. and the clotting times recorded.
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The concentration of the thrombin solution is so adjusted
that 0.1 ml from the control mixture containing no plasma clots
the fibrinogen in 10-15 seconds. The concentration of the test
plasma is also so adjusted tnat the fibrinogen clotting time of
the highest concentration of plasma does not exceed 60 seconds.
Calculation Antithrombin concentration = .JL. ( 1 - t / t )----------  o n
n
where a = the concentration of thrombin in units/ml.,
n = the amount of undiluted plasma in each mixture,
t = the fibrinogen clotting time of the control with no plasma,
t = the fibrinogen clotting times with the various plasma
concentrations.
The values t /t^ are plotted against the concentration of
plasma on ordinary graph paper and the best line is drawn through
the points. From this line is read the corrected values for
t /t which are used for the calculation of the antithrombin o' n
concentration that is expressed in units/ml plasma.
Though this method gives a direct estimate of the antithrombin 
activity in terms of units/ml without reference to a control 
normal plasma, it was thought better to include testing the control 
human plasma tinder the same conditions and express the result as 
a percentage of the control value.
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12. Measurement of prothrombin
A. One-stage method of Koller, Loeliger, and Duckert, 1951
Adsorbed oxalated bovine plasma is used as substrate to supply 
constant amounts of factor V and of fibrinogen. It is prepared 
by obtaining bovine blood over sodium oxalate (1.34$) in the ratio 
of 9 to 1 respectively. The plasma is separated and adsorbed 
with tricalcium phosphate (50 mg/ml plasma) for 10 minutes at room 
temperature with occasional stirring, the plasma finally centrifuged 
to separate the precipitate. This plasma was prepared fresh for 
each assay. Prothrombin-free oxalated human serum (or purified 
factor VII prepared therefrom) is used to supply factor VII. It 
is preiDared as described in appendix III, 5, then tested for its 
prothrombin content as follows:- 0.1 ml volumes of adsorbed 
human or bovine plasma, undiluted serum (under test), and brain 
thromboplastin are placed in a tube in a water bath at 37°C. and 
after 20 seconds 0.1 ml of M/40 CaCl? solution is added and the 
clotting time recorded. It should be more than 90 seconds, 
otherwise the serum is not suitable for this assay system.
Test procedure
In a clotting tube in a water bath at 37°C. is placed 0.1 ml 
of the test plasma diluted 1 in 10 in veronal buffer, 0.05 ml of
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the adsorbed bovine plasma (substrate), 0.05 ml of the prothrorabin- 
-free oxalated serum (oxalated 1 in 10 with 1.34$ sodium oxalate), 
and 0.1 ml of brain thromboplastin. After 20 seconds 0.1 ml of 
M/40 CaCl^ solution is added and the clotting time of the whole 
mixture recorded.
A normal standard dilution curve is made by substituting the 
test plasma by various dilutions of normal plasma made with veronal 
buffer ranging from 1 in 10 (100$) to 1 in 640 (1.5$). The 
standard curve gives a straight line when the prothrombin concentration 
in percentage is plotted against the clotting times in seconds on 
double logarithmic paper.
In the original assay the authors used acetone-dried human 
brain, also they used human oxalated serum (or factor VII purified 
from human serum) in the test mixtures. Experiments mentioned in 
this work using this technique were carried out using a saline 
brain extract (appendix III, 13, I) instead of the acetone-dried 
preparation. Also combinations of human and bovine brain extracts 
with human and bovine prothrombin-free sera were used in testing 
the same samples of pooled plasmas in the same day, all other 
reagents being kept constant.
The concentration of prothrombin of the test plasma was read 
off from the standard dilution curve plotted using the same kind 
of brain thromboplastin and serum in the mixture, the result is
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expressed in percentage, designating the 100$ value to the 1/10 
dilution of the normal plasma.
B. Globulin fraction method of Douglas and Biggs, 1953
This is a method for the estimation of prothrombin in a system 
free of antithrombin.
To 1 ml of citrated plasma is added 9 mis distilled water, and 
the pH adjusted to 5 by the addition of 1$ acetic acid. The 
mixture is centrifuged and the supernatant discarded. The ppt. 
is washed twice with distilled water whose pH has previously been 
adjusted to 5. The ppt. is then dissolved in 2 mis of citrate 
saline (appendix I, 12) and the pH readjusted to 7 by adding 0.5$ 
Na^CO^ solution. The prothrombin content of this globulin fraction 
is estimated as follows
In a clotting tube is placed 0.3 ml amounts of the test 
solution, brain thromboplastin, and M/40 CaCl2 and the mixture 
incubated at 37°C. for 30 minutes, then 0.1 ml amounts are 
transferred into 0.4 ml amounts of fibrinogen solution previously 
pipetted in clotting tubes in the water bath, and the clotting 
times recorded. Two or three readings are taken for each 
mixture and the average calculated. The same procedure is made 
for the standard normal plasma, also for the citrated sera.
The results are expressed in terms of thrombin units as read from
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the thrombin-fibrinogen dilution curve, figure 1.
The prothrombin concentration of the test plasma is then 
expressed in percentage as compared with the standard plasma, 
using the following equation:-
Thrombin units of test mixture 
------------------------------  x 100
Thrombin units of the standard
C* Two-stage area method of Biggs and Douglas, 1953a
To a mixture of 0.4 ml citrated plasma and 0.4 ml brain extract 
at 37°C. is added 0.4 ml M/40 CaCl2 and a stop watch is started.
At 15, 30, 45, 60 seconds, and thereafter at one minute intervals 
0.1 ml samples are removed from this incubation mixture and added 
to 0.4 ml volumes of fibrinogen solution warmed to 37°C. in the 
water bath. The clotting times are recorded and the test continued 
until these exceed 3 minutes. Clotting usually occurs in the 
incubation mixture itself, the clot should then be removed by 
winding it on a wooden swab stick. The clotting times of the 
fibrinogen samples are converted into thrombin units as read from 
the thrombin-fibrinogen dilution curve, figure 1. A curve of 
thrombin generation and dissappearance can then be drawn on 
ordinary graph paper and the area enclosed under the curve measured 
either by counting the squares on the grg,ph paper or by weighing 
the cut-out area under the curve. The same procedure is carried
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out for the normal standard plasma and the test plasma. The 
area obtained with test plasma is expressed as a percentage of 
the normal plasma.
As this test system is affected by the antithrombin content 
of the plasma in the mixture, it is an essential prerequisite that 
the antithrombin content of both test and normal plasmas are of 
similar magnitude. The antithrombin content of the plasmas was 
therefore measured by the method of Douglas and Biggs (1953) as 
described in appendix IV, 11, A, or by the modified method of 
Astrup and Darling (I942d) described in appendix IV, 11, B.
Biggs and Douglas (1953a) have shown that variation in the 
potency of the brain thromboplastin does not affect the results.
This method was carried out using both the human brain 
preparation as well as brain preparations from other species, all 
other reagents being constant. The species of the brain extract 
utilised is mentioned with the results of each experiment.
13. Prothrombin consumption test
A. Method of Biggs and Macfarlane, 1957
The test serum is prepared by allowing the blood used for the 
estimation of the coagulation time by the Lee and "White method (1913) 
in ordinary glass tubes to stand for 50 minutes at 37°C. after
- 65 - (Appendix IV)
the coagulation time. The clots are then gently freed from the 
sides of the tubes with a wooden swab stick and the serum pooled 
in one tube after centrifugation at 1,500 r.p.m. for 5 minutes.
At exactly one hour after coagulation has occured a prothrombin 
consumption test is carried out, as follows:-
Four tubes are prepared in the water bath at 37°C., each 
containing 0.4 ml of fibrinogen solution. In another clotting 
tube in the water bath is delivered 0.2 ml test serum, 0.2 ml of 
brain thromboplastin, 0.2 ml saline, and immediately on the 
addition of 0.2 ml M/40 Ca01o a stop watch is started, the contents 
rapidly mixed and the tube replaced in the water bath. At exactly 
45 seconds after recalcification, 0.1 ml of the incubation mixture 
is transferred into one of the tubes containing fibrinogen and the 
clotting time recorded by another stop watch. At 90 seconds a 
further 0.1 ml of the incubation mixture is transferred onto 
another fibrinogen tube and its clotting time observed.
The whole procedure is repeated using test citrated plasma 
instead of the test serum. In this case, shortly after the 
recalcification the incubation mixture itself forms a clot which 
should be rapidly removed on a wooden applicator stick while 
carefully squeezing out all fluid trapped in it. The clotting 
times of subsamples at 45 and 90 seconds' intervals are recorded 
as previously. It should be noted that in original test the
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intervals for subsampling were 30 and 60 seconds with which it 
was sometimes difficult to subsample in case of plasma as by the 
time the clot was removed the 30 seconds' interval has elapsed. 
Using the slightly longer interval of 45 seconds was quite adequate. 
Calculation
Prothrombin consumption index = °.f Plasma x 100
(P.C.I.) mean clotting time of serum
This test suffers from the fact that low values represent the
normal, while high values are abnormal. The normal range for
human blood is from 0 to 40$. The normal serum time should be
more than 30 seconds.
B. Method of Douglas and Biggs. 1953
This method estimates the prothrombin content of the test 
plasma and serum by the globulin fraction technique described 
in appendix IV, 12, B.
After the preparation of the serum as in the method of Biggs 
and Macfarlane (1957) described above, at exactly one hour from 
the clotting of the blood the serum is citrated by adding one part 
of 3.8$ sodium citrate solution to four parts of serum, thus 
preventing further conversion or utilization of prothrombin into 
thrombin, and the preparation of the globulin fraction can then 
be done at leisure.
~ t ,. „ „ T thrombin units in serum 1nn
Calculation P.C.I.  ________— ------------ x 100
thrombin units in plasma
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14. Measurement of factor V 
Essentially the same method as described by Biggs and 
Macfarlane (1957) was used, testing the ability of the test plasma 
to correct the clotting time of plasma artificially made factor V 
deficient, as compared to the standard normal plasma. However, 
since Katz and Ducci (1957) have shown that various factors are 
affected when the exact amount of plasma (to be rendered factor V 
deficient) and the size of the container are not strictly adhered 
to as described by them, their method for the preparation of the 
factor V deficient plasma was used. The dilution of test plasma 
in the substrate factor V deficient plasma was also modified from 
that described by Biggs and Macfarlane (1957), designating the 
100$ value to the 1 in 10 dilution of the test or standard plasma. 
Preparation of factor V deficient plasma (Katz and Ducci, 1957) 
Five millilitres of human plasma (oxalated in the proportion 
of 9 parts blood to 1 part 1.85$ potassium oxalate solution) are 
placed in a test-tube measuring 13 x 100 mm. (or 55 mis oxalated 
plasma in a 50 ml conical flask). The tube is stood in a water 
bath at 37°C. for 24 hours exactly. Plasma samples thus treated 
which give clotting times around 30 seconds (by Quick's one—stage 
test) are then stored in the refrigerator at 4 C. in 5 ml amounts. 
The reactivity of the plasma is checked daily by Quick's one—stage
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test, the clotting time should be between 45 and 90 seconds. If 
it is less than 45” the plasma should be stored further, while if 
it is longer than 90" the plasma becomes unsuitable and should be 
discarded. Such prepared plasma was shown by the authors to 
behave similar to plasma stored at 4°C. for 15-25 days, giving 
good clots with no granulation. They also found that the different 
behaviour of this deficient plasma on the addition of normal plasma 
is not explained by changes in prothrombin or factor VII as their 
concentrations were normal in all these plasmas, and could only 
be related to changes in factor V concentrations.
Test procedure
Various dilutions of the normal plasma in the factor V 
deficient plasma are made by mixing 0.1 ml of the normal plasma 
with 0.9 ml of the deficient plasma to constitute the 100$ value 
for factor V. From this mixture 0.3 ml is transferred into a 
tube containing 0.3 ml deficient plasma to make a solution with 
50$ of factor V concentration, and after thorough mixing further 
double-folding dilutions are made in the deficient plasma to 
represent factor V concentrations of 25, 12.5, 6.2, 3.1, 1.5, and 
0$. Each of these dilutions is then tested by Quick's one-stage 
test in duplicate and the average clotting times noted and plotted 
against the factor V concentrations in percentage on double 
logarithmic paper when an approximate straight line is obtained.
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Dilutions of the test plasma in the deficient plasma 
corresponding to l/lO, 1/20, and 1/40 are made and tested as 
above. The factor V content of each dilution is read from the 
standard dilution curve and multiplied by the dilution factor, 
considering the l/lO dilution equivalent to 100$, and the average 
of the readings reported. If the concentration of factor V in 
the test plasma is much greater than that in the normal human 
plasma, further dilutions are made as required e.g. 1/80, so that 
their clotting times fall on the part of the curve between 100 and 
10$ which is the most exact part of the curve.
15. Measurement of factor VII 
A. By correction of phenindione plasma
Essentially the same procedure as that for factor V estimation 
described above, except for substituting phenindione human plasma 
instead of the stored plasma. The phenindione plasma was obtained 
from patients under anticoagulant therapy during the first few 
days only, at the time when the factor VII content is at a very 
low level, while prothrombin and factor X are very slightly 
reduced (Douglas, 1962). Plasmas having clotting times twice 
the control plasma are suitable. The ability of the test plasma 
to correct the factor VII deficiency is compared with that of the 
control by reading the test result from the control dilution curve.
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B* By correction of Seitz-filtered bovine plasma (method of 
Koller, Loeliger, and Duckert, 1951).
Preparation of the Seitz-filtered plasma: bovine blood oxalated
in the proportion of 9 parts blood to 1 part of M/lO sodium 
oxalate is spun and the plasma separated. The plasma is filtered 
at room temperature through an asbestos filter pad containing 20$ 
asbestos, then through another pad containing 30$ asbestos (appendix 
I, 35). The filtration speed is maintained at approximately one 
drop per second, so as to effect the proper separation of factor VII. 
The filtrate is collected in aliquots, and the prothrombin content 
of each estimated by the method of the same authors as described 
in appendix IV, 12, A. Batches of filtrate with prothrombin values 
above 15$ are suitable for use in this test.
Test procedure
0.1 ml of the test oxalated plasma (appendix III, 3) diluted 
1 in 10 in veronal buffer, is added to 0.1 ml of the Seitz-filtered 
bovine plasma and 0.1 ml of brain thromboplastin. After 20 
seconds, 0.1 ml M/40 CaCl2 is added and the clotting time recorded. 
Further dilutions of the test plasma in veronal buffer are made 
as required so that the clotting times can be read on the part of 
the standard dilution curve between 100 and 10$.
The standard dilution curve is made by testing dilutions of 
normal oxalated human plasma ranging from l/lO to 1/640 (equivalent 
to 100$ and 1.5$ respectively) and testing them as above. The
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average of the clotting times (made in duplicate) in seconds are
plotted against percentage concentrations of factor VII on double 
logarithmic paper, when an approximate straight line is ootained, 
designating the 100$ value to the l/lO dilution.
In the original authors' method human acetone-dried brain was 
used. In view of the fact that the use of human brain to measure
the factor VII content of plasmas from various animals gave
artifically fallacious results due to the species specificity of 
their interaction, the test was also carried out using brain extracts 
of other species prepared in the same was as the human.
It should also be noted that this method is sensitive to, and 
therefore a measure of, factor X in the test plasmas, since the 
Seitz-filtered plasma is virtually free from both factors VII and 
X.
16. Brain thromboplastin - factor V specificity 
The method used to investigate the species specificity of the 
brain thromboplastin - factor V interaction was a two-stage procedure 
in which the brain preparation was incubated at 37 C. with the 
adsorbed plasma diluted 1 in 5 in saline (appendix III, 4, A), 
together with M/40 CaGl^ solution, in equal amounts. At one 
minute intervals after recalcification, 0.1 ml amounts are 
transferred from the incubation mixture and added together with
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0.1 ml M/40 CaCl^ to 0.1 ml of the substrate and the clotting time 
recorded. The substrate was either fresh human plasma, fresh 
plasma from the species under investigation, or human plasma 
artificially rendered factor V deficient by storage (appendix IV, 14).
In some tests the adsorbed plasmas were substituted by the 
purified factor V prepared as described in appendix III, 9, and 
diluted so that the factor V concentration would be equivalent to 
that in adsorbed plasma diluted 1 in 5 in saline.
Brain preparations were made by Owren's method (appendix III, 13, 
and further diluted 1 in 2 or 1 in 4 in saline according to their 
potency.
The results of the mixtures containing the test plasma or 
factor V preparation were compared with those of mixtures containing 
the control human plasma or factor V preparation. Saline control 
mixtures were also included in which saline was substituted for 
the adsorbed plasma or the purified factor V.
17. Brain thromboplastin - factors VII and X specificity
Essentially the same procedure was used as for the brain 
thromboplastin - factor V specificity, except for substituting 
the human or test serum diluted 1 in 10 in saline for the adsorbed 
plasma or the purified factor V. Sometimes a purified factor H I  
preparation (appendix III, 10) was used instead of the serum.
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The substrate was either fresh human citrated plasma, fresh 
citrated plasma of the species under investigation, or human 
phenindione plasma. The results of the heterologous mixtures 
were compared to those of homologous mixtures. Saline control 
mixtures were also tested in which saline was used instead of the 
serum or factor VII preparation.
18. Measurement of factor X 
(method of Bachmann, Duckert, and Koller, 1958)
Reagents
1. Oxalated control and test plasma: 9 parts blood added to one 
part M/lO sodium oxalate and centrifuged at 2,500 r.p.m. for 5*.
2. Veronal buffer, (appendix I, 41).
3. M/40 CaCl^ solution, (appendix I, 10, A).
4. Cephalin: in the original authors* paper, crude cephalin 
prepared from human brain by ether extraction was used. In 
this work, Bell and Alton's acetone-insoluble chloroform- 
soluble cephalin extract of human brain was used (appendix III, 14). 
It was dissolved in veronal buffer so as to contain approximately
0.06 gm active material per cent. (Authors used cephalin 
suspension containing about 0.047 gm $).
5. Russell's viper venom — cephalin: (R.V.V.—cephalin) ii.V.V.
of a concentration of 1/200,000 in cephalin (appendix III, 17, B) 
was used. After thawing at 37°C., it is shaken vigorously to
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obtain a good suspension yielding maximum activity.
Seitz-filtered oxalated bovine plasma: (substrate) should be 
prepared very carefully since small amounts of Stuart-Prower 
factor (factor X) in it render the dilution curve very flat.
In a two litre original Seitz filter apparatus with 14 cm diameter, 
place two asbestos filter pads, the lower with 30$ asbestos, 
and the upper with 20$ asbestos (Sterimats, appendix I, 35).
About 1,500 mis oxalated bovine plasma are poured in the filter 
apparatus and filtration carried out at room temperature. The 
filtration speed is maintained at 1 drop per second by occasional 
increase of the air pressure. Speeds higher than 1-2 drops per 
second cause inefficient separation of the prothrombin from the 
Stuart-Prower factor and factor VII, and the yield will be poor.
The first 200 mis of the filtrate are discarded, then fractions 
of 50 mis each are collected and assayed for their prothrombin 
content by the method of Koller et al (1951) which if above 25$, 
the zero value of such suitable fractions is determined by the 
mixing of 0.1 ml filtered plasma fraction with 0.1 ml veronal 
buffer and 0.1 ml of R.V.V.-cephalin suspension. The mixture 
is stood for 30 seconds at 37°C. then 0.1 ml M/40 CaCl2 solution 
is added and the clotting time recorded. Each fraction wnich 
has a zero value more than 80-90 seconds is suitable for use as 
substrate for the test. Suitable fractions are distributed in
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small amounts sufficient for one assay and one dilution curve done 
in duplicate (usually 2.5 mis) and kept at -20°C.
Test procedure
The tubes containing the R.V.V.-cephalin reagent and the CaCl2 
solutions are placed in the water bath. In another two clotting 
tubes (duplicate) is delivered the following: 0.1 ml substrate
Seitz-filtered bovine plasma, 0.1 ml test plasma or serum diluted 
1/10 in veronal buffer, and 0.1 ml R.V.V.-cephalin solution.
After 30 seconds incubation at 37°C., 0.1 ml of M/40 CaCl2 solution 
is added and the clotting time recorded. The average of the two 
tubes is reported. Further dilutions of the test plasma or serum 
are tested similarly if required.
Construction of the normal dilution curve
Various dilutions of the normal plasma or serum in veronal 
buffer ranging from 1 in 10 (designated 100$) to 1 in 2560 (0.37$) 
are tested as above. A blank with veronal buffer instead of the 
plasma constitutes the 0$ value. Plotting the clotting times in 
seconds against the plasma concentration in percentage on double 
logarithmic paper gives a straight line from 100$ to 2$, but the
0.5$ concentration still gives significantly shorter clotting times 
than the zero value. This means that the adsorption of factor X 
by the asbestos is 100$. The authors recommend the 5-40$ zone 
of the dilution curve as the best part, yet that values between
- 76 - (Appendix IV)
50 and 100$ can be assayed with satisfactory accuracy.
Experiments in this work for the assay of factor X were 
carried out on plasma, both for the dilution curve and the test 
sample. On some occasions, however, serum was used instead, 
again both for the calibration curve and the test sample.
19. B.V.V.-cephalin clotting time of plasma 
To a clotting tube containing 0.1 ml of plasma is added 0.1 ml 
of R.V.V.-cephalin reagent (appendix III, 17, B) and left at 37°C. 
for 30 seconds. As 0.1 ml li/40 CaCl^ solution is blown into the 
tube a stop watch is started and the clotting time of the mixture 
recorded. Various concentrations of R.V.V. in cephalin were used 
and are mentioned in the appropriate tables.
20. Thromboplastin generation test 
(method of Biggs and Douglas, 1953b)
Reagents
1. Control and test adsorbed plasmas: prepared as described in 
appendix III, 4, A. For use they were diluted 1 in 5 in saline.
2. Control and test sera: (appendix III, 5) They were diluted
1 in 10 with saline and stood at room temperature for about one 
hour before use.
3. Platelet suspension: appendix III, 15.
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4. High-spun plasma: ap|>endix III, 2.
5. M/40 CaCl2 : appendix I, 10, A.
Procedure
The CaCl2 solution is kept in the water bath at 37°C. The 
incubation mixture is pipetted into a clean clotting tube in the 
water bath in the following order:- 0.3 ml adsorbed plasma diluted 
1 in 5, 0.3 ml serum diluted 1 in 10, 0.3 ml platelet suspension, 
and 0.3 ml M/40 CaCl2 solution. As the latter is added a stop 
watch is started and at one minute intervals up to and including 
6 minutes, 0.1 ml amounts of the incubation mixture are removed 
and together with 0.1 ml M/40 CaCl^ solution are simultaneously- 
added to 0.1 ml amounts of high-spun plasma previously pipetted 
out in clotting tubes placed in the water bath. The clotting 
times of the substrate tubes are recorded using extra stop watches.
The incubation mixture sometimes forms a clot which then has 
to be removed by winding it on a wooden swab stick.
The test is repeated with various alternative combinations of 
control and test adsorbed plasmas with the control and test sera 
in the incubation mixture.
Modifications
These were made by substituting some reagents with others as 
follows:-
a. Platelet suspension: was sometimes substituted by crude human
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cephalin (appendix III, 14), bovine platelets, horse platelets, 
rabbit platelets, or chicken thrombocyte suspension (appendix 
III, A, B, and C).
b. Adsorbed plasma: substituted by purified A.H.G. (appendix III,
11) together with purified factor V (appendix III, 9).
c. High-spun substrate plasma: substituted by tne homologous
plasma, namely chicken, bovine, equine, or rabbit high-spun 
plasmas, to test for substrate reactivity.
d. Correction of haemophilic plasma: various dilutions of the
adsorbed normal or test plasma made in adsorbed haemophilic 
plasma were tested to detect the ability of the test plasma to 
correct the deficiency in the haemophilic plasma as compared 
with that of the normal plasma.
e. Correction of Christmas serum: various dilutions of normal 
and test sera in Christmas serum were substituted for the whole 
serum usually used, to test their ability to correct Christmas 
serum deficiency.
The above modifications whether applied singly or in combination
are mentioned where appropriate.
20, A. Intrinsic thromboplastin dilution curve 
(Biggs and Macfarlane, 1957)
An ordinary thromboplastin generation test is set up with
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completely normal reagents. When the minimum substrate clotting 
time has been reached, the tube containing the incubation mixture 
is placed at the temperature of melting ice, and double-folding 
dilutions of this mixture are made in saline previously cooled in 
the ice bath. 0.1 ml amounts of each dilution are then transferred 
together with 0.1 ml of M/40 CaCl^ onto 0.1 ml high-spun plasma at 
37°C. as performed in an ordinary T.G.T. and the clotting times 
recorded. The clotting times in seconds are plotted against the 
intrinsic thromboplastin concentration in percentage on double 
logarithmic paper, designating the value of 100$ to the dilution 
which clots the substrate in 10 seconds. Using the dilution curve 
thus obtained (figure 2) all the results of the T.G.T. were converte< 
from clotting times in seconds into per cent values of active 
thromboplastin. It should be noted that in the construction of 
the chicken intrinsic thromboplastin dilution curve, since the most 
potent incubation mixture using homologous chicken reagents was 
still much weaker than any human mixture, the 100$ value was 
ascribed to the dilution which clotted the substrate in 20 seconds.
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HUMAN ACTIVE THROMBOPLASTIN DILUTION CURVE.
A » ■O with Human Platelets.200
Cephalin.
100
0.1 0.18 0.37 0.75 6 251.5 12.5 1003 50
Concentration of Thromboplastin.
Figure 2. Human intrinsic thromboplastin dilution curve.
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21. Measurement of anti-haemophilic globulin 
(method of Pitney, 1956)
This method is based on the thromboplastin generation test, 
estimating the degree of correction of adsorbed haemophilic plasma 
by the test adsorbed plasma as compared to the control adsorbed 
plasma assayed in various dilutions to construct a calibration curve. 
Reagents
1. Haemophilic plasma: is obtained from a severely haemophilic
patient. The venous blood is obtained with a siliconed syringe 
and is citrated in a siliconed centrifuge tube. The plasma is 
separated after centrifuging at 3,000 r.p.m. for 10 minutes, 
then distributed in about 1 ml amounts and stored at -20°C.
For use, an aliquot is thawed, tested by Quick's one-stage test 
which should give a normal result, thus ensuring a normal content 
of factor V. The plasma is then adsorbed with alumina and the 
supernatant tested again by Quick's one—stage test which should 
be more than 60 seconds. The supernatant is then diluted one 
in five with veronal buffer and kept at 4°C. till use.
2. Control a-nH test plasmas: are collected at the same time, the 
plasma separated as above, adsorbed with alumina, and dilutions 
made with veronal buffer. For the control plasma six dilutions 
are made ranging from 100$ to 1$ (i.e. 1/20 designated lOQffo, 1/40,
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l/80, 1/200, 1/400, and 1/2000). The test plasma after its
adsorption is prepared in three dilutions depending on the
probable A.H.G. content. For plasma suspected of having a
normal A.H.G. content the dilutions 1/20, 1/40, and 1/80 are
suitable; while plasmas with low A.H.G. concentrations are
tested at 1/5, l/lO, and 1/20; whereas plasmas with high A.H.G.
content are tested at 1/80, 1/200, and 1/400. This is to
ensure that the substrate clotting times of such dilutions
would fall on the most accurate part of the control dilution
o
curve. The various dilutions are kept at 4 C. till ready for 
use which should be as soon as possible.
3. Normal serum: normal venous blood is allowed to clot and
kept at 37°C. for 24 hours, the serum is then separated and 
stored at -20°C. until required. On the day before the test 
1 ml of the serum is thawed, diluted 1 in 10 with veronal 
buffer and left at 4°C. overnight.
4. Platelet suspension: appendix III, 15, A.
5. High-spun plasma: appendix III, 2.
6. Veronal buffer : appendix I, 41.
7. M/40 CaCl^ solution: appendix I, 10, A.
Preparation of the standard dilution curve
Into a clotting tube placed in the water bath are pipetted
0.1 ml volumes of adsorbed haemophilic plasma (diluted 1/5),
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adsorbed normal plasma (each dilution at a time), normal serum 
(diluted l/lO), and platelet suspension. After the mixture has 
reached the temperature of the water bath, 0.1 ml of previously 
warmed M/40 CaCl^ solution is added and a stop watch started.
Exactly 4 minutes after the addition of the calcium chloride,
0.1 ml of the incubation mixture together with 0.1 ml M/40 CaC^ 
are transferred to a clotting tube containing 0.1 ml of substrate 
normal high-spun plasma and its clotting time recorded by another 
stop watch.
In practice it is possible to set four tubes for the incubation 
mixtures, each containing a different dilution of the standard plasma 
and recalcifying them at one minute intervals, thus the subsampling 
is also carried out at the end of the four minutes again in turn 
at one minute intervals, using four stop watches to record the 
clotting times of the substrates. Thus the six dilutions of the 
normal plasma and the saline blank required for the construction 
of the standard dilution curve are tested in about 15 minutes.
The thromboplastin times recorded are plotted on ordinary graph 
paper against the plasma dilution to construct a curve.
Assay of test plasma A.H.Gr. content
Three suitable dilutions of the adsorbed test plasma are used 
in place of the normal plasma m  the reacting incubation mixture, 
p-nri the 4 minute thromboplastin times are recorded. The amount
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of A.H.G. in each dilution is read off from the dilution curve.
Calculation: A.H.G. concentration in test plasma =
1/20 (dilution of control designated 100J6)
 --------------------   — x percentage reading.
dilution of test plasma
The mean A.H.G. concentration of the test plasma is obtained 
by averaging the results obtained for the three dilutions tested.
22. Measurement of Christmas factor 
(based on the method of Pitney, 1956)
This method is essentially the same as that for the measurement 
of A.H.G. except for the substitution of Christmas serum and control 
and test sera instead of the haemophilic plasma and test and control 
plasmas, while normal adsorbed plasma is added to the mixture to 
supply the necessary amounts of A.H.G. and factor V. Thus the 
method was adapted to measure the degree of correction of Christmas 
serum by the test serum as compared to the control serum.
Reagents
1. Christmas serum: whole blood is obtained from a patient with
a severe deficiency of Christmas factor, and allowed to clot at 
37°C. for 4 hours, the serum is then separated by centrifugation 
ft-nH distributed in 1 ml amounts in lusteroid tubes and kept at 
-20°C. till required. On the day before the test, 1 ml is
thawed and diluted 1 in 10 in veronal buffer and kept in the 
refrigerator overnight.
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2. Control and test sera: whole blood is obtained and allowed
o
to clot and stand at 37 C. for 4 hours then the serum is 
separated. The control serum is diluted in diluted in veronal 
buffer ranging from l/20 (designated 1007°) to 1/1280 (1.5$).
The test serum is also diluted from 1/5 to 1/320, sera suspected 
of having a low Christmas factor activity are tested at three 
of the low dilutions, while those with high activity are tested 
at the higher dilutions.
3. Adsorbed normal plasma: prepared as described in appendix III,
4, A, except for being diluted 1 in 5 in veronal buffer instead 
of in saline.
4. Platelet suspension: appendix III, 15, A.
5. High-spun plasma : appendix III, 2.
6. Veronal buffer : appendix I, 41.
7. M/40 CaC^ solution: appendix I, 10, A.
Preparation of the standard dilution curve
Into four clotting tubes placed in the water bath is pipetted
0.1 ml volumes of adsorbed normal plasma (diluted l/5), Christmas 
serum (diluted 1/10), control or test serum (various dilutions), 
and of platelet suspension. As 0.1 ml of M/40 CaCl^ solution is 
added to the first tube a stop watch is started and at one qainute 
intervals further 0.1 ml amounts of calcium chloride solution are 
added consecutively to the other three tubes. At exactly four
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minutes after the addition of the calcium chloride solution to 
each tube, 0.1 ml of each incubation mixture is removed and 
together with 0.1 ml M/40 CaCl2 is delivered into a clotting tube 
containing 0.1 ml high-spun plasma previously distributed and 
warmed to 37°C. and the clotting time recorded. This procedure 
is repeated till all the dilutions have been tested.
The thromboplastin times recorded are plotted on ordinary 
graph paper against the serum dilutions to construct the standard 
dilution curve.
Assay of test serum Christmas factor content
The same procedure is carried out using various dilutions of 
the test serum instead of those of the control serum in the 
incubation mixtures, and the four minute thromboplastin times 
recorded. The concentration of Christmas factor in each dilution 
is read off from the dilution curve.
Calculation: Christmas factor concentration in test serum =
1/20 (dilution of lOQg control) x peroentage reading. 
dilution of test serum
The mean Christmas factor concentration of the test serum is 
obtained by averaging the results obtained at the various dilutions 
tested.
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23. Demonstration of inhibitors of human intrinsic thromboplastin 
in thromboplastin generation mixtures
(Biggs and Macfarlane, 1957)
The presence of an inhibitor of human intrinsic thromboplastin 
in a plasma or serum sample from various animal species was 
investigated by testing mixtures of the test sample with normal 
human reagents, performing a thromboplastin generation test on an 
aliquot of the mixture, and incubating the other aliquot at 37°C. 
for two hours at the end of which the mixture is again tested in 
a T.G.T. Comparison of the substrate clotting times reveals any 
inhibitory effect that might be present.
Reagents
1. Control and test adsorbed plasmas: prepared as described in
appendix III, 4, A, and diluted 1 in 5 in saline.
2. Control and test sera: appendix III, 5, diluted 1 in 10.
3. Cephalin 1/100 : appendix III, 14. This was used
instead of the human platelet suspension.
4. High-spun plasma : appendix III, 2.
5. M/40 CaCl2 solution : appendix I, 10, A.
Procedure
Mixtures are made containing equal parts of human adsorbed 
plasma (or human serum) and the test adsorbed plasma (or test
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serum), and tested in the following incubation mixture immediately 
after preparation and again after two hours incubation at 37°C.
For a control, saline is substituted for the test preparation. 
Incubation mixture: 0.1 ml human ads.pl. (1/5),
0.1 ml test ads.pl. (l/5),
0.2 ml human normal serum (l/lO),
0.2 ml cephalin (l/lOO),
0.2 ml M/40 CaCl2.
Immediately on recalcification a stop watch is started and at one 
minute intervals 0.1 ml amounts are transferred together with 0.1 
ml amounts of M/40 CaCl2 solution onto 0.1 ml volumes of the human 
substrate high-spun plasma previously distributed and warmed to 
37°C. and the clotting times recorded.
The incubation mixture for testing the inhibitory activity of 
serum would be as follows:-
0.2 ml human normal ads.pl. (l/5),
0.1 ml human normal serum (1/10),
0.1 ml test serum (1/10),
0.2 ml cephalin (l/lOO),
0.2 ml M/40 CaCl2.
Effect of plasma defibrination: was investigated by heating the
test adsorbed plasma for 15' at 56°C., centrifuging and diluting 
the supernatant 1 in 5 in saline before making the mixtures.
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24. Measurement of Hageman factor
!• Method of Ratnoff and Rosenblum, 1958
This method measures the degree of shortening in clotting times 
of normal platelet-deficient intact plasma on the addition of 
maximally activated plasma, whether control or test, after 
recalcification. The degree of shortening in the clotting times 
is indicative of the Hageman factor content of the plasma added. 
Materials
1. Normal platelet-deficient citrated intact plasma: (substrate). 
Normal blood is collected with siliconed needles and syringes 
and citrated 1 : 10 in siliconed graduated centrifuge tubes, 
then centrifuged at 2,000 r.p.m. for 15 minutes at 4°C. The 
plasma is removed and high-spun at 27,000 r.p.m. for 10 minutes 
at 4°C. and the clear supernatant removed and kept in lusteroid 
tubes at -20°C. till required. It keeps well for up to two months.
2. Test and control plasmas: the blood is collected with siliconed
precautions and oxalated 1 in 10, centrifuged at 2,000 r.p.m. 
for 15 minutes and the supernatant plasma adsorbed with washed 
BaS04 (appendix I, 3, B) using 100 mg/ml, in siliconed lusteroid 
tubes. The mixture is stirred thoroughly with a siliconed glass 
rod and incubated at room temperature for 10 minutes, then
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centrifuged. The supernatant plasma is incubated at 56°C. for 
30 minutes and centrifuged again.
Such treated plasmas are rendered deficient in all known 
coagulation factors except plasma thromboplastin antecedent and 
Hageman factor. It is incoagulable, and did not alter the 
recalcification time of normal intact plasma in siliconed tubes.
But when the normal plasma preparation is treated with glass, it 
accelerated the clotting time of the normal intact plasma.
Glass activation
1.5 ml amounts of the control and test plasma preparations 
are shaken by the hand with 300 mg of glass powder (appendix I, 17) 
in pyrex tubes for 10 minutes at room temperature, then immediately 
put in ice-water and used within few minutes of preparation. 
Procedure
The test is carried out in duplicate, at room temperature, and 
in siliconed clotting tubes into each of which is delivered 0.1 ml 
of normal platelet-deficient citrated intact plasma, 0.1 ml of the 
test or control plasma preparation before the glass activation, 
and as 0.1 ml of M/20 CaCl2 is added a stop watch is started and 
the clotting time of the mixture recorded. Each tube is tilted 
once per minute, the end point being a firm clot. The longer 
clotting time of each pair of duplicate tubes is reported, this 
is usually within 2 minutes of each other when the clotting time
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is 40 minutes or less. The same procedure is carried out at the 
same time for the test and control plasma preparations after glass 
activation, the results of which are indicative of the Hageman 
factor activity as compared to the results of the same preparations 
before glass activation.
At the time this method was published the authors believed that 
the shortening of the clotting time was due to the combined 
activities of Hageman factor and P.T.A. However, later this 
concept was revised, as it was found that the test is mainly 
sensitive to P.T.A. activity, (Ratnoff, 1962).
II. By correction of Hageman factor deficient plasma
This method measures the activity of Hageman factor in plasma 
by its ability to correct the recalcification time of Hageman factor 
deficient plasma, as compared to the ability of the normal plasma 
to do so.
Reagents
1. Hageman factor deficient plasma: plasma from a known patient 
with Hageman factor deficiency was obtained through the kindness 
of Dr.W.J.Jenkins, The National Blood Transfusion Service, 
Brentwood, Essex. The plasma was distributed in 3 ml amounts 
in lusteroid tubes and stored at — 20 C. till required.
2. Test and control plasmas: using siliconed glassware throughout,
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whole blood was obtained over trisodium citrate in the proportion 
of 9 to 1, and mixed by inversion while covering the tubes with 
paxafilm covers. The plasma was separated after centrifuging 
for 15 minutes at 2,000 r.p.m. and kept at 4°C. till used.
3. J^ /lO CaCl^ solution ; appendix I, 10, A.
4. Cephalin 0.6 gn$ (appendix III, 14) diluted 1 in 10 in veronal 
buffer. It was added to the test mixtures to obviate the effect 
of the varying concentrations of phospholipids and platelets in 
the different samples of plasma used.
5. Ballotini glass beads.
Glass activation
Maximal activation of both test and control plasmas was carried
out before testing them. This was achieved by contact with glass,
shaking by the hand 1 ml of plasma with 1 gm of ballotini glass 
beads in a bijou bottle for 10 minutes at room tenqperature, then 
immediately put in an ice-water bath and tested as soon as possible. 
Construction of the standard dilution curve
Immediately after glass activation, 0.1 ml of the normal plasma 
sample is mixed with 0.4 ml Hageman plasma (this 1 in 5 dilution 
was designated the 100^ value for Hageman factor), then 0.1 ml from 
this mixture is further diluted in 0.2 ml Hageman plasma previously 
distributed in siliconed clotting tubes placed in the ice—water 
bath. This three-fold dilution is repeated three more times, thus
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giving a range of dilutions from 1 in 5 (100%) to 1 in 405 (1.2%). 
Two of these tubes at a time are transferred to a water bath at 
37°C. and after few minutes 0.05 ml of cephalin solution together 
with 0.05 ml of M/10 CaCl2 solution are added and a stop watch 
started and the clotting times recorded. The clotting times in 
seconds are plotted on double logarithmic paper against the 
calculated percentage of Hageman factor, the 1 in 5 dilution of 
the control plasma being designated the 100% value.
Assay of test plasma Hageman factor content
This is done in the same way as for the control plasma, using 
the most suitable three dilutions of the maximally activated plasma 
depending on a pilot test run. The amount of Hageman factor in 
each dilution is directly read from the standard dilution curve. 
Calculation: concentration of Hageman factor in test plasma =
l/5 (dilution of control designated 100%)
 1...    — ---   x percentage reading
dilution of test sample 
The mean Hageman factor concentration of the test plasma is 
obtained by averaging the results obtained for the various dilutions 
tested.
25. Measurement of the esteratic activity of thrombins 
(method of Sherry and Troll, 1954)
This method demonstrates the esteratic activity of thrombin, 
utilizing TAMe (p-Toluene sulphonyl-L-arginine methyl ester) as
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substrate. Such activity is followed by the liberation of 
carboxyl groups which are split at the ester link, the activity 
can thus be measured by titrating the liberated carboxyl groups. 
Reagents
appendix I, 37. 
appendix I, 39. 
appendix I, 15. 
appendix I, 24. 
appendix I, 34, B.
1. TAMe substrate, 0.2 molar solution
2. Tris buffer, 0.5 molar, pH 9
3. Formaldehyde, 37%, pH 8
4. Phenol red indicator, 0.01%
5. Sodium hydroxide, N/20
6. Thrombin solution under test.
Method
To 0.2 ml TAMe solution is added 0.2 ml thrombin solution 
containing about 1-10 units (or other test solution), then 0.6 ml 
of Tris buffer is added and the mixture shaken and incubated for 
30 minutes exactly at 37°C., after which time 1 ml of 37% solution 
of formaldehyde is added to stop further digestion of TAMe.
A blank is prepared as above except for adding the formaldehyde 
solution at zero time before the addition of the thrombin solution. 
Titration
To each of the above tubes, after completion, is added 0.2 ml 
phenol red indicator, and the solution is titrated against 0.05 N 
standard sodium hydroxide using a syringe type microburette 
(appendix II, 9).
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A unit of enzymatic activity (TAMe unit) is defined as that 
amount of thrombin which will release 1 |jM of acid from TAMe in 
10 minutes under the conditions of the test. This unit has been 
so selected as to be approximately comparable in size to the N.I.H. 
clotting unit.
To calculate the arbitrarily defined units, the alkali consumed 
by the blank is subtracted from the amount consumed by the test, 
and converted to micromoles (pM) of acid liberated, then divided
by 3 to give pM/lO minutes, i.e.
• x • ^ i x x ix. (Test - Blank) x 50,000TAMe units in 0.2 e L test solution = ------------------ -----
1,000 x 3
( T - B ) x 50 
3
* X K X X X X * X X X X X * X -X X  » X X « *  X * * *
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CONCENTRATION OF COAGULATION FACTORS 
IN THE CONTROL HUMAN PLASMA USED AS STANDARD 
The plasma used as reference control for all the quantitative 
assays was from the same individual (the author) throughout as to 
maintain a conceivably constant concentration of the various blood 
coagulation factors compared to which the concentration of animal 
coagulation factors were expressed in terms of percentages.
The control plasma itself was assayed against human plasma 
pooled from ten normal individuals to ascertain the exact levels 
of its coagulation factors as shown in table i. The methods used 
for these assays were as follows
Factor V : correction of factor V deficient plasma (appendix IV, 14).
Factor VII : correction of phenindione plasma (appendix IV, 15, A).
Factor VIII: correction of haemophilic plasma by the method of
For qualitative tests, pooled animal test samples were compared 
with control blood collected from three normal human subjects, the 
plasmas being pooled after centrifugation
Pitney, 1956, (appendix IV, 21).
Factor IX : correction of Christmas serum (appendix IV, 22).
Factor X : correction of Seitz-filtered bovine plasma by the
method of Bachmann et al, 1958, (appendix IV, 18).
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Table i. The concentration of coagulation factors 
in the control human plasma
Plasma F V F VII F VIII F IX F X
dilution Clotting times (seconds)
P O O L E D  H U M A N P L A S M A
1/10 20 23 — —— 24|
1/20 26 31 10 10 32!
1/40 34 33 12 13 0
0 Ml-
*
1/80 40 37 15 17 43
1/160 49i 39 21 22 61*
1/320 53 40 49 40 73
1/640 55 41 65 60 83!
1/1280 58 44 80 72 96!
C O N T R O L  P L A S M A
1/10 20 24 — —
25
1/20 25! 31 si 9
32
1/40 33 33 10*
11 39
1/80 — — 14
13 -
1/160 — — 18
— — —
Concentration 105 $ 90 fo 151 1°
200 # 91 Jt
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Table ii. Thrombin-fibrinogen dilution curves 
The reference thrombin-fibrinogen dilution curve (figure 1) 
was drawn from the results obtained for the first experiment.
Later batches of thrombin or fibrinogen preparations were tested 
against stock standardised fibrinogen or thrombin solutions and 
only reagents giving results conforming to the original curve were 
released for use in later experiments. In experiments 2 and 4 
the solution under test was fibrinogen, while in experiments 3 and 
5 thrombin was the solution under test. These experiments are 
cited as examples of the several batches that were similarly tested 
as described in appendix IV, 7.
Concentration of thrombin (nominal units/ml)
50 40 30 25 20 15 124
1 10
8 6i 5 4 3 3.11 2 1.55
Clotting times of fibrinogen solutions (seconds)
Expt.l 4 5i 6 — 8 11 — 14.4 19 — 344 35.2 40 — 64 —
Expt.2 5 7 12 21 36 75
Expt.3 4± 7 13 21 38 74
Expt.4 4 \ 7 13 22 374 69
Expt.5 4* 7i 12 2l£ 39 76
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R E S U L T S  O F  E X P E R I M E N T S  
O N  F O W L  B L O O D
All the following data were obtained 
from experiments carried out on blood samples 
obtained from chicken of the Light Sussex 
strain, using pooled plasma or serum samples 
from at least three animals for each experiment 
to obviate as much as possible any individual 
variations from affecting the final levels 
of the various coagulation factors.
Blood samples were obtained fresh on the 
day of the test concerned as described in 
appendix II, 1, ii.
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Table 1. Chicken plasma fibrinogen estimation 
(micro-Kjeldahl method of Cullen and van Slyke, 1920, appendix IV,2,1) 
Experiment 1
This will be described in detail as an example for the calculation.
Blank titration (B) = 14 mis.
Test titration (T) = 12.1 mis.
Standard titration (S) = 9.5 mis.
Conversion factor = AP.-* --*28 x 6,25 = 1.25
A
a^l_culaction for standard:
(14 - 9.5) x 1.25 = 5.62 mg protein/ 5 mis standard solution.
Since this should have been 6.25 mg (equivalent to 1 mg N/ 5 mis)
6 25we have to correct for a recovery factor which equals — - = 1.1
5.62
Calculation for tests.
mg fibrinogen/ ml citrated plasma = ( B — T ) x 1.25
= (14 -12.l)x 1.25 
= 2.375
mg fibrinogen/100 mis plasma = 237.5
Corrjjction_f^r^r^covery: 237.5 x 1.1 = 261.25
Correction for plasma rn this example
the hematocrit values for the individual blood samples were 
estimated and the supernatant plasma volumes read off accurately, 
giving an average of 8 mis plasma from each 10 mis citrated blood.
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Since the plasma contains virtually all the citrate added, i.e. 1 ml, 
this 8 mis actually contains 7 mis of absolute plasma. Therefore
O
the result should be multiplied by the factor as follows
8 7 
Plasma fibrinogen = 261.25 x -y- = 298.5 mg/100 mis absolute plasma.
Table 1 (ctd.). Chicken plasma fibrinogen content
mg/100 mis citrated plasma mg/100 mis absolute plasma
Experiment 1 261.25 298.5
Experiment 2 200.70 250.8
Experiment 3 222.59 261.8
Experiment 4 209.10 246.0
Average 223.41 264.0
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Table 2. Chicken plasma fibrinogen estimation 
(Stirland's turbidimetric method, 1956, appendix IV, 2, III)
mgs fibrinogen/100 mis plasma
Expt. 1 130
Expt. 2 100
Expt. 3 25.7
Expt. 4 100
Plasma used in experiment 3 was also estimated by the micro- 
kjeldahl method which gave a fibrinogen concentration of 172.3 mg 
per 100 mis of plasma. In view of this gross discrepancy, 
Stirland’s method was found unsuitable for the estimation of 
chicken plasma fibrinogen which may have different precipitation 
characteristics.
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Table 3. Thrombin-fibrinogen reaction of the plasma
(method described in appendix IV, 8 and 9)
Substrate
Plasma
Mixture
Thrombin topical (P.D.& Co.)in units/ml
50 25 12.5 6.25 3.1 1.55
Clotting times in seconds (at 37UC.)
0.2 ml Chicken pi. 
0.2 ml Saline 
0.2 ml Thrombin
90
115
125
180 + 
180 + 
180 +
180 + 
180 + 
180 +
180 + 
180 + 
180 +
180 + 
180 + 
180 +
180 + 
180 + 
180 +
0.2 ml Human pi. 
0.2 ml Saline 
0.2 ml Thrombin
5
6 
6
6
6
6
- ■y t -
io
9
13
16
15
22
28
24
33 -
58
50
0.2 ml Chicken pi. 
0.1 ml Saline 
0.1 ml M/40 CaCl 
0.2 ml Thrombin
40 
42
41
38
41
42
42 
44
43
55
60
58
90
75
80
150
120
135
0.2 ml Human pi. 
0.1 ml Saline 
0.1 ml M/40 CaCl 
0.2 ml Thrombin
3
3
3
4
->2
4
5
54
64
8
13
12
164
18
18
31
34
35
0.2 ml Chicken pi. 
0.1 ml Pyrocatechol 
0.1 ml M/40 CaCl2 
0.2 ml Thrombin
11
13
11
13
15
13i
15 
18
16
25
30
29
64
58
60
132
97
130
0.2 ml Human pi.
0.1 ml Pyrocatechol 
0.1 ml M/40 CaCl 
0.2 ml Thrombin
2
2
2
3
3
3
4
4
4
6
9
8
11
12
12
19
20 
20
0.2 ml Chicken pi. 
0.1 ml Toluidine bl 
0.1 ml W/40 CaCl 
0.2 ml Thrombin
49
ue47
46
50
48
494
52
50
51
67
65
644
86
87
86
143
139
141
0.2 ml Human pi. 
0.1 ml Tol. blue 
0.1 ml M/40 CaCl2 
0.2 ml Thrombin
3
3
3
3
3-1-
3
5
5
5
9
10
10
16
164
16
32
33 
32
M  <vkt-iup times in seconds lax
0.2 ml Chicken pi. 
0.1 ml Saline 
0.1 ml M/40 CaCl2 
0.2 ml Thrombin
45 41 44 60 85 137
Human control pi.j 3' 4 5 10 16
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THROMBIN -  FIBRINOGEN REACTION OF PLASMA.
180 H
160-
140-
120-
100-
c
E
^  8 0 -
O)c
. /  o
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u  6 0 -
-cr'
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___ O'
2 0 - • ao
12.5 6.2
Thrombin in Units per ml.
Figure 3. Thrombin-fibrinogen reaction of chicken plasma.
Curve a •• human plasma + saline•
Curve al
•« human plasma + CaCl2 + saline.
Curve a2 : human plasma + CaCl2 +
toluidine blue.
Curve a
3
• human plasma + CaCl.2 +
pyrocatechol.
Curve b • chicken plasma + saline,»
Curve bi
•• chicken plasma + CaCl2 + saline.
Curve b2 •
chicken plasma + CaCl2 + toluidine blue.
Curve
b3
•
• chicken plasma + CaCl2 + pyrocatechol.
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Table 4. Antithrombin assay in chicken plasma 
(modified method of Astrup and Barling, 1942d, appendix IV, 11, B) 
Experiment 1
Mixture A B C D
Saline ml. 0.3 0.2 0.15 0.1 0.0
Plasma (dil.l/5) ml. 0.0 0.1 0.15 0.2 0.3
Thrombin (30 U/ml)ml. 1 1 1 1 1
Clotting times 
of fibrinogen Ck. 14 15 16 17 20
in seconds* Hm. 14 15 16 18 20
T/T
Ck. 1 0.93 0.87 0.82 0.70
o n Hn. 1 0.93 0.87 0.77 0.70
Corrected Ck. 1 0.91 0.87 0.82 0.72
T /T o' n Hn. 1 0.90 0.85 0.80 0.70
n values in ml. 0 0.02 0.03 0.04 0.06
* Mean of duplicate estimations.
Calc^ilation: is described in detail as an example for later experiments, 
The concentration of antithrombin in chicken plasma in mixture 
A according to the equation that antithrombin concentration equals
30- ( 1 - 0.91) = 135 units.. ( 1 - T /T ) would therefore be
n o' n 0.02
Similarly mixture B was found to contain 130 units, while mixtures 
C and D contained 135 and 140 units respectively. The average of 
the four mixtures was 135 units.
The antithrombin concentration in human mixture A was 150 units, 
while mixtures B, C, and D all had values of 150 units, with an 
average of 150 units.
. 135 x 100
Therefore, chicken plasma antithrombin = - wnicn
150
equals 90^ of human plasma antithrombin content.
This experiment is illustrated in figure 4 from which the
corrected T /T values were obtained, 
o n
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ANTITHROMBIN ASSAY.
Modified method of Astrup & Darling, 1942.
1.0
0.8-
0.6-
0.4- Chicken Plasma.
• Human Plasma.
0.2-
0 0.1 0.2 0.3
_____________________Plasma Concentration________________
Figure 4. Antithrombin assay in chicken plasma.
Curve A * values obtained with human plasma, experiment 1, table 4. 
Curve B : values obtained with chicken plasma, experiment 1, table 4.
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Table 5. Antithrombin assay in chicken plasma 
Experiment 2
A B C D
Clotting times Ck. 13 15 18 20 23
of fibrinogen Hn. 13 14i 17 19 22
Computed conc. Ck. 240 240 240 235
of antithrombin Hn. 225 220 217 215
Experiment 3
Clotting times Ck. 13 14 16 19 24
of fibrinogen Hn. 13 14 15
H
n 
00 
1—1 23
Computed conc. Ck. 225 230 232 230
of antithrombin Hn. 195 200 195 200
Table 6. Average antithrombin concentration of chicken plasmas
Experiment
Chicken plasma antithrombin concentration
in units in per cent of human antithrombin
1 135 90 fo
2 238 108
3 229 116 <fo
Average 200.6 104.6 fo
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Table 7. Species specificity of the thrombin-fibrinogen reaction
(method described in appendix IV, 10)
Substrate
Thrombin solution
Human Chicken Bovine(50 U/ml)
Clotting times (seconds)*
0.4 ml human fibrinogen 
0.1 ml saline -?2 8 ■>2
0.4 ml chicken fibrinogen 
0.1 ml saline
21 26 27
0.4 ml human fibrinogen 
0.1 ml pyrocatechol Ifo 4 6 3
0.4 ml chicken fibrinogen 
0.1 ml pyrocatechol Ifo 15 13 12
* Average of two estimations.
Table 8. Thrombin clotting times of chicken plasma 
0.1 ml amounts of thrombin solution (P.D.& Co.) containing 
50 units/ml were added to 0.4 ml of the plasma mixture and the 
clotting times recorded. The plasma was heated at 56 C. for 15 
minutes to defibrinate it, then it was spun to get rid of the 
precipitate, and the supernatant tested as to its inhibitory 
effect when added to normal untreated human plasma.
Hum.PI. + Ck.Pl. Hum.PI. + Heated Ck.Pl. Heated Ck.Pl. Hum. PI. Ck.Pl.
37” 19" 180 + 4" 77"
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Table 9. Quick1 s one-stage prothrombin time
(method described in appendix IV, 6)
Test plasma
Human brain j Chicken brain
Clotting times (seconds)
217 16
Chicken plasma 435 14
146 14
15 132
Human plasma 13 172
14 138
24 29
Human pi. + chicken pi, 22 28
23 24
20 205
Human pi. + saline 19 160
19 150
355 22
Chicken pi. + saline 318 24
162 15
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Table 10. Factor V - brain thromboplastin species specificity
(method described in appendix IV, 16)
Incubation
mixture Substrate
Incubation time (minutes)
1 2 3 4 5 6
Clotting times (seconds)
Hum. brain l/4 
Hum.ads.pi.1/5 
CaCl2 M/40
Fresh hum.pl. 
F V~def.pl.
31 29 28 24 2l| 13| 
34 30 30 26 22 15
Hum. brain 1/4 
Ck.ads.pl. 1/5 
CaCl2 M/40
Fresh hum.pl. 
F V~def.pl.
35 32| 32-| 32 32 31 
64 66 65i 65 63 60
Hum. brain 1/4 
Saline 
CaCl2 M/40
Fresh hum.pl. 
F V-def.pl.
32 32 33 33 33 34 
65 64j 66 66 65 651
Ck. brain 1/2 
Ck.ads.pl. 1/5 
CaCl2 M/40
Ck.fresh pi. 
Hum.fresh pi. 
F V~def.pl.
21 13f 13 13| 13 12 
150 40 25 22 22 24 
180+ 75 67 63 63 80
Ck. brain l/2 
Hum.ads.pi.1/5 
CaCl2 M/40
Ck. fresh pi. 
Hum.fresh pi. 
F V-def.pl.
23 23 24 23 23 24 
180+ 160 180+ 120 180+ 135 
180+ 180+ 180+ 180+ 180+ 180+
Ck. brain l/2 
Saline 
CaCl2 M/40
Ck. fresh pi. 
Hum.fresh pi. 
F V-def*pl.
23 23 23 23f 23 24 
135 180+ 180+ 180+ 150 110 
180+ 180+ 180+ 180+ 180+ 180+
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Table 11. Factor V assay
In view of the strong species specificity of chicken factor V 
and brain thromboplastin, dilution curves of normal plasma in the 
homologous plasmas rendered deficient in factor V were compared 
with each other, each being clotted with the homologous brain extract.
Factor V concentration (per cent)
100 30 25 12.5 6.2 3.1 1.5 0
Clotting times (seconds)
Human experiment 1 25i 28i 33 38 42^ 45 49 50
Human experiment 2 22 30 37 42 50 55 62 70
Human experiment 3 21 26 30 37 50 54 62 86
Chicken experiment 1 27 31 34 37 39 40 41 42
Chicken experiment 2 29 36 45 53 62 70 80 87
Chicken experiment 3 27 32 36£ 40 46 52 57? 61
The 1 in 10 dilution of the normal fresh plasma in the stored 
factor V deficient plasma was designated the 100$ value for factor
V concentration.
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FACTOR V ASSAY.
using Homologous Systems.
100
<A
TJ
COu
OJ
(A
0)
E
O)c
_o
O
60 80 100
Percentage of Normal Plasma
Figure 5. Factor V assay.
Curve A
Human factor V dilution curye, constructed by clotting the 
normal human plasma dilutions in stored human plasma by the addition 
of human brain thromboplastin and recalcification with £^40 CaC^.
It illustrates experiment 2 from table 11.
Curve B
Chicken factor V dilution curve, constructed by clotting the 
chicken normal plasma dilutions made in stored chicken plasma by 
the addition of chicken brain thromboplastin and recalcification 
with M/40 CaCl2. It illustrates experiment 2 from table 11.
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Table 12. Factors VII and X — brain thromboplastin species specificity
(method described in appendix IV, 17)
Incubation
mixture Substrate
Incubation time (minutes)
1 2 3 4 5 6
Clotting Times (seconds)
Hum. brain 1/4 
Hum. serum 1/5 
CaCl2 H/40
Fresh hum.pl. 
Phenindione pi.
22 18 18 19 19} 18 
18 18 15} 17 18 17
Hum. brain 1/4 
Ck. serum 1/5 
CaCl2 M/40
Fresh hum.pl. 
Phenindione pi.
45 35 35 38 38 38 
65 63 59 59 58 60
Hum. brain l/4 
Saline 
CaCl2 M/40
Fresh hum.pl. 
Phenindione pi.
36 37 36 36 38} 38} 
66 63 60 64 64 63
Ck. brain 1/2 
Ck. serum l/5 
CaCl2 M/40
Fresh Ck.pl. 
Fresh Hum.pl. 
Phenindione pi.
12} 12 12} 13 14} 14 
34 38 46 50 51 57 
67 63 62 60 100 100
Ck, brain l/2 
Hum.serum l/5 
• CaCl2 M/40
Fresh Ck,pl. 
Fresh hum.pl. 
Phenindione pi.
24 22} 23 22 23 23} 
168 162 162 180 180 190 
180 191 - 194 196 201
Ck, brain 1/2 
Saline 
CaCl2 M/40
Fresh Ck.pl. 
Fresh hum.pl. 
Phenindione pi.
23 22 22} 22 22 22 
190 180 163 188 190 190 
240 210 260 332 264 335
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Table 13. Stuart-Prover factor assay 
(method of Bachmann, Duckert, and Roller, 1958; appendix IY, 18)
Plasma Concentration
Clotting times (seconds)
dilution of factor X Expt. 1 Expt. 2 Expt. 3 !
Hum. Plasma Hum. Plasma Hum. Serum
1/10 100 $ 20 19i 22
1/20 50 $ 24J 25 25
1/40 25 fo 30 32 31
1/80 12 $ 38 36 36
1/160 6 f> 46 45 44
1/320 3 $ 55 51 50
1/640 1.5$ 63 58 65
1/1280 0.75$ 80 70 77
1/2560 0.36$ — 80^ 83
Buffer 0.0 $ 141 91 100
Ck. Plasma Ck.Plasma Ck. Serum
1/10 73 72 92
1/20 81 83 —
1/2 — 99
Calculated factor X conc. 1.2 $ 0.62 $ 0.1 %
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Table 14. R.V.V.-cephalin clotting time of plasma 
(method described in appendix IV, 19)
Concentration of
Plasma dilution in veronal buffer
R.V.V.-cephalin Plasma 1 1/2 1/4 1/8 1/16
Clotting time (sec.)-5t
1/40,000 - 0.06 gm fo Human 8 9 13 20 40
Chicken 17 18 23 35 54
1/80,000 - 0.06 gm fo Human 8 10 13 20 35
Chicken 17 18 22 35 53
1/200,000- 0.06 gm fo
Human
Chicken
9
20
12
2li
* Average of three estimations.
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Table 15. Measurement of prothrombin 
Prothrombin was estimated by the two-stage area method of 
Biggs and Douglas, 1953a (appendix IV, 12, C), using the brain 
thromboplastin of the same species as the plasma under test, and 
subsampling onto human fibrinogen solution.
Incubation
mixture Expt.
Incubation time (minutes) Number of
12 \ 1 2 3 4 squares
Clotting times (seconds) under curv#
Hum. pi. 1 12 13 14 29 86 180+
with 2 12* 13* 15 31 90 180+
Hum. brain 3 — — 12 21 43 133
Ck. pi. 1 32 73 100 180+ 180+ 180+
with 2 30 40 93 180+ 180+ —
Ck. brain 3 32 60 81 180+ 180+ —
Thrombin units / ml.
1 13* 12 11 4.4 1.2 0.0 508
Human 2 12* 11.2 10.4 4.3 1.2 O.o 480
3 — — 13.5 7 2.9 0.7 592
1 4.1 1.5 1.0 0,0 0.0 63
Chicken 2 4.5 3.3 1.1 0.0 0.0 75
3 4.1 1.9 1.38 0.0 0.0 73
.i
* Each square = l/lOO th square inch
The average area for human plasma = 526.6 squares.
The average area for chicken plasma = 70.3 squares.
70.3 x 100
Thus, chicken plasma prothrombin — ——— — — ———
526.6
a= 13.3 io of human prothrombin.
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MEASUREMENT OF PROTHROMBIN.
14-.
#  Human Plasma.1 2 -
V) O Chicken Plasma.
_c
IE
Eo
480
1 320 4 5
Time in Minutes
Figure 6. Measurement of prothrombin.
(the two-stage area method of Biggs & Douglas, 1953a)
Curve a
Human plasma tested with human brain, (table 15, experiment 2). 
Curve b
Chicken plasma tested with chicken brain, (table 15, experiment 2).
Subsampling in both cases was onto human fibrinogen, and the 
clotting times converted into thrombin units from the thrombin— 
fibrinogen dilution curve illustrated in figure 1.
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Table 16. Measurement of prothrombin
Prothrombin was estimated by the globulin fraction method of 
Douglas and Biggs, 1953, (appendix IV, 12, B), using human brain 
thromboplastin only for both plasmas.
Experiment 1 Experiment 2
Human Chicken Human Chicken
Clotting times of 
substrate (seconds) 12* 41 13i 46
Thrombin units/ml. 13 3.1 11.5 2.7
Prothrombin conc.
L
100 fo 23.8 fo 100 fo 23.4 fo
Table 17* Thrombocyte count
(method described in appendix IV, 1, B)
Experiment Total count of W.B.Cs./c.ram.
Percentage of 
thrombocytes
Calculated No. 
of thrombocytes
1 38,500 50 fo 19,250
2 40,500 52 fo 21,060
3 45,000 45 f> 20,250
4 38,000 55 f 20,900
5 28,000 60 f 16,800
The average thrombocyte count = 19>650 /c.ram. whole blood.
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Table 18. Chicken whole blood clotting time 
(method of Lee and White, 1913; appendix IV, 3)
Clotting times*
in ordinary glass in siliconed glass
Hen 1 11' 12" 13’ 23"
Hen 2 32* 41' 30"
Hen 3 45' 51' 20"
Hen 4 16* 30" 18*
Hen 5 17' 17' 20"
Average 24' 20" 28* 18"
* Average of two tubes1 readings.
Table 19. Reealcification time of plasma 
(method: appendix IV, 5)
Clotting times (seconds)
Human plasma Chicken plasma
165 1157
160 480
160 512
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Table 20. Hageman factor and -plasma thromboplastin antecedent activity 
(method of Ratnoff and Rosenblum, 1958j appendix IV, 24, I)
Test plasma 
preparation
Clotting time in minutes of substrate plasma 
(normal citrated platelet-deficient Intact plasma)
Human Chicken
64 60
Human, intact 43 (66)* 120+ (120+)
90 120+
120+ 120+
Chicken, intact 120+ (120+) 120+ (120+)
120+ 120+
13 50
Human, glass activated 15 (13) 38 (38)
10 27
120+ 120+
Chicken,glass activated 120+ (120+) 120+ (120+)
| 120+ 120+
* Values between brackets are the average of the three experiments.
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Table 21. Thromboplastin generation test 
(method of Biggs and Douglas, 1953bj appendix IV, 20)
Human platelets and M/40 CaCl2 solutions were constant (0*2 ml each).
Substrate; human high-spun plasma.
Incubation 
mixture (ml) Expt.
Incubation time (minutes)
1 2 3 4 5 6
Noo Clotting times (seconds)
1 63 59 48 44 36 31
1 0.2 Chicken plasma 2 24 14 15 15 15 15JL 0.2 Human serum 3 96 82 73 62 50 29
Avg. 61 52 45 40 34 25
1 157 70 49 28 25 25
2 0.2 Chicken plasma 2 62 35 25 28 37 45
0.2 Chicken serum 3 150 140 127 90 84 53
Avg. 123 82 67 49 49 41
1 100 91 81 78 95 96
3 0.2 Chicken plasma 2 132 115 105 92 83 63
0.2 Saline 3 107 112 120 145 152 180+
Avg. 113 106 102 105 110 113
1 30 11 11 11 11 11
4 0.2 Human plasma 2 60 11 9 9 9 9
0.2 Human serum 3 73 27 10 9* 10 10
Avg. 54 16 10 10 10 10
1 70 72 130 77 117 100
0.2 Human plasma 2 88 105 90 120 111 102
j 0.2 Chicken serum 3 122 108 104 100 110 120
Avg. 93 95 108 99 113 107
1 98 94 101 99 130 105
c. 0.2 Human plasma 2 93 98 92 104 104 99o 0.2 Saline 3 180 178 127 144 132 120
Avg. 124 123 107 116 122 108
1 180+ 118 180+ 180+ 180+ 180+
0.2 Saline 2 97 133 100 145 132 120
7 0.2 Chicken serum 3 180+ 180 163 170 175 92
Avg. 152 144 147 165 162 131
1 80 71 60 52 38 32
O 0.2 Saline 2 79 64 50 41 33 26O 0.2 Human serum 3 78 70 58 50 45 37
Avg. 79 68 56 48 38 32
1 85 64 53 40 32 32
Q 0.2 Haemophilic pi, 2 78 62 45 33 33 34
7 0.2 Human serum 3 90 75 62 52 37 37
Avg. 84 67 53 42 34 34
Table 21,continued
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Incubation 
mixture (ml) Expt.
Incubation time (minutes)
1 2 3 4 5 6
No. Clotting times (seconds)
10 0.2 Human plasma 0.2 X-mas serum
1
2
3
91 79 64 45 34 32 
73 55 45 39 32 32 
172 160 135 104 68 45
Avg. 112 98 81 63 45 36
11
0.2 Haemophilic pi 
0.1 Human ads.pl. 
0.2 Human serum
1
2
3
60 21 11 11 11 ll
55 15 9 9 9 9 
68 30 11 9 10 10
Avg. 61 22 10 10 10 10
12
0.15Haemophilic pi 
0.05 Human.ads.pl. 
0.2 Human serum
1
2
3
72 40 12} 12} 13 13 
70 39 11 12 12 12
Avg. 71 39} lli 12i 12i 12i
13
0.175 Haemoph.pl. 
0.025 Hum.ads.pl. 
0.2 Hum. serum
1
2
3
7 6 47 16 15 14 14 
71 44 15 14 13} 14
Avg. 73 45 15i 14i 13i 14
14
0.19 Haemoph.pi. 
0.01 Hum.ads.pl. 
0.2 Hum.serum
1
2
3
90 49 18 17 17 16 
70 47 19 16i 16i 16
Avg. 80 48 18i 16} 16} 16
15
0.1 Haemophilic pi. 
0.1 Chicken plasma 
0.2 Human serum
1
2
3
60 42 30 30 21 21 
46 24 19 18 17 15} 
78 62 55 43 28 24
Avg. 62 43 37 30 22 20
16
0.1 Haemophilic pi.
0.1 Saline
0.2 Human serum
1
2
3
65 56 42 31 30 29 
67 50 38 26 28 29 
63 62 46 37 31 32
Avg. 65 56 42 31 30 30
The results in every fourth line for each mixture are the 
average of the above three experiments. The first experiment for 
all mixtures are directly comparable with each other as they were 
obtained with the same platelet preparation and the same set of 
reagents. Likewise, all second and third experiments are comparable 
with each other respectively being obtained with the same set of 
reagents for each experiment, though different from those of other 
experiments. However, all the results are approximately of the 
same magnitude of activity or lack of activity, sufficiently 
enough to justify taking their average as a general guide for the 
comaprison between the activity of the various mixtures. These 
averages were converted into percentage active thromboplastin in 
the following table.
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Table 22. Thromboplastin generation test 
Compilation of data in table 21 in terms of percentage active 
human thromboplastin as read from the thromboplastin dilution curve
A in figure 2 (page 80) which was constructed with human platelets.
Incubation Incubation time (minutes)
mixture (ml) 1 2 3 4 5 6
No. Percentage active thromboplastin
1 0.2
0.2
Chicken plasma 
Human serum 2.2 3 4.2 5.4 7.5 15
2 0.20.2
Chicken plasma 
Chicken serum 0.4 1.2 1.8 3.5 3.5 5.2
3
0.2
0.2
Chicken plasma 
Saline 0.5 0.6 0.7 0.6 0.6 0.5
4 0.2
0.2
Human plasma 
Human serum 3 40 100 100 100 100
5
0.2
0.2
Human plasma 
Chicken serum 0.9 0.8 0.6 0.7 0.6 0.6
6 0.20.2
Human plasma 
Saline
0.4 0.4 0.6 0.5 0.5 0.6
7 0.20.2
Saline
Chicken serum 0.3 0.3 0.3 0.2 0.2 0.4
8
0.2
0.2
Saline 
Human serum 1.3 1.7 2.5 3.7 6 8.5
9 0.20.2
Haemophilic plasma 
Human serum
1.1 1.7 3 5.2 7.5 7.5
10 0.20.2
Human plasma 
X-mas serum 0.5
0.8 1.2 2 4.2 6.8
11
0.1
0.1
Haemophilic plasma 
Human plasma 2.2 19 100 100 100 100
0.2 Human serum
12
0.15
0.05
Haemophilic plasma 
Human plasma 1.6 5.6 78 68 65 65
0.2 Human serum
13
0.175 Haemophilic plasma 
0.025 Human plasma 1.5 4.2 42 47 54 50
0.2 Human serum
14
0.19
0.01
Haemophilic plasma 
Human plasma 1.2 3.7 28 35 35 38
0.2 Human serum
15
0.1
0.1
Haemophilic plasma 
Chicken plasma 2.1 4.6 6.4 10 19 24
0.2 Human serum
16
0.1
0.1
Haemophilic plasma 
Saline 1.9 2.6 4.9 9.2 10 10
0.2 Human gerum j
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Table 23. Thromboplastin generation test 
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Human cephalin (appendix III, 14) and M/40 CaCl2 solutions (0,2 ml 
each) were constant. Substrate: human high-spun plasma.
The fifth line for each mixture represents the percentage of 
active thromboplastin as read from the dilution curve B in figure 2,
which was constructed using human cephalin, plasma, and serum.
Incubation time (minutes)
Incubation Expt. 1 2 3 4 5 6
No. mixture (ml) Clotting times (seconds)
1 15 15 15 15 15 15
0.2 Chicken plasma 2 14 12 12 14 13* 15
17 0.2 Human serum 3 51 23 20 19 23 21
Avg. 27 17 16 16 17 17
f 9.5 29 33 33 29 29 f>
" ' 1" ■.86. .28"" 24 24 25 27
18 0.2 Chicken plasma 0.2 Chicken serum
2
3
45
45
20
31
23
29
33
30
39
32
55
31
Avg. 59 26 25 29 32 38
f> 1.5 10 11.5 8 6.4 4.2f>
1 180+ 180+ 97 92 93 95
19 0.2 Chicken plasma 0.2 Saline
2
3
88
93
85
100
72
90
50
120
46
87
42
130
Avg. 120 122 86 87 75 89
2 0.2 0.2 0.5 0.5 0.8 0.5f
1 45 11 9 9 10 9
20 0.2 Human plasma 0.2 Human serum
2
3
50
75
11
35
8i
10
8|
10
9
10
9
9
Avg. 57 19 9 9 9 9
fo 1.6 22 130 130 130 130
1 95 91 95 88 110 90
21 0.2 Human plasma 
0.2 Chicken serum
2
3
110
97
93
104
95
100
88
120
120
110
96
110
Avg. 101 96 97 99 113 99
fo 0.4 0.4 0.4 0.4 0.3 0.4fo
1 99 99 121 98 130 134
22 0.2 Human plasma
2
3
109
101
93
98
76
102
78
107
120
124
110
112OcLJLlIlG Avg. 103 99 100 94 124 119
fo 0.4 0.4 0.4 0.4 0.2 0.2fo
Table 23. continued
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Incubation Incubation time (minutes)Expt. 1 1 2 3 4 __5 1 6
No. Clotting times (seconds)
1 93 91 105 95 85 80
23 0.20.2
Saline
Chicken serum
2
3
104
113
110
110
104
180+
173
104
180+
129
180+
173
Avg. 103 103 129 124 131 141
fo 0.4 0.4 0.2 0.2 0.2 0.1 fo
24 0.2
0
Saline 
Human serum
1
2
3
96
65
81
97
65
72
85
68
71
73
64
63
78
62
70
93
60
68
Avg. 81 78 75 67 70 74
0.7 0.7 0.8 1 0.9 0.8 fo
i 86 75 73 71 69 63
25 0.2 Haemophilic pi. 0.2 Human plasma
2
3
69
72
69
73
62
71
63
67
57
63
54
60
Avg. 76 72 69 67 63 59 |
* 0.8 0.9 1 1 1.2 1.4 fo
1 103 66 30 28 30 34
26 0.2 0 2
Human plasma 
X-mas serum
2
3
127
134
97
133
87
101
90
115
82
84
68
108
Avg. 121 99 73 78 65 70
f 0.3 0.4 0.9 0.7 1.1 0.9 f
1 70 25 10 9 9 9
27
0.1
0.1
Haemophilic pi. 
Human plasma
2
3
68
67
19
30
9
11
9
10
8i
10
9
10
0.2 Human serum Avg. 68 25 10 9.3 9.1 9.3
* 1 11 100 120 125 120 fo
1 68 30 11 9 9 9
0.15 Haemophilic pi. 2 55 18 9 9 9 9
28 0.05 Human plasma 3 72 45 13 10 10 10
0.2 Human serum Avg.
fo
65
1.1
31
7
11
80
9.3
120
9.3
120
9.3
120 fo
1 70 48 19 12 12 12
! 29
0.175 Haemophilic pi. 
0.025 Human plasma
2
3
67
67
55
56
21
26
10
14
10
12
10 
12 ;
0.2 Human serum Avg.
f
68
1
53
1.9
22
17
12
66
11.3
75
11.3 
75 1
1 80 66 25 20 16 15
30
0.19 Haemophilic pi. 
0.01 Human plasma
2
3
70
76
59
58
21
20
16
15
15
15
14
15
0.2 Human serum Avg. 75 61 22 17 15.3 14.6
$ 0.8 1.4 IT 29 36 40 fo i
1 68 30 16 15i 15 15 i
31
0.1
0.1
Haemophilic pi. 
Chicken plasma 
Human serum
2
3
25
70
15
41
15
23
15
17
14
17
144
17
0.2 Avg.
*
54
1.8
29
8
18
25
16
33
15.3
36
15.5
35
32 0.10.1
Haemophilic pi. 
Saline
I
3
m i2§
85
m
82
1§9
175
§8
70
0.2 Human serum Avg.
^0.4 90.4 10l  3 0.4
100 „0.4 830.6 °/o
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CHICKEN ACTIVE THROMBOPLASTIN DILUTION CURVE
100
80
(A■ocou0)
in
W
E
h-
O)c
_o
O
12.5 100 150
Concentration of Thromboplastin (per cent).
Figure 7. Chicken active thromboplastin dilution curve.
The same method as for the construction of the human dilution 
curve was used as described in appendix IV, 20, A, except for the 
substitution of chicken reagents instead of the human in the incubation 
mixture as follows
Incubation mixture: 0.2 ml chicken adsorbed plasma, diluted 1/5,
0.2 ml human serum, diluted 1/10,
0.2 ml chicken thrombocyte suspension,
0.2 ml M / 4 0 CaCl2 solution.
The shortest thromboplastin time which was 20 seconds was 
designated the 100 per cent value.
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Table 24. Modified thromboplastin generation test 
(method of Biggs and Douglas, 1953b; appendix IV, 20) 
Chicken thrombocyte suspension (appendix III, 15, B) and the 
M/40 CaCl^ solution were constant (0.2 ml each) in all mixtures. 
Substrate: human high-spun plasma. Percentage thromboplastin
was read off from the chicken active thromboplastin dilution curve 
illustrated in figure 7.
No.
Incubation 
mixture (ml) Expt.
Incubation time (minutes)
Clotting times (seconds)
33 0.2 Chicken plasma 0.2 Human serum
1 53 25 25 24 22\ 24
2 66 26 21 19 21 19
3 72 30 21 20 19 18
Avg.
%
64
5.4
27
45
22
80
21
90
21
90
20
100 f
34 0.2 chicken plasma 0.2 chicken serum
1 49 24 25 32 38 42
2 124 98 82 45 30 25
3 125 75 30 25 22 22
Avg,
fo
99
1.8
66
5
46
12
34
30
30
35
30
35 fo
35
0*2 Chicken plasma 
0.2 saline
1 75 70 50 45 42 40
2 102 106 93 95 115 97
3 105 101 125 95 97 90
Avg.
fo
94
2
92
2.2
89 78
2.4 3.
85 
2 2.6
76
3.5 f
36
0.2 Human plasma 
0.2 Human serum
1 76 53 45 39 39 37i
2 75 67 55 35 26 20
3 120 90 73 62 41 22
Ivg. 90 70 58 45 35 27
fo 2.3 4.3 6.8 13 24 45 %
37
0.2 Human plasma 
0.2 Chicken serum
1 122 82 150 130 85 140
2 104 104 102 90 97 97
3 98 92 99 92 97 140
Avg,
fo
108
1.5
93
2.1
110 104
1.3 l.<
93
2.1
126
1
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Table 24, continued
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No.
Incubation
mixture
Expt,
Incubation time (minutes)
Clotting times (seconds)
38
0.2 Human plasma 
0.2 Saline
1 77 65 63 63 66 64
2 95 90 100 130 105 110
3 110 110 112 115 122 120
Avg.
CL
94
2
88
2.5
92
2.2
102
1.7
101
1.7
98 
1.9 f
.
39
0.2 Saline
0.2 Chicken serum
1
2
3
120
102
85
180+
98
90
144
110
89
145
134
84
180+
116
90
180+
109
92
Avg.
f
102
1.7
123
1.1
114
1.3
121
1.1
129
0.9
127
1 *
1 105 134 87 180+ 180+ 180+
2 85 82 89 89 85 76
40 0.2 Saline 3 85 99 92 89 79 100
Avg. 92 105 89 T1'9 114 118
fo 2.2 1.6 2.4 1.1 1.3 1.2
1 93 92 85 85 80 82
2 85 78 88 84 85 74
41 0.2 Haemophilic pi. 3 90 90 100 102 100 980.2 Human serum Avg. 89 87 91 90 88 84
2.4 2.5 2.2 2.3 2.5 2.7 f
1 160 162 150 155 130 102
2 115 130 132 160 162 105
I 42 0.2 Human plasma 3 180 180 120 90 157 1100.2 X-mas serum Avg. 152 157 134 135 150 106
* less than one per cent 1.5 f
1 90 85 66 64 43 24
0.1 Haemophilic pi. 2 80 78 64 58 40 25
43 0.1 Human plasma 3 85 80 68 62 45 26
0.2 Human serum Avg. 85 81 66 61 43 25
fo 2.6 3 5 6 14 56 7°
1 102 83 45 29 27 27
0.1 Haemophilic pi. 2 88 80 43 26 26| 26
44 0.1 Chicken plasma 3 96 79 40 26 26 25
0.2 Human serum Avg. 95 81 43 27 26 26
fo 2 3 14 45 50 50 f
I 110” 92 ' 8u 4y
0.15 Haemophilic pi. 2 — — — — — —
45 0.05 Chicken plasma 3 107 90 84 70 50 40
0.2 Human serum Avg. 109 91 82 71 49 39
f 1.4 2.2 2.9 4.1 10 18 %
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Table 24. continued
Incubation
Expt.
Incubation time (minutes)
No.
mixture (ml) 1 i  2 3 4 5 6
Clotting times (seconds)
1 90 38 29 20 20 20
0.2 chicken plasma 2 — — — — — —
46 0.1 X-mas serum 3 90 38 30 20 20 20
0.1 Human serum Avg. 9o 33 20 20 20
* 2.:3 19 35 100 100 100 fo
1 96 43 20 20 20 20
0.2 Chicken plasma 2 — — — — — —_
47 0.15 X-mas serum 3 97 42 20 19 19 19
0.05 Human serum Avg. 96% 42^ 20 19% 19% 19%
f l.<) 15 100 105 105 105 fo
1 105 61 21 21 21 21
0.2 Chicken plasma 2 — — — — — —
48 0.175 X-mas serum 3 100 62 20 19 19 19
0.025 Human serum Avg. 102i 6li 2 0% 20 20 20
* 1.7 5.9 94 100 100 100 fo
"1 95 92 4 0 21 21 21
0.2 Chicken plasma 2 — — — — — —
49 0.19 X-mas serum 3 93 98 44 19 19 19
0.01 Human serum Avg. 94 95 42 20 20 20
fo 2 2 15 100 100 100 fo
1 101 98 66 35 26 26
0.2 Chicken plasma 2 — — — — — —
50 0.1 X-mas serum 3 100 98 67 35 26 25
0.1 Chicken serum Avg. 100% 98 6 6 % 35 26 25%
fo 1.8 1.9 4.8 24 50 56 f
1 100 101 95 60 40 31
0.2 Chicken plasma 2 — — — — -- —
51 0.15 X-mas serum 3 92 150 105 55 36 29
0.05 Chicken serum Avg. 96 125 100 57 38 30
fo 1.9 1 1.8 7 19 35 fo
1 105 110 111 110 112 110
0.2 Chicken plasma 2 — — — — — —
52 0.2 X-mas serum 3 102 104 115 115 117 115
Avg. 103i 107 113 112% 114% 112%
96 1.7 1.5 1.3 1.3 1.3 1.3 f
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Table 23. Chicken substrate reactivity in T.G.T.
Incubation mixture: 0,2 ml adsorbed plasma, diluted 1/5, as shown,
0,2 ml serum, diluted l/lO, as shown,
0.2 ml human platelets,
0.2 ml M/40 CaCl^ solution.
Substrate: chicken high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt. 1 2 i 3 4 5 6
No. Clotting times (seconds) j
1 46 40 31 26 20 19
53 Chicken ads.pl. 3 64 42 27 24 24 24 |
Human serum Avg. 55 41 29 25 22 21-5- j
* 2.7 5.1 11 15 19 20 fo
1 155 110 63 41 36 30
54 Chicken ads.pl. 3 170 140 115 105 65 55Chicken serum Avg. 162 125 89 73 50 42 |
* 0.2 0.4 1 1.5 3.4 4.9$!
1 60 27 23 24 26 27 i
55 Human ads.pl. 3 62 25 25 30 30 32 ;Human serum Avg. 61 26 24 27 28 29i j
f° 2.2 13 16 12 11 10 $ |
1 180+ 180+ 170 150 145 157
56 Human ads.pl. 3 180+ 180+ 180+ 180+ 180+ 180+Chicken serum Avg. 180+ 180+ 180+ 180+ 180+ 180+ j
fo 0 0 0 0 0 0 fo\
1 65 62 63 51 46 49 !
57 Haemophilic ads.pl. 3 60 62 62 75 30 30 !Human serum Avg. 62^ 62 62i 63 38 40 |
$ 2 2 2 2 6 5 f
1 180+ 180+ 160 123 140 120
58 Human ads.pl. 3 180+
180+ 180+ 180+ 160 140 !
Christmas serum Avg.
fo
180+
0
180+
0
180+
0
180+
0
150
0.3
130
0.4$
Experiments 1 and 3 have been performed on the same day and with 
the same preparations of plasma, serum, and platelets as was used for 
experiments 1 and 3 in table 21. Therefore, mixtures number 53, 54,
55, 56, 57, and 58 are directly comparable with mixtures No. 1, 2,
4, 5, 9, and 10 respectively, as regards the effect of different 
substrate plasmas. Experiment 2 was not continued due to the 
exhaustion of the particular platelet preparation used in that experiment.
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Table 26. Chicken substrate reactivity in T.G.T.
Incubation mixture: 0.2 ml. adsorbed plasma, diluted 1/5, as shown,
0.2 ml. serum, diluted l/lO, as shown,
0.2 ml. cephalin l/lOO,
0.2 ml. M/40 CaCl^ solution.
Substrate: chicken high-spun plasma.
Incubation
Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 16 20 23 25 24 24
59 Chicken ads.pl. Human serum
2
3
37
32
33
17
25
18
22
19
21
20
22
20
Avg.
*
28
8.7
23
14
22
15i
22
15i
22
15i
22
15i ?
1 40 39 39 45 52 55
60 Chicken ads.pl. Chicken serum
2
3
137
98
80
40
95
48
120
50
142
65
163
64
Avg.
°/0
92
0.5
53 61 
1.9 1.3
72
0.9
86
0.6
94
0.5?
1 62 21 19 22 20j 22
61 Human ads.pl. Human serum
2
3
45
44
20
39
18
20
18
18
19
19
20
19
Avg.
$
50
2.2
27 19
9.5 22
19
22
19*
21
20
19.5?
1 180+ 180+ 180+ 180+ 180+ 180+
Human ads.pl.
2 180+ 180+ 180+ 180+ 180+ 180+
62 3 150 150 150 155 160 155Chicken serum Avg.
1o
180+ 180+ 180+ 180+ 180f 180+
. 0 0 0 0 0 o io
1 69 70 75 77 78 76
63 Haemophilic ads.pl. Human serum
2
3
68
50
71
50
69
48
71
51
70
52
64
55
Avg.
*
62
1.3
64
1.2
64
1.2
66
1.1
66
1.1
65
i.i?;
1 180+ 180+ 180+ 180+ 180+ 180+
64
Human ads.pl. 
Christmas serum
2
3
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
Avg. 180+ 180+ 180+ 180+ 180+ 180+
* 0 0 0 0 0 0 fo
Experiments 1, 2, and 3 were performed with the same reagents used 
for experiments 1, 2, and 3 in table 23, and on the same day. Thus, 
mixtures 59, 60, 61, 62, 63, and 64 are directly comparable with 
mixtures 17, 18, 20, 21, 25, and 26 respectively, as regards substrate 
reactivity, as well as with each other.
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Table 27. Chicken substrate reactivity in T.G-.T.
Incubation mixtures 0,2 ml adsorbed plasma, diluted 1/5, as specified,
0.2 ml serum, diluted 1/10, as specified,
0.2 ml chicken thrombocyte suspension,
0.2 ml M[/40 CaCl^ solution.
Substrates chicken high-spun plasma.
Incubation
mixture
Incubation time (minutes)
Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 45 32 28 29 32 31
65 Chicken ads.pl. Human serum
2
3
67
50
26
46
23
45
24
40
21
35
25
31
Avg. 54 35 32 31 29 29
8 24 30 33 38^ r 38^ r fc
i 103 37 41 55 80 130
66 Chicken ads.pl. Chicken serum
2
3
180+
180+
180+
180+
180+
180+
140
177
80
105
130
96
Avg. 154 132 133 126 88 97
$ 0 0 0 1 2.4 1.91o
1 124 180+ 175 180+ 180+ 163
67 Human ads.pl. Human serum
2
3
146
99
125
97
130
92
113
65
87
60
74
60
Avg. 123 134 132 119 109 99
f° 1.1 0 0 1.2 1.4 1.8$
1 more than 180 in all tubes
68 Human ads.pl. 
Chicken serum
2
3
more than 
more than
180
180
in all tubes 
in all tubes
Avg. more than 180 in all tubes
0 0 0 0 0 0 $
69 Haemophilic ads.pl. Human serum
1
2
3
97
106
97
120
94
124
99
122
104
117
98
124
Avg. 101 108 109 110 110 111
fo 1.7 1.5 1.4 1.4 1.4 1.4$
70 Human ads.pl. 
Christmas serum
1
2
3
more
more
than
than
180
180
in all tubes 
in all tubes
Avg.
*
more than 180 in all tubes
0 0 0 0 0 o $
Experiments 1, 2,&3 were performed using the same reagents used for 
the same numbered experiments in table 24 and on the same day. Thus, 
mixtures 65, 66, 67, 68, 69, and 70 are directly comparable with 
mixtures 33, 34, 36, 37, 41, and 42 respectively.
Percentage active thromboplastin is expressed in terms of chick- 
active thromboplastin as read from figure 7.
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ANTIHAEMOPHILIC GLOBULIN ACTIVITY IN TG.T
120  -
■2 100- -• a
8 0 -
6 0 -
4 0 -
2 0 -
1 2 3 54 6
a
1 2 3 4 5 6
Tim e in M inutes
Figure 8. Antihaemophilie globulin activity of chicken adsorbed plasma.
Incubation mixture: 0*2 adsorbed plasma l/5, variable.
0,2 human serum 1/10,
(ml.) 0.2 human platelets.
0.2 M/40 CaCl2 solution, 
human high-spun plasma.Substrate:
Figure I
Curve a
Curve b
Curve c
Curve d
Figure II
Curve a^
Curve a2
Curve a^
Curve a. 4
Curve b^ 
Curve c.
Human ads.pl. l/5 (Mixture No. 4, tables 21 and 22)
Chicken ads.pl. l/5 (Mixture No. 1, tables 21 and 22)
Saline (Mixture Mo. 8, tables 21 and 22)
Haemophilic pi. 1/5 (Mixture No. 9, tables 21 and 22)
Hum.ads.pl. l/2 in haemophilic ads.pl.(Mixture 11, tables 21 & 22)
Hum.ads.pl. l/4 in haemophilic ads.pl.(Mixture 12, tables 21 & 22)
Hum.ads.pl. 1/8 in haemophilic ads.pl.(Mixture 13, tables 21 & 22)
Hum.ads.pl. l/20in haemophilic ads.pl.(Mixture 14, tables 21 &  22) 
Ck.ads.pl. l/2 in haemophilic ads.pl. (Mixture 15, tables 21 & 22)
Saline l/2 in haemophilic ads.pl.(Mixture 16, tables 21 & 22)
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ANTI HAEMOPHILIC GLOBULIN ACTIVITY IN TG.T
140 -
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1 2 0 -
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Figure 9. Antihaemophilic globulin activity of chicken adsorbed plasma.
Incubation mixture: 0*2 ml adsorbed plasma, variable,
0.2 ml human serum l/lO,
0.2 ml human cephalin l/lOO,
0.2 ml W/40 CaCl^ solution.
Substrate: human high-spun plasma.
Figure III
Curve a
Curve b
Curve c
Curve d
Figure IV
Curve a.
Hum.ads.pl. l/5 (Mixture 20, table 23).
Ck.ads.pl. l/5 (Mixture 17, table 23).
Saline (Mixture 24, table 23).
Haemoph.ads.pl.l/5 (Mixture 25, table 23).
Curve a,.
c
Curve a. 
Curve a, 
Curve bj 
Curve c.
Hum.ads.pl. l/2 in haemophilic ads.pl.(Mixture 27, Table 23).
Hum.ads.pl. 1/4 in haemophilic ads.pl. (Mixture 28, table 23).
Hum.ads.pl. l/8 in haemophilic ads.pl.(Mixture 29, table 23).
Hum.ads.pl. l/20 in haemophilic ads.pl.(Mixture 30, table 23).
Ck.ads.pl. l/2 in haemophilic ads.pl.(Mixture 31, table 23).
Haemophilic ads.pl. diluted l/lO with saline(Mixt.32, table 23)
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CHICKEN A.H.G. ACTIVITY IN MODIFIED T.G.T.
120 H
■S 100-Q.o
Si
g 80-
60 -H
20 H
d
654321
Tim e in
Figure 10. Antihaemophilic globulin activity of chicken adsorbed plasma.
Incubation mixtures 0.2 ml adsorbed plasma, 1/5, variable,
0.2 ml human serum, l/lO,
0.2 ml chicken thrombocyte suspension,
0.2 ml M/40 CaCl^ solution, 
human high-spun plasma.
Hum.ads.pl,, (Mixture 36, table 24)
Ck.ads.pl., (Mixture 33, table 24)
Saline, (Mixture 40, table 24)
Haemophilic ads.pl. (Mixture 41, table 24)
Hum.ads.pl. l/2 in haemophilic ads.pl.(Mixture 43, table 24)
Ck.ads.pl. l/2 in haemophilic ads.pl.(Mixture 44, table 24)
Ck.ads.pl. l/4 in haemophilic ads.pl.(Mixture 45, table 24)
Substrate: 
Figure I : 
Curve a : 
Curve b s 
Curve c : 
Curve d : 
Figure II 
Curve a^ : 
Curve b^ s 
Curve b„ :
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Table 28. Assay of chicken plasma A.H.G. activity 
(method of Pitney, 1956; appendix IV, 21)
Plasma A.H.G. Clotting times (seconds)
dilution concentration Expt. 1 Expt. 2 Expt. 3
Hum. pi. Hum. pi. Hum. pi.
1/20 100 fo 12 10 15
1/40 50 fo 15 14 20
1/80 2 5  fo 16 20 27
1/200 10 lo 19 35 40
1/400 5 fo 25 40 48
1/2000 1 fo 26 45 63
Buffer 0 fo 31 55 66
Ck. pi. Ck. pi. Ck. pi.
1/5 23 40 82
1/10 23| 43 66
1/20 27 — 69
1/40 27! 46 68
1/80 29 50 —
Calculated A.H.G. conc. 1.5 f 1.5 fo 0 fo
Such nearly nil activity of chicken adsorbed plasma in 
correcting haemophilic adsorbed plasma thromboplastin time is 
attributed to the specificity of chicken A.H.G. and factor V against 
the human platelets which were used as the thromboplastic agent in 
this assay system, as demonstrated in tables 29 and 30, and figure 
11 to follow. Substituting chicken thrombocytes for the human 
platelets would be of no benefit, since they are also species specific 
as regards human A.H.G., thus there are no means of directly comparing 
chicken and human A.H.G. activities in one system.
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Table 29» Chicken A.H.G. specificity in modified T.G.T.
Incubation mixture
0.2 ml purified A.H.G. (appendix III, 11), variable, 
0.2 ml purified factor V, (appendix III, 9), variable, 
0.2 ml human serum, diluted l/lO,
0.2 ml human cephalin l/lOO (appendix III, 14),
0.2 ml M/40 CaCl^ solution.
Substrate : human high-spun plasma.
Mixture
No.
Incubation time (minutes)
Variable Expt. 1 2 3 4 5 6
Clotting times (seconds)
1 76 40 16 12 12 11
71 Human A.H.G. 2 65 32 15 12 12 11
Human factor V Avg. 70 36 15j 12 12 11
* 1 4.8 36 65 65 CO o
1 139 120 121 117 116 121
71 b Chicken A.H.G. 2 113 112
112 113 117 123
Human factor V Avg. 126 116 117 115 116} 122
fo 0.2 0.3 0.3 0.3 0.3 0.2fo
1 100 83 89 82 82 80
71 c Chicken A.H.G. 2 96 78 92 79 78 76
Chicken factor V Avg. 98 80 90 80 80 78
fo 0.4 0.7 0.5 0.7 0.7 0.7fo
Percentage thromboplastin was expressed in terms of human active 
thromboplastin as read from the dilution curve B in figure 2, which 
was constructed with human cephalin.
- 140 - (Appendix V, A)
Table 30. Chicken factor V specificity in modified T.G.T.
Incubation mixture
0*2 ml purified human A.H.G., (appendix III, 11),
0*2 ml purified factor V, variable, (appendix III, 9), 
0.2 ml human serum, diluted l/lO,
0.2 ml human cephalin 1/100 (appendix III, 14),
0.2 ml ^40 CaCl^ solution.
Substrate s human high-spun plasma.
Mixture Species of 
factor V
Incubation time (minutes)
No. Expt. 1 2 ’ 1
4 5 6
Clotting times (seconds)
1 76 40 16 12 12 11
71 Human
2 65 32 15 12 12 11
Avg. 70 36 15i 12 12 11
f 1 4.8 36 65 65 80 fo
1 80 66 56 49 41 24
72 Chicken
2 66 60 54 46 35 22
Avg. 73 63 55 47i 38 23
fo 0.8 1.2 1.7 2.5 4.2 14 fo
1 90 81 65 58 47 31
73 Saline
2 88 82 65 60 48 30
Avg. 89 00
 
i—1 65 59 47i 30£
f 0.5 0.6 1.1 1.5 2.5 7 f
Percentage thromboplastin was expressed in terms of human active 
thromboplastin as read from the dilution curve B in figure 2, which 
was constructed with human cephalin.
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HUMAN BLOOD THROMBOPLASTIN -  FACTOR V SPECIFICITY, 
(modified T.G.T.)
100 -
.= 80-
(AjS
a0
1 60 -
I-
>
o< 40-
ca>u
a>
20-
■- c
0-
64 5321
Time in Minutes
Figure 11. Chicken factor V specificity in modified T.G-.T.
Incubation mixture: 0.2 ml purified human A.H.G-.,
0.2 ml purified factor V, variable.
0.2 ml human serum l/lO,
0.2 ml human cephalin 1/100,
0.2 ml M/40 CaCl2 solution.
Substrate: human high-spun plasma.
Curve a : Human factor Y preparation, (Mixture 71, table 30).
Curve b : Chicken factor V preparation, (Mixture 72, table 30).
Curve c : Saline, (Mixture 73, table 30).
- 142 - (Appendix V, A)
CHRISTM AS FACTOR A C T IV IT Y  IN TG .T
1 4 0 -
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■Q 100 - a
F  8 0 -
6 0 -
4 0 -
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b,c,d
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Figure 12. Christmas factor activity of chicken serum in T.G.T.
Incubation mixture : 0.2 ml human ads.pl. l/5,
0.2 ml serum, variable,
0.2 ml human platelets, or cephalin l/lOO, 
0.2 ml M/40 CaCl2 solution.
Substrate s human high-spun plasma.
Curve a 
Curve b 
Curve c 
Curve d
Figure II 
(with cephalin) 
Mixture 20 
Mixture 21 
Mixture 22
Christmas serum l/lO.. Mixture 10 .... Mixture 26
Human serum, l/lO 
Chicken ser. l/lO 
Saline
Figure I 
(with platelets) 
, Mixture 4 ..
. Mixture 5 
Mixture 6
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CHICKEN X -M A S  FACTOR A C TIV ITY  IN MODIFIED TG .T
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Figure 13. 
Incubation
Substrate 
Figure 13. 
Curve a 
Curve b 
Curve c 
Curve d 
Figure 13.
Christmas factor activity of chicken serum in modified T.G.T.
mixture : 0.2 ml chicken ads.pl., l/5,
0.2 ml serum, l/lO, variable.
0.2 ml chicken thrombocyte suspension,
0.2 ml M/40 CaCl^ solution.
human high-spun plasma.
I
human serum 
chicken serum 
saline
Christmas serum
(Mixture 33, table 24) 
(Mixture 34, table 24) 
(Mixture 35, table 24) 
(Mixture 52, table 24)
II
Curve al : human serum l/2 in X-mas serum (Mixture 46, table 24)
Curve a2 : human serum l/4 in X-mas serum (Mixture 47, table 24)
Curve a3 : human serum l/8 in X-mas serum (Mixture 48,
table 24)
Curve a4 : human serum l/20 in X-mas serum (Mixture 49, table 24)
Curve bl ! chicken ser.l/2 in X-mas
serum (Mixture 50, table 24)
Curve >2 = chicken ser.l/4 in X-mas serum (Mixture 51, table 24)
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Table 31. Christmas factor assay in chicken serum 
(based on the method of Pitney, 1956, as described in appendix IV, 22)
Serum Cone entrati on Clotting times (seconds)
dilution of X-mas factor Expt. 1 Expt. 2 Expt. 3
HUMAN CONTROL SERUM
1/20 100 fo 18 10 10
1/40 50 fo 35 10 11
1/80 25 fo 62 11 12i
1/200 10 fo 120 12 15
1/400 5 f 113 14 23
1/2000 1 % 121 21 45
Buffer 0 fo 155 55 85
CHICKEN TEST SERUM
1/5 162 88 120
1/10 171 90 132
1/20 118 133 129
Calculated X-mas factor conc. 0 fo 0 fo 0 fo
Incubation mixture
0,1 ml adsorbed normal human plasma, diluted 1/5,
Ool ml Christmas disease serum, diluted l/lO,
0*1 ml human platelets,
0.1 ml control or test serum, various dilutions,
0.1 ml M/40 CaCl2 solution.
Subsampling performed at exactly 4 minutes, onto human H.S.plasma.
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CHICKEN BLOOD THROMBOPLASTIN GENERATION.
120 -
'C
(A
(0 1 0 0 -
ao
n
E 8 0 -o
■C
1- 6 0 -
0)_>
5
o
< 4 0 -
c
a> 2 0 -
o
a>
0. 0-
31 2 54 6
T im e  in M inutes
Figure 14. Chicken blood thromboplastin generation.
Incubation mixture: 0.2 ml chicken adsorbed plasma, diluted l/5,
0.2 ml chicken serum, diluted 1/10,
0.2 ml Variable,
0.2 ml M/40 CaCl^ solution.
Substrate: human high-spun plasma.
Curve A
With human platelets, (Mixture 2, tables 21 and 22).
Curve B
With human cephalin 1/100, (Mixture 18, table 23)
Pe
rc
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t 
Ac
tiv
e 
Th
ro
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SUBSTRATE REACTIVITY IN TG.T
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Figure 15. Chicken plasma substrate reactivity in T.G-.T*
Incubation mixture: 0.2 ml human ads.pl., diluted 1/5,
0*2 ml human serum, diluted 1/10,
Oo2 ml human platelets (figure I), 
or human cephalin (figure II),
0.2 ml M / 4 0 CaCl^ solution.
Substrate : variable.
Curves a : using human H.S.plasma as substrate, (Mixtures 4 and 20) 
Curves b : using chicken H.S.pl. as substrate, (Mixtures 55 and 61)
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SUBSTRATE REACTIVITY IN TG.T
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Figure 16. Chicken plasma substrate reactivity in T.G-.T. 
Figure III
Incubation mixture: 0.2 ml chicken ads.pl., diluted 1/5,
0.2 ml human serum, diluted l/lO,
0.2 ml chicken thrombocyte suspension,
0.2 ml 14/40 CaCl^ solution.
Curve a : subsampling over human H.S.plasma, (Mixture 33, table 24)
Curve b : subsampling over chicken H.S.pl., (Mixture 65, table 27)
Figure IY
Incubation mixture: 0.2 ml chicken ads.pl., diluted 1/5,
0.2 ml chicken serum, diluted l/lO,
0.2 ml chicken thrombocyte suspension,
0.2 ml M/40 CaCl^ solution.
Curve a : subsampling over human H.S.plasma, (Mixture 34, table 24)
Curve b : subsampling over chicken H.S.pl., (Mixture 66, table 27)
This curve represents a completely homologous chicken 
thromboplastin generation mixture and substrate, which it is noted 
has virtually no activity.
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Table 32. Demonstration of inhibitor against human intrinsic
thromboplastin in chicken adsorbed plasma in T.G.T.
(method described in appendix IV, 23)
Incubation mixture: 0.1 ml human normal adsorbed plasma, diluted l/5,
0.1 ml variable,
0.2 ml human serum, diluted l/lO,
0.2 ml human cephalin 1/100,
0.2 ml M/40 CaC^ solution.
Substrate : human high-spun plasma.
A- Before incubation
Plasma Incubation time (minutes)
mixture (ml) Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 65 24 14 11 10 10
74 0.1 Hum.ads.pl. 2 60 21 13 10 10 10
0.1 Saline Avg. 621 22\ 13^ 10| 10 10
fo 1.3 16 50 90 100 100 fo
1 68 25 16 11 11 10
75
0.1 Hum.ads.pl. 2 62 20 14 10 10 10^
0.1 Ck.ads.pl. Avg. 65 22\ 15 io£ 10i 10*
f> 1.2 16 39 90 90 94 fo I
1 48 16 10 9 9 9
76 0.2 Hxm.ads.pl.
2 49 15 10 H 9 9i
Avg. 48£ 15i 10 9i 9
f 2.3 36 100 120 130 120 f
Percentage figures for the human active thromboplastin were
read from the thromboplastin dilution curve B in figure 2.
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Table 32, continued
B~ After incubation at 37°C. for 2 hours
Incubation time (minutes)
Plasma 
mixture (ml)
Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 72 26 15 12 10 10
77
0.1 Hum.ads.pl. 2 65 25 144 12 11 11
0.1 Saline Avg. 684 254 144 12 104 104
fo 1 11 42 66 90 90 fo
1 99 59 31 25 18 16
78 0.1 Hum.ads.pl. 2
110 60 30 24 184 17
0.1 Ck.ads.pl. Avg. 1044 594 30i 244 184 164
* 0.4 1.4 7 12 24 31 f
1 50 17 11 io4 10 104
79 0.2 hum.ads.pl. 2 53 15i
11 10 10 10
Avg. 5li 164 11 104 10 104
fo 2 32 80 95 100 95 f
1 76 30 17 134 11 11
80 0.1 Hum.ads.pl. 2 70 23 16
12 n4 11
0.1 Heated Ck.ads.pl. Avg. 73 264 164 12| n 4 11
fo 0.9 10 31 58 78 80 f>
Percentage values for the active human thromboplastin were read 
from the thromboplastin dilution curve B in figure 2.
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PLASMA INHIBITORS OF BLOOD THROMBOPLASTIN.
(M odified T G I )
140-
J  120 -
£ 100- > ■ — •  a
  -o b-o* .•------•  a
o  c
% 6 0 -
4 0 -
1 3 55 1 2 32 6 44 6
Tim e in Minutes
Figure 17. Chicken plasma inhibitors of human intrinsic thromboplastin.
Incubation mixture: 0.2 ml plasma mixture, diluted l/5,
0.2 ml human serum, diluted l/lO,
0.2 ml human cephalin 1/100,
0.2 ml M/40 CaCl^ solution.
Substrate : normal human high-spun plasma.
Figure A : Before incubation of the plasma mixture.
Curve a : Hum.ads.pl. alone (Mixture 76, table 32)
Curve a^ : Hum.ads.pl. + saline (Mixture 74, table 32)
Curve b : Hum.ads.pl. + Ck.ads.pl. (Mixture 75, table 32)
Figure B : After 2 hours incubation at 37°C.
Curve a : Hum.ads.pl. alone (Mixture 79, table 32, B)
Curve a^ : Hum.ads.pl. + saline (Mixture 77, table 32, B)
Curve b : Hum.ads.pl. + Ck.ads.pl. (Mixture 78, table 32, B)
Curve c : Hum.ads.pl. + Heated Ck.ads.pl. (Mixture 80, table 32, B)
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Table 33. Investigation for inhibitors against human intrinsic
thromboplastin in chicken serum in the T.G.T.
(method described in appendix IV, 23)
Incubation mixture; 0*2 ml human adsorbed plasma, diluted l/5,
0*2 ml serum mixture, diluted l/lO,
0.2 ml human cephalin 1/100,
0.2 ml M/40 CaCl^ solution.
Substrate : human normal high-spun plasma.
A- Before incubation
Serum 
mixture (ml)
Incubation time (minutes)
Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 60 20 10 9 10 9
81 0.2 Human serum 2 56 18 10 9 8 9
Avg. 58 19 10 9 9 9
* 1.5 22 100 130 130 130 fo 1
1 69 24 H i 10 10i ioi
82 0.1 Human serum 2 67 20 10i 10 9i 9i
0.1 Saline Avg. 68 22 11 10 10 10
* 1 15 80 100 100 100 fo
1 67 24 12 11 11 10
83 0.1 Human serum 2 66 22 11 10 10 10
0.1 Chicken serum Avg. 66i 23 n i 10i ioi 10
* 1.1 14 74 90 90 100 fo
Percentage values of human active thromboplastin were read from 
the thromboplastin dilution curve B, figure 2.
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Table 33, continued
B- After incubation at 37°C. for 2 hours
Serum 
mixture (ml) Expt.
Incubation time (minutes)
1 2 3 4 5 6
No. Clotting times (seconds)
1 66 20 lo t 10 10 10
84 0.1 Human serum 2 67 20 10 10 10 10
0.1 Saline Avg. 66i 20 i o i 10 10 10
f 1.1 19.5 100 100 100 100 fo
1 73 22 12 11 10 11
85 0.1 Human serum 2 67
20 10 10 10 10
0.1 Chicken serum Avg. 70 21 11 10j 10 lo t
fo 0.9 17 80 90 100 90 fo
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SERUM INHIBITORS OF BLOOD THROMBOPLASTIN.
(Modified T.G.T)
140 -
4  a
100 -
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2 0 -
Time in Minutes
Figure 18. Chicken serum inhibitors of human intrinsic thromboplastin.
Incubation mixture: 0*2 ml human adsorbed plasma, diluted l/5,
0.2 ml serum mixture, diluted l/lO,
0.2 ml human cephalin l/lOO,
0.2 ml M/40 CaCl^ solution.
Substrate : human normal high-spun plasma.
Figure A Before incubation of the serum mixture
Curve a •• human serum alone, (Mixture 81, table 33 A)
Curve ai
• human serum + saline (Mixture 82, table 33 A)
Curve b # human serum + chicken serum (Mixture 83, table 33 AJ
Figure B After incubation at 37°C. for 2 hours
Curve a1
»• human serum + saline (Mixture 84, table 33 B)
Curve b • human serum + chicken serum (Mixture 85, table 33 B)
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Table 34. Clot retraction 
(method of Macfarlane, 1938; appendix IT, 4)
Percentage retraction in 1 hour*
Experiment 1 15 #
Experiment 2 25 £
Experiment 3 22 %
Experiment 4 17 $
Experiment 5 20 %
Average 19*8
* Mean of duplicate estimations.
Table 35. Prothrombin consumption index 
(method of Biggs and Macfarlane, 1957; appendix IT, 13, A)
Expt. 1 Expt. 2 Expt. 3
Chicken pi. time (sec) 33 30 32
Chicken ser.time (sec) 360+ 360+ 360+
P.C.I. 9.1 4.1 8.8 $
Average P.C.I. of chicken blood = 7.3
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O N  B O V I N E  B L O O D
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R E S U L T S  O F  E X P E R I M E N T S  
O N  B O V I N E  B L O O D
All the following results were obtained 
from experiments carried out on blood samples 
obtained from domestic cattle of several breeds 
at the slaughter house, using pooled plasma 
or serum samples from at least three animals 
for each experiment to obviate as much as 
possible any individual variations from affecting 
the final levels of the various coagulation 
factors.
Blood sanoples were obtained fresh on the 
day of the test concerned as described in 
appendix II, 1, vi.
- 157 - (Appendix V, B)
Table 36. Measurement of fibrinogen in bovine plasma
Turbidimetric method 
of Stirland, 1956 
(appendix IV, 2, III)
Micro-Kjeldahl method of 
Cullen & van Slyke, 1920 
(appendix IV, 2, I)
mgms fibrinogen /lOO mis absolute plasma
Expt. 1 750 744
Expt. 2 620 661.1
Expt. 3 720 692
Average 696.6 699
The average of both methods = 697.8 mg fibrinogen/100 mis plasma.
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Table 37. Thrombin-fibrinogen reaction of plasma 
(method described in appendix IV, 8 and 9)
Clotting
mixture
Thrombin topical (P.D.& Co.) in units / ml.
Sxpt, 50 25 12.5 6.25 3.1 1.55
(ml) Clotting times (seconds)
0.1 Bovine pi. 1 5 7 15 33 68 90
0.1 Saline 2 6 7 10 154 29 58
0.1 Thrombin 3 6 8 11 16 30 58
Avg. 5.4 7.3 12 21.5 42 69
0.1 Human pi.
1 4 5 10 20 32 65
0.1 Saline 2 5 7 9 13 26 52
0.1 Thrombin 3 5 6 10 14 27
44
Avg. 4.6 6 9.6 15.6 28.3 53.6
0.1 Bovine pi.
1 2i 34 5 8 16 24
0.1 Pyrocatechol 2 3 34 5 11 134 25
0.1 Thrombin 3 2\ 34 44
8 144 24
Avg. 2.6 3.5 4.8 9 14.6 24.3
0.1 Human pi.
1 24 34 5 8 14 22
0.1 Pyrocatechol 2 3 3 4 9 13 19
0.1 Thrombin 3 3 34 5 84
16 23
Avg. 2.8 3.3 4.6 8.5 14.3 21.3
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THROMBIN -  FIBRINOGEN REACTION OF PLASMA.
8 0 -
6 0 -
4 0 -
20-
1.56.2 3.112.550 25
Thrombin in units per ml.
Figure 19. Throrabin-fibrinogen reaction of bovine plasma.
Curve a s Human plasma + saline.
Curve b s Bovine plasma + saline.
Curve a^ : Human plasma + pyrocatechol 1%
Curve b^ : Bovine plasma + pyrocatechol 1$.
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Table 38. Antithrombin assay in bovine -plasma 
(modified method of Astrup and Darling, 1942d, appendix IV, 11, B)
Mixture A B C D 1
Saline ml • 0.3 0.2 0.15 0.1 0.0
Plasma (dil. 1/5) ml » 0.0 0.1 0.15 0.2 0.3
Thrombin(30 U/ml) ml »
1
1 1 1 1 1
Expt
Clotting time Human 1 10
12 14* 16 22
of 2 18 21 25 30 38
fibrinogen Bovine
1 10 13 15 15* 24
(seconds*) 2 18 20 23 28 35
T / T o n
Human 1
2
1
1
0.83
0.86
0.71
0.72
0.62
0.60
0.45
0.47
Bovine 1
2
1
1
0.77
0.90
0.66
0.78
0.64
0.64
0.4! I 
0.5! 1
Corrected
Human 1
2
1
1
0.81
0.83
0.72
0.74
0.63
0.65
0.45
0.47
T / T o n Bovine 1
2
1
1
0.80
0.84
0.70
0.76
0.60
0.68
0.40
0.53
Calculated 
units of
Human
1
2
270
212
260
216
240
219
265
220
Antithrombin 
per ml plasma
Bovine
1
2
255
200
290
200
285
200
290
204
* Mean of duplicate estimations,
Average value for human plasma =
Average value for bovine plasma =
Bovine plasma antithrombin content 
in percentage of human antithrombin =
Therefore, bovine plasma antithrombin 
plasma antithrombin content.
Expt. 1 
258 
280
Expt. 2
216.7 U./ml. 
201 U./ml.
108.5$ 93 $
content equals 100.75 $ of human
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ANTITHROMBIN ASSAY.
Modified method of Astrup & Darling 1942.
1.0
0.8-
0.6 -
0 0.1 0.2 0.3 0 0.1 0.2 0.3
Plasma Concentration
Figure 20. Antithrombin assay in bovine plasma.
Figure A
Curve a ; human plasma 
Curve b : bovine plasma
Figure B
Curve a : human plasma
Curve b : bovine plasma
(experiment 1, table 38) 
(experiment 1, table 38)
(experiment 2, table 38) 
(experiment 2, table 38)
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Table 39. Antithrombin assay in bovine plasma 
(method of Douglas and Biggs, 1953; appendix IV, 11, A)
Incubation Incubation time (minutes)
mixture Expt.
1 14 1 2 3 4 5
Clotting times (seconds)
0.5 ml Hum.pl. 1 22 28 35 53 128 180+ 180+
0.5 ml Thrombin 2 —
— 16 37 90 180+ 180+
(50 units/ml) 3 26 29 42 80 170 180+ 180+
Avg. 24
T-lf'l
00CM 31 57 129 180+ 180+
1 22 30 42 80 180+ 180+0.5 ml Bov.pl.
0.5 ml Thrombin 2 — — 2 0 61 180+ 180+
3 24 3 5 45 100 180+ 180+(50 units/ml)
Avg. 23 3 2 £ 36 80 180+ 180+
Units of residual thrombin
Human plasma Avg. 5.8 4 . 8 4.3 2.1 0.8 0
Itovine plasma Avg. 6.2 4 3.6 1.4 0.5 0
The incubation time at -which thrombin reaches zero activity is 
read from curves a and b in figure 21 and is as follows:—
Value for human plasma = 3 
Value for bovine plasma = 2.3
v  3x100
Therefore, bovine plasma anti thrombin--------—
2.3
= 130.4$ of human plasma antithrombin.
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ANTITHROMBIN ASSAY.
Method of Douglas & Biggs,1953.
o \
Incubation Time in Minutes
Figure 21. Antithrombin assay in bovine plasma.
Curve a s human plasma , average values (Table 39)
Curve b : bovine plasma, average values (Table 39)
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Table 40. Quick’s one-stage prothrombin time test
Test plasma Human brain Bovine brain
Clotting times (seconds)
Bovine plasma
43
21 (31) 
29
18
13 (14.8)
134
Human plasma
16i
15 (15.8)
16
37 .
34 (36.3)
38
Bov.pl. + Hum.pl.
18
16 (16.3) 
15
22
18 (19) 
17
Bov.pl. + Saline
37
27 (32.6) 
34
17
15 (16.3) 
17
Hum.pl. + Saline
20
164(18.8)
20
44
44 (45.3) 
48
The figure between brackets is the mean of each 
group of three experiments carried out with different 
batches of brain thromboplastin and different plasma pools.
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Table 41. Factor V - brain thromboplastin species specificity
(method described in appendix IV, 16)
Incubation mixture: 0.3 ml Brain extract, diluted 1/4, variable,
0.3 ml Purified factor V, (appendix III, 9), variable, 
0.3 ml human serum, diluted l/lO,
0.3 ml M/40 CaCl2 solution.
Substrate: Human normal plasma.
Variables Expt.
Incubation time (minutes)
12 1 2 3 4 5 6
Clotting times (seconds)
Human brain 1 13 11 10 9 10 10 10
Human factor V 2 15 9 7 7 8 8 9
Human brain 1 10 7 6 5i 5i 6 6
Bovine factor V 2 10 5 5 5 5 5 5i
Human brain 1 13 13 12j 13 13 12i 13
Saline 2 15 14 13 13 13 13j 14
Bovine brain 1 16 13 12 11 11 12 12
Human factor V 2 20 15 9i 8 10 9 10
Bovine brain 1 16 11 8 6 7 8
Bovine factor V 2 15 6i 5i 5i 6i 6
Bovine brain 1 20 17 16 14 14 15 15
Saline 2 17 16 15 14 15 16 17
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Table 42. Assay of bovine plasma factor V activity 
By correction of human stored factor V-deficient plasma, as 
described in appendix IV, 14. Human brain thromboplastin was
used for all mixtures.
Plasma
dilution
Factor V 
percentage
Clotting times (seconds)
Expt. 1 Expt. 2 Expt. 3
Human control plasma
1/10 100 fo 21 30 32^
1/20 50 fo 26 35 37
1/40 25 % 30 45 42
1/80 12.5 % 37 50 44
1/160 6.2 fo 50 55 46
1/320 3.1 f 54 59 52
1/640 1.5 % 62 64 51
0 % 86 66 51
Bovine test plasma
1/10 19i 23 26£
1/20 20 29i 29
1/40 25 33 34
1/80 30 40 40
1/160 34 47 44
Calculated factor V conc. 244 fa 272 $ 288 f>
The average of the three experiments for bovine plasma factor 
V concentration equals 268 f> of human plasma factor V activity.
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BOVINE FACTOR V ASSAY
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</>■ocoo0)
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Percentage of Human Factor V
Figure 22. Bovine plasma factor V assay.
The dilution curve shown above is for human normal plasma 
diluted in human stored plasma, and clotted with human brain in the 
presence of calcium chloride solution. It represents the results 
obtained in experiment 1, table 42.
The dotted lines show how the clotting times obtained with 
every dilution of the test bovine plasma were converted into percentage 
values of factor V activity which is then multiplied by the dilution 
factor to arrive at the final bovine plasma factor V concentration 
in percentage of human plasma factor V  activity.
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Table 43. Factors Vll and X - brain thromboplastin species specificity
(method described in appendix IV, 17)
Incubation mixture
0*3 ml brain extract, diluted 1/4, variable.
0.3 ml purified factors VII and X, variable, (appendix III, 10), 
0.3 ml M/40 CaC^ solution.
Variables Substrate
Incubation time (minutes)
1 1 2 3 4 5 6
Clotting times (seconds)
Human brain Fresh hum.pl. 11 10 9 9 9 9 9
Hum. VII & X Phenindione pi. 15 13 13 12i 13 13 13
Human brain Fresh hum.pl. 20 16 H i 10 10 10 9
Bov. VII &  X Phenindione pi. 27 20 15 12 10 10 10
Human brain Fresh hum.pl. 29 26% 26 27 26 26 26
Saline Phenindione pi. 50 55 60 58 60 60 60
Bovine brain Fresh hum.pl. 20 17 12 11 10 10 10
Hum. VII & X Phenindione pi. 32 25 18 19 17 18 17
Bovine brain Fresh hum.pl. 8 7 7 7 8 7 7
Bov. VII & X Phenindione pi. 9 9 8 8 8 8 8
Bovine brain Fresh hum.pl. 47 47 49 52 48 49 50
Saline Phenindione pi. 73 115 90 115 105 108 110
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44« Bovine plasma factor VII assay
Method A : by correction of human phenindione plasma, using human
brain extract, (method of Biggs and Macfarlane, 1957, 
appendix IV, 15, A).
Method B : by correction of Seitz-filtered bovine plasma using either 
human or bovine brain extracts, (method of Koller et al, 
1951, appendix IV, 15, B).
Clotting times (seconds)
Plasma Factor VII Method A Method B
dilution percentage Expt. 1 Expt. 2 Human brain Bovine brain
Hum. pi. Hum. pi. Hum.pl. Bov.pl.
1/10 100 i* 28 28 40 48
1/20 50 fo 33 34 57 65
1/40 25 % 37 36i 97 84
1/80 12.5 % 42 42 167 117
1/160 6.2 fo 45 45 265 169
1/320 3.1 f 48 49 556 215
1/640 1.5 f> 50 52 930 272
0 f 60 62 — 321
Bov.pl. Bov.pl. Bov.pl. Hum.pl.
1/10 38 40 142 82
1/20 43 45 254 123
1/40 4 6 i 47 — 175
Calculated F VII conc. 2 1  fo 18 fo 13.7 fo 23 fo
It should be noted that in the first two experiments using human 
brain, the bovine factor VII gave a value of 18-21 f  of human factor 
VII activity. "While in method B, with human brain, the human factor 
was still much higher than the bovine factor VII, but with bovine
brain it was 23 fo of the bovine factor VII.
It should also be mentioned that method B is sensitive to factor
X in the test plasma, since the Seitz-filtered bovine plasma is
virtually free from both factors 711 and X.
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1000 BOVINE FACTOR VII ASSAY.
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Figure 23. Bovine plasma factor VII assay.
(Human plasma s black dots. Bovine plasma : white dots.)
Curve A s human plasma dilution curve in phenindione human plasma, 
using human brain, (table 44, method A, experiment 2).
The bovine plasma factor VII reads 18 fo of the human.
Curve B : human plasma dilution curve in bovine Seitz-filtered plasma, 
using human brain, (table 44, method B, human brain).
The bovine plasma factor VII reads 13.7 f  of the human.
Curve C s bovine plasma dilution curve in bovine Seitz-filtered plasma, 
using bovine brain, (table 44, method B, bovine brain).
The human plasma factor VII reads 23 fo of the bovine.
The dotted lines show how the clotting times obtained with each 
dilution of plasma were converted into percentage values of factor 
VII, which when multiplied by the dilution factor gave the final factor
VTI percentages.
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Table 45. Bovine plasma and serum factor X assay
(method of Bachmann, Duckert, and Roller, 1958; appendix IV, 18)
Plasma Concentration Expt.l Expt.2 Expt.3 Expt.4 Expt.5
or
serum of
Clotting times (seconds)
dilution factor X Human plasma Human serum
1/10 100 $ 21 22* 19* 22 20
1/20 50 f 24 25 23* 25 23*
1/40 25 fo 29 32 31* 31 32
1/80 12.5 f> 36* 37 39 36 38
1/160 6.2 $ 42 48 42 44 46
1/320 3.1 fo 51 51* 53 50 53
1/640 1.5 fo 60 61 62 65 62
1/1280 0.75f 75 74 73 77 72*
1/2560 0.36$ 
0 fo
82*
94i
83
93
84
94
83
100 100
Bovine plasma Bovine serum
1/10
1/20
1/40
1/80
20
24
31
36
22
25
30*
36
21
241
31*
38
22*
26
32
23*
26
30
37
CalculatecL factor X conc. 101.5$ 109 $
94 fo 89.5$ 92.2$
Average factor X concentration in bovine plasma = 101.5 *  of human plasma. 
Average factor X concentration in bovine serum = 90.6 f, of human serum.
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Table 46. Bovine plasma prothrombin assay
(by the one-stage method of Roller et al, 1951; appendix IV, 12, A)
Incubation mixture: 0*1 ml test plasma diluted in veronal buffer,
0*05 ml adsorbed bovine plasma,
0,05 ml oxalated human serum (prothrombin-free),
0.1 ml brain extract, as shown,
0.1 ml M / 4 0 CaC^ solution.
Human brain Bovine brain
Plasma Prothrombin Expt. 1 Expt. 2 Expt. 3
dilution concentration Clotting times (seconds)
Hum.pl. Bovine plasma
1/10 100 f> 28 15 20
1/20 50 fo 40 21 24
1/40 25 f 64 to * 34
1/80 12.5 f 73 33 38
1/160 6 .2 $ 79 46 41
1/320 3.1fo 87 51 44
1/640 1.5 f 103 63 55
o
200 — —
Bov.pl. Human plasma
1/10 40 21 22
1/20 58 28 31
1/40 — 32 40
Prothrombin conc. 45 f 48 fo 57 fo
Bovine plasma prothrombin estimated with human brain (expt. 1) 
had a concentration of 45f> of the human control plasma prothrombin.
In experiments 2 and 3, the use of bovine brain gave shorter clotting 
times with bovine plasma, which therefore was considered the control 
for the construction of a dilution curve, from which the human plasma 
prothrombin was calculated to be 48 - of the bovine plasma prothrombin
activity.
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MEASUREMENT OF PROTHROMBIN. 
One-stage method of Roller et al,1951.
200
100
60 80 100
(1/io)Concentration of Prothrombin in percentage
Figure 24. Bovine plasma prothrombin assay.
(Human plasma : black dots. Bovine plasma : white dots) 
Curve A : human plasma dilution curve, using human brain extract, 
illustrating experiment 1, table 46.
Curve B • bovine plasma dilution curve, using bovine brain extract, 
representing experiment 2, table 46.
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Bovine plasma prothrombin assay 
(Two-stage area method of Biggs and Douglas, 1953a; appendix IV, 12, C)
Incubation Incubation time (minutes) Weight of area
mixture Expt. i
1
J 1 1 2 3 4 5 under curve &
Clotting times (seconds) its percentage
1 Human plasma 1 14 — 15 22 55 180+ 180+
with 2 — — 13 20 61 180+ 180+
human brain 3 14 — 21 28 82 180+ 180+
Bovine plasma 4 — 15 16 25 42 150 180+
with 5 — 13 14 16 25 69 180+
bovine brain 6 — — 10 8 14 35 94 180
Bovine plasma 
with 7 — — 17 13 12% 36 91 155
human brain 8 — 40 — 20 25 66 180+ 180i
Thrombin units / ml. Weight $
1 11 —  10 6.4 2.3 0.5 0
2 — —  12 7.3 1.6 0.3 0
3 11 — 7 4.8 1.3 0.2 0
Avg. 11 9.6 3.1 1.7 0.3 0 175 100
4
— 10 9.6 5.6 3 0.7 0 178 101.7
5 — 12 11 9.5 5.6 1.6 0.3 0 284 162.2
6 — -  16.5 22 11 3.7 1.1 524 299.4 '
7 8.6 12 13 3.6 1.2 0.( 408 233.1 I
8
— 3 7.3 5.6 1.7 0.3 0 203 116
To compare the effect of using brain extracts of different species 
the bovine plasmas used in experiments 5 and 8 were from the same pool, 
and similarly plasmas used in experiments 6 and 7 were the same.
The human control plasma was from the same subject.
With bovine brain, bovine plasma prothrombin was 162$ of human 
plasma prothrombin (experiment 5), while on using human brain its 
prothrombin was 116$ of human plasma prothrombin (experiment 8).
Similarly, another plasma pool gave a result of 299$^of human 
prothrombin when estimated with bovine brain (experimen^  ), an 0 
233$ of human prothrombin when estimated with human brain (experiment 7).
A third bovine plasma pool had 101$ of human eVen
on using the homologous bovine brain extrac ( p
- 175 - (Appendix V, B)
MEASUREMENT OF PROTHROMBIN.
Two-stage Area method of Biggs & Douglas,1953.1 2 -
10 -
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Figure 25. Bovine plasma prothrombin assay.
Curve A : obtained for human plasma using human brain extract.
It represents the average of the experiments 1, 2, and 3, 
from table 47. Veight of cut-out area under curve equals 
175 mg which was designated the 100 $ value of prothrombin. 
Curve B : represents experiment 5 (table 47) on bovine plasma with 
bovine brain. Veight of cut-out area under curve equals 
284 mg which was equivalent to 162.2$ of human prothrombin. 
Curve C : represents experiment 8 (table 47) on the same plasma pool 
using human brain. Veight of enclosed area equals 203 mg 
which was equivalent to 116 $ of human plasma prothrombin.
It is noted that the use of the homologous brain extract yields a 
higher prothrombin activity.
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Table 48. Bovine plasma prothrombin assay 
(Globulin fraction method of Douglas and Biggs, 1953; appendix IV, 12, 
Both globulin fractions were tested with human brain extract.
Experiment 1 Experiment 2
Hum.pl. Bov.pl. Hum.pl. Bov.pl.
Clotting time of 
substrate (seconds) 25^ 26 21 23
Thrombin units / ml. 5.2 5 6.6 5.9
Prothrombin concentration 100 fo 96 f> 100 fo 89.3 fo
Table 49. Bovine prothrombin consumption index
A. Method of Biggs and Macfarlane, 1957, (appendix IV, 13, A) using 
bovine brain extract.
Incubation time (seconds)
45 90 45 90
Expt. 1 Expt. 2
Bovine plasma time (sec.) 16 16 15i 15£
Bovine serum time (sec.) 40 44 32 51
Prothrombin consumption inde> 40 fo 36 f 48 fo 30 f>
Average P.C.I. 38 fo 39 fo
B. Globulin fraction method of Douglas and Biggs, 1953, (appendix IV,
13, B), using human brain extract.
Bovine plasma Bovine serum
30 minute clotting time (sec.) 
Thrombin units per ml.
26
5
120
0.78
Prothrombin consumption index 15.6 fo
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Table 50. R.V.V.-cephalin clotting time of plasma 
(method described in appendix IV, 19)
Concentration of 
R.V.V. - cephalin R.
Plasma Clotting times (seconds)*
Expt. 1 Expt. 2 Expt. 3
1/40,000 - 0.06 gm f Human 7 si 8
Bovine 10 10 12
1/200,000- 0.06 gm fo Human si 9 9
Bovine 12 13 14
* Average of duplicate estimations.
Table 51. Bovine blood platelets* count
(method described in appendix IV, 1, A)
Total count / c.mm. whole blood*
Experiment 1 331,000
Experiment 2 261,000
Experiment 3 324,400
Experiment 4 278,000
Experiment 5 387,700
Experiment 6 292,000
Average 312,350
* Mean of duplicate estimations.
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Table 52. Bovine -whole blood clotting time 
(method of Lee and White, 1913; appendix IV, 3)
Clotting times*
Ordinary glass Siliconed glass
Experiment 1 7’ 20" 13' 30"
Experiment 2 6' 29" 12* 10"
Experiment 3 6' 15" 14' 5"
Average 6' 41" 13' 15"
* Mean of two tubes' readings.
Table 33. Eecalcification time of plasma 
(method described in appendix IV, 5)
Clotting times
Human plasma Bovine plasma
Experiment 1 106" 164"
Experiment 2 129" 151"
Experiment 3 120" 122"
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Table 54. Hageman factor and plasma thromboplastin 
antecedent activity in bovine plasma 
(method of Ratnoff and Rosenblum, 1958; appendix IV, 24, I)
Test plasma 
preparation
Clotting time (minutes) of substrate normal 
citrated platelet-deficient Intact plasma
Experiment 1 Experiment 2 Experiment 3
Human untreated plasma 145 125 120+
Bovine untreated plasma 160 120+ 120+
Human activated plasma 14 16 13
Bovine activated plasma 15 15 14
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Table 55. Thromboplastin generation test
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixture: 0.2 ml adsorbed plasma, variable, diluted 1/5,
0.2 ml serum, variable, diluted l/lO,
0.2 ml human platelets,
0.2 ml M/40 CaCl2 solution. 
Substrate : human H.S.plasma.
Incubation 
mixture (ml) Expt.
Incubation time (minutes)
1 2 3 4 5 6
No. Clotting times (seconds)
86 0<>2 Hum.ads.pl. 0.2 Hum. serum
1
2
3
41
62
70
9
11
24
9
9i
10..
9
9
10
9*
si
10
94
9
11
Avg.
fo
58
2.6
14.*
46
T-|OJ
O' o
 
1—1 
1—1
9.:
117
3 9.3 
117
9.8 
103 f
1 12 10 10 10 9i 11 1
2 10 10 10 10 10 9i
87
0.2 Bov.ads.pl. 3 9 11 10 10 11 11Doy#s6ruiii Avg. 10.3 10.3 10 10 10.2 10.4
94 94 100 100 96 90 fo
1 8 9 9 Si 94 9
2 10 10 9 9 9 9
88 0.2 Bov.ads.pl. 3 22 12 11 12 11 104XlLLHi• Oul Uili Avg. 13.3 10.3 9.6 9.8 9.8 9.5
* 56 94 110 103 103 110
1 15 9i 104 10 104 104
2 11 9 10 10 10 9
89
0.2 Hum.ads.pl. 3 15 11 10 lOi 10 110.2 Bov.serum Avg. 13.6 9.8 10.2 10.2 10.2 10.2
fo 54 103 96 96 96 96
1 25 9i 9i 10 10 10
0.15 Haemophilic pi 2 31 11 10 9i 9i 9i
90 0.05 Hum.ads.pl. 3 91 32 13 12i 11 11
0.2 Hum. serum Avg. 49 17i 10.8 10.5 10.2 10.2
* 3.5 31 88 90 96 96 fo
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Table 55. continued
Incubation Incubation time (minutes)
mixture (ml) Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 30 16 15 15 13 12*
0.175 Haemophilic pi. 2 35 17 17 16 16 15
91 0.025 Hum.ads.pl. 3 58 20 17 15 14 15
0.2 Hum. serum Avg. 41 17.6 16.3 15.2 14.2 14.2
f> 5 31 36 41 48 49 f
1 88 7li 29 18 17 17
0.19 Haemophilic pi. 2 90 73* 30 17 17 17*
92 0.01 Hum.ads.pl. 3 92 77 31 19 18 18
0.2 Hum.aerum Avg. 90 74 30 18 17i 17*
95 1 1.5 9.8 29 28 28 fo
1 12* 8* »i 9 9 9
0.15 Haemophilic pi. 2 15 9 9 9i 9 ' 9
93 0.05 Bovine ads.pl. 3 45 12 12 11 ioi 11
0.2 Hum. serum Avg. 24 9.8 9.8 9.8 9.5 9.6
fo 15 103 103 103 110 110 fo
1 25 10 9* 9i 9 9
0.175Haemophilic pi. 2 36 H i 10i ioi 10 10
94 0.025Bovine ads.pl. 3 47 13 u i 11 11 11
0.2 Hum. serum Avg. 36 Hi ioi 10.3 10 10
# 6.8 76 90 95 100 100 fo
1 37 10 10 10 9 9
0.19 Haemophilic pi. 2 52 13i 11 11 ioi 10*
95 0.01 Bovine ads.pl. 3 68 17 12 12 12 12
0.2 Hum. serum Avg. 5li 13i 11 11 10.8 10.8
95 3 54 84 84 90 90 fo
1 58 17 16 12i 12* 12
0.19 Haemophilic pi. 2 — — — — — —
96 0.01 Bov.ads.pl. l/lO 3 86 22 16 14 13 13
0.2 Hum. serum Avg. 72 19i 16 13* 12.7 12.5
95 1.5 25 38 56 64 65 fo
1 72 28 20 17 16 16
0.19 Haemophilic pi. 2 — — — — — —
97 0.01 Bov.ads.pl. l/20 3 88 30 28 25 18 18
Avg. 80 29 24 21 17 17
95 1.3 10.5 16 21 33 33 fo
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Table 55. continued
Incubation 
mixture (ml) Expt.
Incubation time (minutes)
1 2 3 4 5 6
No. Clotting times (seconds)
98
0.20 Human ads.pl. 
0.15 X-mas serum 
0.05 Human serum
1
2
3
39 19 11 10 10 9 
50 19 10 10 10 10 
100 30 12 11 10 10
Avg.
fo
63 23 11 10.3 10 9.6 
2 17 84 94 100 110 f
99
0.20 Human ads.pl. 
0.175 X-mas serum 
0.025 Human serum
1
2
3
88 25 13 11 11 11 
90 27 13 12 12 11 
105 28 14 13 12 12
Avg. 94.3 26.6 13.3 12 11.6 11.3 
0.9 12.5 56 70 74 80 f
100
0.20 Human ads.pl. 
0.19 X-mas serum 
0.01 Human serum
1
2
3
101 82 30 16 14 14 
110 91 30 16 15 15 
126 97 33 16 15 14
Avg.
*
112 90 31 16 14.6 14.3 
0.6 1 9 37.5 46 48 fo
101
0.20 Human ads.pl. 
0.10 X-mas serum 
0.10 Bovine serum
1
2
3
11 11 lli 11 12
12 12 12 H i  11 11
13 12i 12 lli 12 12i
Avg.
*
12i 11.8 11.6 11.5 11.3 11.8 
54 74 76 76 80 74 fo
102
0.20 Human ads.pl. 
0.15 X-mas serum 
0.05 Bovine serum
1
2
3
40 16 15i 14 14i 14i 
32 17 15 15 15 15 
23 15i 15 15 15 15
Avg.
%
3li 16.2 15.2 14.6 14.8 14.8 
8.8 36 41 46 45 45 fo
103
0.20 Human ads.pi. 
0.175 X-mas serum 
0.025 Bovine serum
1
2
3
42 19 17 17i 16i 16 
38 21 19 19 18 18 
34 20 19 19 18i 17i
Avg.
*
38 20 18.3 18.4 17.6 17.2 
6 23 28 28 31 32 fo
Experiments 1, 2, and 3 each was made with a different set of
reagents. Thromboplastin percentages were read from the human active 
thromboplastin dilution curve constructed with human platelets,
(figure 2, curve A).
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Table 56. Thromboplastin generation test, modified
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixtures 0*2 ml adsorbed plasma, variable, diluted l/5,
0.2 ml serum, variable, diluted 1/10,
0.2 ml bovine platelets, (appendix III, 15, C)
0.2 ml M / 4 0 CaCl^ solution. 
Substrate : human H.S.plasma.
Incubation Incubation time (minutes)
mixture (ml) Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 40 22 12 10 10 10
104 0.2 Human ads.pl. 0.2 Human serum
2
3
82
68
28
15
12
10
12
11
ioi
11
ioi
11
Avg.
#
63 23 11.3 11 10.5 10.5
2.1 17 80 84 92 92 io
1 20 12 12 12 13 12j
105
0.2 Bovine ads.pl. 
0.2 Bovine serum
2
3
12
20
11
Hi
11
n i
11
12
12i
13
12i
13
Avg.
1°
17.3
32
11.5
76
11.5
76
11.7
74
12.7
62
12.7
62 1o
106 0.2 Bovine ads.pl. 0.2 Human serum
1
2
3
18 j
13i
15
13
10
11
12i
10
11
10
9i
H i
9
9i
11
9
9i
11
Avg. 15.3
40
11.3
80
11.1
82
10.3
94
9.8 9.8 
103 103 fo
i 20 12 12 13 13 13i
107 0.2 Human ads.pl.
2
3
16
20
11
12
11
12
lli
13i
12
13
11
13
0.2 Bovine serum Avg.
56
18.6
27
11.7
74
11.7
74
12.7
62
12.7
62
12.5 
64 %
Xn view of the similar activities of human and bovine platelet
suspensions, the percentage values of active thromboplastin were read 
from the human dilution curve A, figure 2.
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PLASMA ACTIVITY IN TG.T
120 -
-o b
100 -
8 0 -
6 0 -
1 2 3 4 5 6
>o-------o b
^ ------- •  a
p .—
1 2 3 4 5 6
Time in Minutes
Figure 26. Bovine plasma activity in the T.G.T.
Figure A : using human platelets
Curve a : human ads.pl. + human serum
Curve b s bovine ads.pl. + human serum
Figure B : using bovine platelets
Curve a : human ads.pl. + human serum
Curve b : bovine ads.pl. + human serum
(Mixture 86, table 55) 
(Mixture 88, table 55)
(Mixture 104, table 56) 
(Mixture 106, table 56)
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A.H.G. ACTIVITY IN MODIFIED TG.T.
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Figure 27. Bovine plasma A.H.G. activity in T.G-.T.
Figure A
Human adsorbed plasma diluted l/4, l/8, and l/20 in haemophilic 
adsorbed plasma, (Mixtures 90, 91, and 92 respectively, table 55).
Figure B
Bovine adsorbed plasma diluted 1/4, l/8, l/20, l/4Q, and 1/80 in 
haemophilic adsorbed plasma, (Mixtures 93, 94, 95, 96, and 97, table 55).
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Table 57. A.H.G. assay in bovine plasma 
(method of Pitney, 1956; appendix IV, 21)
Plasma
dilution
A.H.G.
concentration
Clotting times (seconds)
Expt.l Expt.2 Expt.3 Expt.4 Expt.5 Expt.6
Human control plasma
1/20 100 % 16£ 19 18 20 15 20
1/40 50 %
CMCM 25 23 25 23 27
1/80 25 % 35 30 28 32 26 34
1/200 io % 52 40 43 38 35 42
1/400 5 i 59 45 47 57 38 65
1/2000 i % 60 55 53 80 42 74
o i 78 60 56 82 38 80
Bovine test plasma
1/80 14 — — — — —
1/100 16 14 18 18 14 17
1/200 26 17 22 23 16 20
1/400 29 24 28 30 21 28
1/800 42 29 34 35 29 36
Calculated A.H.G. conc. 633 i 1107 i 590 i 673 i 973 i 920 i
The average A.H.G. concentration in the six bovine plasma pools
tested is 816 fo of the human control plasma A.H.G. content.
Statistical analysis of the data obtained from the above table
gave a mean value of A.H.G. of 781.05 $  of the human, with a standard
error (S ) of 63.3, and a coefficient of variation (fractional S) of 
m
34.85 io. The corrected coefficients of variation amongst the values 
obtained for the various dilutions tested of each plasma pool were 
29.54 fo, 11.68 i, 23.18 fo, 4.55 %  21.8 %  and 8.7 i  respectively.
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A.H.G. ASSAY. 
Method of Pitney, 1956.
40 H
"O
30 H
20 H
0 20 40 60 80
A.H.G. Percentage
Figure 28. A.H.G. assay in bovine plasma.
A diagrammatic presentation of experiment 6, table 57, showing
the curve obtained with various dilutions of normal human adsorbed
plasma in haemophilic adsorbed plasma, when plotting the percentage
of A.H.G. in each mixture (dilution l/20 designated 100$) against
substrate clotting times. Calculation is made as follows
Dilution 1/200 reads 100$ thus bov.pl. contains — 1000 $ A.H.G.
Dilution 1/400 reads 46$ thus bov.pl. contains = ^20 ^ A.H.G.
21 x 800
Dilution 1/800 reads 21$ thus bov.pl. contains ~  = 840 $ A.H.G.
Average of the three dilutions = 920 $
Standard of deviation (S) = 80.41
Coefficient of variation = 8.7 $
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SERUM ACTIVITY IN TG.T
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Figure 29. Activity of bovine serum in T.Gr.T.
Figure A : using human platelets
Curve a : human ads.pl. + human serum
Curve b : human ads.pl. + bovine serum
Figure B ; using bovine platelets 
Curve a : human ads.pl. + human serum
Curve b : human ads.pl. + bovine serum
(Mixture 86, table 55) 
(Mixture 89, table 55)
(Mixture 104, table 56) 
(Mixture 107, table 56)
It is noted that the use of bovine serum causes very rapid 
generation of active thromboplastin which is apparent in the first 
minute reading.
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X-MAS FACTOR ACTIVITY IN MODIFIED TG.T.
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Figure 30. Bovine serum Christmas factor activity in the T.Gr.T. 
Figure A
Correction of Christinas serum activity by human normal serum 
diluted l/4, l/8, and l/20 in X-mas serum, (Mixtures 98, 99, and 
100 respectively, table 55).
Figure B
Correction of the Christmas serum by bovine serum diluted in 
it in the proportion of l/2, l/4, and 1/8, (Mixtures 101, 102, and 
103 respectively, table 55).
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Table 58. Christmas factor assay in bovine serum
(based on method of Pitney, 1956; appendix IV, 22)
Serum
dilution
X-mas factor 
concentration
Clotting times (seconds)
Expt.l Expt.2 Expt.3 Expt.4 Expt.5 Expt.6
Human control serum
1/20 100 % 9 10 10 14 H i 11
1/40 50 fo 10 11 11 16 12* 12*
1/80 25 fo 12 12* 12 21 14 13*
1/160 12.5 fo — — 14 27* 16* 16
1/200 10 fo 15 15 — — — —
1/320 6.2fo — — 19 49 20 17*
1/400 5 fo 18 23 — — — —
1/640 3.1fo — — 29 63 27 25
1/1280 1.6fo — — 40 72 42 35
1/2000 1 fo 31 45 — — — —
0 fo 80 85 85 81 64 56
Bovine test serum
1/5 — 12 — — 13 —
1/10 — — 11 18 15 14
1/20 13 13 12 23 18 16
1/40 15 142 13 25 20 17*
1/80 18 18 14 27 — 19*
Calculated X-mas factor 20 fo 22.5f 33.5$ 25 f 10.5% 13.3%
The average Christmas factor concentration for the six bovine 
serum pools is 20.8 % of the human control serum Christmas factor 
content.
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CHRISTMAS FACTOR ASSAY. 
Modified method of Pitney, 1956.
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Figure 31. Christmas factor assay in bovine serum.
A schematic illustration of experiment 4, table 58, shoving the 
curve obtained vith various dilutions of normal human serum in 
Christmas disease serum, vhen plotting the percentages of Christmas 
factor in the mixtures (dilution 1/20 designated 100 f>) against the 
substrate clotting times.
Dilution 1/10 reads 40 f  thus bov. serum contains = 20 fo X-mas F
Dilution l/20 reads 21 fo thus bov. serum contains ^ ^  = 21 fo X-mas F
17 x 40Dilution 1/40 reads 17 fo thus bov.serum contains —  --- =34 fo X-mas F
The average Christmas factor concentration of this particular 
bovine serum pool therefore contains 25 fo of human serum Christmas 
factor activity.
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PLATELET ACTIVITY IN T.G.T.
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Figure 32. Thromboplastic activity of bovine platelets in T.G.T.
Figure A : Bovine ads.pl. and bovine serum are constants.
Curve a : using human platelets, (Mixture 87, table 55)
Curve b : using bovine platelets, (Mixture 105, table 56)
Figure B : Human ads.pl. and human serum are constants.
Curve a : using human platelets, (Mixture 86, table 55)
Curve b s using bovine platelets, (Mixture 104, table 56).
It is noted that the bovine platelet preparations used are 
weaker than the human preparations which were similarly made.
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Table 59. Bovine plasma substrate reactivity in the T.Gr.T.
Incubation mixture j 0.2 ml adsorbed plasma, diluted 1/5,
0.2 ml serum, diluted l/lO,
0.2 ml human platelets,
0.2 ml M / 4 0 CaCl2 solution. 
Substrate : bovine high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 25 15 17 19 19 18
108 Human plasma 2 39 13 15 144 15 16Human serum Avg.
*
32
8.6
14
50
16
37
16i
34
164
35
17
33 fo
1 25 15 16 17 174 174
109 Bovine plasma 2 17 164 15 15 16 16Bovine serum Avg. 21 15i 15± 16 164 164
i 21 39 4C 37 34 34 fo
i 14 15 15 16 16 16
110 Bovine plasma
2 i3i 15 15 144 15 15
Human serum Avg.
f °
134
54
15
43
15
43
154
41
154
40
154
40 fo
1 37 20 20 25 24 25
111 Human plasma 2 21 20 184 184 20
21
Bovine serum Avg.
*
29
10.5
20
23
19i
25
21 i 
20
22
19
23
17 fo
Percentage active thromboplastin values were read from the human
thromboplastin dilution curve A, figure 2.
Incubation mixtures 108, 109, 110, and 111 were from the same 
reagents used in making mixtures 86 , 87, 88, and 89, table 55, and 
are therefore directly comparable with them as regards the effect 
of using bovine substrate plasma instead of the human substrate used 
in the latter mixtures.
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Table 60. Bovine plasma substrate reactivity in the T.G-.T.
Incubation mixture: 0.2 ml adsorbed plasma, diluted 1/5,
0.2 ml serum, diluted l/lO,
0.2 ml bovine platelets,
0.2 ml )A/AQ CaCl^ solution. 
Substrate : bovine high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
: n o . Clotting times (seconds)
1 61 30 22 20 21 20
112 Human ads.pl. Human serum
2
3
63
60
33
29
21
21
20
21
22
23
20|
23
Avg. 61 30.7 21.3 20.3 22 21
f 2.7 9.4 20 21.3 19 21 <fo
1 27 19 19 17 18£ 18^
113 Bovine ads.pl. Bovine serum
2
3
20
35
17
18
17
17?
19
17i
18^
18
18£
19
Avg. 27.3 18 17.8 17.8 18.3 18.6
fo 12 29 30 30 28 27 f
1 30 18 17 17 17 17
114 Bovine ads.pl. 
Human serum
2
3
25
30
17 17i
17i
18
18?
19
18?
19
21
Avg. 28.3 17.5 17.3 17.8 18.1 19
f 11 31 32 30 29 26 f
1 33 26 25 25 25 27
115 Human ads.pl. Bovine serum
2
3
27
42
24
25
24
25
24
29
27
29
26
33
Avg. 34 25 24.6 26 27 28.6
fo 7.5 14.5 15 13.5 12.5 11 f
Mixtures 112, 113, 114, and 115 were tested on the same day as, and 
from the same reagents used for mixtures 104, 105, 106, and 107> table 
56, respectively. They are directly comparable with each other as 
regards the effect of using bovine substrate plasma instead of the human.
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SUBSTRATE REACTIVITY IN TG.T
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Figure 33. Bovine plasma substrate reactivity in the T.G.T.
Figure A (Human ads.pl., human serum, and human platelets are constant) 
Curve as on human high-spun plasma substrate (Mixture 86, table 55)
Curve b : on bovine high-spun plasma substrate (Mixture 108, table 59)
Figure B (Human ads.pl., human serum, and bovine platelets are constant) 
Curve a : on human high-spun plasma substrate (Mixture 104, table 56)
Curve b : on bovine high-spun plasma substrate (Mixture 112, table 60)
It should be noted that the use of bovine high-spun plasma as 
substrate in the T.G.T, does not reflect the true level of active 
thromboplastin generated due to the delay in its reactivity as compared 
with the human high-spun plasma.
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SUBSTRATE REACTIVITY IN TG X
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Figure 34. Bovine plasma substrate reactivity in the T.G.T.
Figure A (Bovine ads.pl., bovine serum, and human platelets are constant) 
Curve a : on human U.S.plasma substrate (Mixture 87» table 55)
Curve b : on bovine H.S.plasma substrate (Mixture 109> table 59)
Figure B (Bovine ads.pl., bovine serum, and bovine platelets are constant) 
Curve a : on human H.S.plasma substrate (Mixture 105, table 56)
Curve b s on bovine H.S.plasma substrate (Mixture 113, table 60)
It is noted that even when using bovine ads.pl. and serum, the 
bovine substrate plasma exhibited the same delayed reactivity to the 
active thromboplastin formed, compared to the human substrate plasma.
Attention is specially drawn to curve b in figure B which represents 
a completely homologous bovine thromboplastin generation system, and 
shows very weak thromboplastin generation as compared to a normal 
human system.
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R E S U L T S  O F  E X P E R I M E N T S  
O N  H O R S E  B L O O D
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R E S U L T S  O P  E X P E R I M E N T S  
O N  H O R S E  B L O O D
All the following data were obtained 
from experiments carried out on blood samples 
obtained from horses, mainly English thoroughbred 
racing horses and Clydesdale horses, using 
pooled plasma or serum samples from at least 
three animals for each experiment to obviate 
as much as possible any individual variations 
from affecting the final levels of the various 
coagulation factors.
Blood samples were obtained fresh on the 
day of the test concerned as described in 
appendix II, 1, iv.
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Table 61. Fibrinogen estimation in horse plasma 
(modified Greenberg method, appendix IV, 2, II)
mg fibrinogen per 
100 mis absolute plasma
Experiment 1 325
Experiment 2 433.8
Experiment 3 567.2
Experiment 4 420
Average 436.5
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Table 62. Thrombin-fibrinogen reaction of plasma 
(method described in appendix IV, 8 and 9)
Clotting Thrombin topical (P.D.& Co.) in units / ml
mixture Expt. 50 25 12.5 6.25 3.1 1.55
(ml) Clotting times (seconds)
1 16 19 25 34 66 1710.2 Horse pi. 
0.2 Saline 2 13 18t 21 30 55 152
3 11 194 23 38 64 163
Avg. 13.3 19 23 34 61.6 162
1 54 7 10 16 26 510.2 Human pi. 
0.2 Saline 2 5 64 9 15 27 48
3 5 64 10 16 25 48v • x ill UlilUAU Avg. 5.1 6.6 9.6 15.6 26 49
0.2 Horse pi. 1 5 7 8* 13 22 374
0.1 Saline 2 5 6 8 13 22 35
0.1 Pyrocatechol 3 5 6 8 12^ 22 32
0.2 Thrombin Avg. 5 6*3 8.1 12.6 22 34.8
0.2 human pi. 1 3 4.1- 5* 9 14 26
0.1 Saline 2 3 4* 5* 9 15 26
0.1 Ityrocatechol 3 3 3* 5* 9 14 22
0*2 Thrombin Avg. 3 4.1 5.5 9 14.3 24.6
0.2 Horse pi. 1 4 5 7* 10 17 30
0.1 Pyrocatechol 2 4 4-2 6i 94 15 28
0.1 M/40 CaCl2 3 4 4* 7 9j 16 28
0o2 Thrombin Avg. 4 4.6 6.9 9.7 16 29
0*2 Human pi. 1 3 4 5 74 12 22
0.1 Ityrocatechol 2 3 3* 44 74 12 | 21
0.1 M/40 CaCl 3 3 3* 4J 74 12 21
0.2 Thrombin Avg. 3 3.6 4.7 7.5 12 21.3
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THROMBIN -  FIBRINOGEN REACTION OF PLASMA.
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Figure 35. Thrombin-fibrinogen reaction of horse plasma.
Curve a^  : human plasma + saline
Curve b^ : horse plasma + saline
Curve s human plasma + saline + lyroeatechol 1 $
Curve b2 s horse plasma + saline + l^rrocatechol 1fo
Curve a^ : human plasma + Pyrocatechol 1 % + M/40 CaCl2
Curve b^ : horse plasma + Pyrocatechol 1y<> + M / 4 0 CaCl2
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Table 63. Species specificity of the thrombin-fibrinogen reaction 
(method described in appendix IV, 10)
Thrombin solution (0*1 ml)
Human Bovine 50 U/ml Horse
Clotting times (seconds)*
0.4 ml Human fibrinogen 
0.1 ml Saline 10 10 24
0.4 ml Horse fibrinogen 
0.1 ml Saline 31 144 85
0.4 ml Human fibrinogen 
0.1 ml Pyrocatechol 1 c/o 7 8 20
0.4 ml Horse fibrinogen 
0.1 ml pyrocatechol 1°/o 12 15 26
* Average of two estimations.
The human fibrinogen solution contained 340 mg/100 mis solution. 
The horse fibrinogen solution contained 240 mg/100 mis solution.
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Table 64. Anti thrombin assay in horse plasma 
(method of Douglas and Biggs, 1953; appendix IV, 11, A)
Incubation Incubation time (minutes)
mixture i i 1 2 3 4 5 6
Clotting times (seconds)
0.5 ml horse pi. 
0.5 ml thrombin 25 29 69 152 180+ 180+
0.5 ml human pi. 
0.5 ml thrombin 15 - o
o Mi-
*
35 70 135 180+ 180+
Units of residual thrombin
Horse plasma - 5.6 4.6 1.6! 0.64 0 
1
0
Human plasma io . : - 8 3.7
1
1.63 0.75 
1 ....
i 0
. . .
0
The incubation times at -which zero activity of thrombin was 
attained were read from curves a and b in figure 36.
Value for human plasma = 6.5 (curve a at 0.1 thrombin units/ml). 
Value for horse plasma = 4.8 (curve b at 0.1 thrombin units /ml). 
Horse plasma antithrombin = 6.5 x 100 + 4.8
= 134.4 fo of human plasma antithrombin.
Re
si
du
al
 
Th
ro
mb
in
 
Un
it
s
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A N T I T H R O M B I N  ASSAY. 
Method of Douglas &  Biggs,1953.
6 -
4 -
0 1 3 4 52
Incubation Time in Minutes
Figure 36. Antithrombin assay in horse plasma.
This figure was drawn from the results presented in table 64. 
Curve a : human plasma.
Curve b i  horse plasma.
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Table 65* Antithrombin assay in horse plasma
(modified method of Astrup and Darling, 1942d; appendix IV, 11, B)
Mixture A B C D
Saline ml. 0.3 0.2 0.15 0.1 0.0
Plasma (dil. 1/5) ml. 0.0 0,1 0.15 0.2 0.3
Thrombin* ml. 1 1 1 1 1
Expt.
1 11 13i 16 18 22
Clotting time Human 2 16 22 25 28 32
of 3 13 15 18 20 22
fibrinogen 1 11 15 16i 21 32
(seconds) Horse 2 16 26 37 41 56^
3 13 17 23 25 35
1 1 0.81 0.68 0.61 0.48
Human 2 1 0.72 0.64 0.57 0.50
T / T 
o ' n
3 1 0.86 0.72 0.65 0.59
1 1 0.73 0.62 0.52 0.34
Horse 2 1 0.61 0.43 0.39 0.28
3 1 0.76 0.56 0.52 0.37
1 1 0.81 0.71 0.62 0.42
Corrected Human
2 1 0.80 0.70 0.60 0.40
3 1 0.84 0.76 0.69 0.54
T / T 
o n
1 1 0.74 0.62 0.50 0.26
Horse 2 1 0.66 0.50 0.33 0.00
3 1 0.76 0.64 0.52 0.28
1 0 313 319 313 319
Calculated Human 2 0 300 300 300 300
units of 3 0 240 240 231 230
antithrombin 1 0 429 418 412 407
per ml plasma Horse 2 0 510 500 502 500
3 0 360 360 360 360
* Thrombin solution used for experiment 1 contained 33 units/ml., while
that used for experiments 2 and 3 contained 30 units/ml.
Expt. 1 Expt. 2 Expt. 3
Average value for human plasma (units/ml) = 316 300 235
Average value for horse plasma (units/ml) = 416 503 360
Horse plasma antithrorabin activity in 
percentage of human plasma antithrombin = 131.6$ 167.6$ 153 $
Average horse plasma antithrombin = 150.7 $ of human plasma antithrombin.
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A N T ITH R O M B IN  A S S A Y  
M odified  m ethod of A strup  & Darling, 1942.
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Figure 37. Antithrombin assay in horse plasma.
Figures A and B represent experiments 1 and 3 (table 65) respectively.
Curves a : human plasma.
Curves b : horse plasma.
The corrected values of T /T in table 65 were derived from these curves.
o n
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Table 66. Quick* s one—stage prothrombin time test
Test plasma Human brain Horse brain
Clotting times (seconds)
16 14
Horse plasma 21 (18) 12 (13)
17 13
12 30
Human plasma 17 (14.1) 27 (27)
13i 24
14 15i
Hse.pl. + Hum.pl. 19 (16) 13 (14.1)
15 14
15i 17
Hse.pl. + Saline 20i(17.3) 15 (15.3)
16 14
14 44
Hum.pl. + Saline 21 (17.5) 37i(37.9)
m 32
Figures between brackets are the mean for each group 
of three experiments carried out with different batches 
of brain thromboplastin and different plasma pools.
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Table 67. Assay of factor V activity in horse -plasma and serum 
By correction of human stored factor V-deficient plasma, as 
described in appendix IV, 14. Human brain thromboplastin was
used for all mixtures.
Plasma Factor V Clotting times (seconds)
dilution percentage Expt. 1 Expt. 2 Expt. 3
Human control plasma
1/10 100 fo 25 25 24
1/20 50 f 30 29 29
1/40 25 f 37 36 33
1/80 1 2 . % 42 40 35
1/160 6.2/^ 49 45 39
1/320 3.1f 52 50 42
1/640 1 . % 53 55i 44
Hse.pl. Hse.pl, Hse.ser. Hse.pl.
1/10 15 15 25 19
1/20 16i 18 29 22
1/40 21 20 — 24
1/80 25 26 — 28
1/160 29 30 — 32
1/320 — 38 — 38
Calculated factor V 864 f 669 f 100 fo 397 f
The factor V activity in horse plasma ranges from 397 to 
864 per cent, with an average of 643 per cent of human plasma
factor V activity.
Horse serum contained factor V activity equivalent to that
of human plasma.
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HORSE FACTOR V ASSAY.
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Figure 38. Factor V assay in horse plasma.
The dilution curve was drawn from the results obtained for 
human normal fresh plasma diluted in stored human plasma and 
clotted with human brain in the presence of CaC^ solution, 
experiment 2, table 67.
The dotted lines show how the clotting times obtained with 
various dilutions of test horse plasma were converted into percentage 
values of factor V activity, which were multiplied by the dilution 
factor to arrive at the final concentration of factor V in horse 
plasma in percentage of the human control plasma factor Y content.
“ 210 - (Appendix V, C)
Table 68. Factors VII and X — brain thromboplastin species specificity
(method described in appendix IV, 17)
Incubation mixture
0*3 ml brain extract, diluted l/4, variable,
0*3 ml purified factors VII and X, variable, (appendix III, 10)
0*3 ml H/40 CaCl^ solution.
Variables Substrate
Incubation time (minutes)
i 1 2 3 4 5 6
Clotting times (seconds)
Horse brain 
Hse. VII & X
Fresh hum.pl. 
Fresh hse.pl, 
Phenindione pi.
28 29 33i 35? 39 41 
23 23^ 23 24-? 26 27? 29 
22 2l£ 22 23£ 25 28^ 30
Horse brain 
Huip. VII &  X
Fresh hum.pl. 
Fresh hse.pl. 
Phenindione pi.
54 47 49? 47 47 49 47? 
39 35 36i 37 40 38 40 
70 65? 60 60 59 60 62
Horse brain 
Saline
Fresh hum.pl. 
Fresh hse.pl. 
Phenindione pi.
85 84 86 87 78 95 93 
31 3li 32 30i 33 32^ 33 
156 155 150 153 152 157 156
Human brain 
Hse. VII & X
Fresh hiim.pl. 
Fresh hse.pl. 
Phenindione pi.
29 28 30 30 32 33 32 
22 18i 18£ 21 23 23^ 25 
34 31 32 34 35 37 36
Human brain 
Hum. VII & X
Fresh hum.pl. 
Fresh hse.pl. 
Phenindione pi.
20 20 19 19 20 20? 22 
18 18J 18£ 18i 19 21 22 
26 25 26 26 25? 24 25
Human brain 
Saline
Fresh hum.pl. 
Fresh hse.pl. 
Phenindione pi.
43 38 42 40 40^ 42 41 
38 40 40 41 40 42^ 41 
100 95 106 137 135 140 150
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Table 69. Horse plasma factor VII assay 
(method of Koller et al, 1951; appendix IV, 15, B)
Plasma Factor VII Clotting times (seconds)
dilution percentage Experiment 1 Experiment 2
Human brain Horse brain Human brain Horse brain
Hum.pl. Hse.pl. Hum.pl. Hse.pl.
1/10 100 fo 34 38 40 31
1/20 50 fo 48 53 53 39
1/40 25 fo 72 65 90 50
1/80 12.5 fo 107 85 140 76
1/160 6.2 f 172 129 215 99
1/320 3.1 fo 290 180 358 148
1/640 1.5 f 390 250 520 220
0 fo 740 643 765 780
Hse.pl. Hxim.pl. Hse.pl. Hum.pl.
1/10 42 1 110 43* 101
1/20 68 154 67 136
1/40 100 216 108 201
Calculated F VII & X 63.3 f 6.9 f 80 f 5.6 f
Since this method is also sensitive to varying concentrations of 
factor X, the measured activity is due to the combined effect of both 
factors VII and X. Plasmas used in each of the experiments were the 
same, the various dilutions being tested with either type of brain extract.
With human brain extract, horse plasma factors VII and X activity 
averages 71 f  of human plasma activity. While with horse brain extract, 
human plasma factors VII and X activity averaged 6.2 fo of horse plasma 
activity. This discrepancy is thought to be due to species specificity 
between the brain extracts and the factors VII and X.
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HORSE FACTOR VII ASSAY.1000
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Figure 39. Horse plasma factors VII and X activity.
(Human plasma : black dots. Horse plasma : white dots)
Curve A : human plasma dilution curve, using human brain extract, 
experiment 1, table 69. The average of the three horse 
plasma dilutions reads 63.3 
Curve B : horse plasma dilution curve, using horse brain extract, 
experiment 1, table 69. The average of the three human 
plasma dilutions reads 6.9
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Table 70. Horse plasma factor X assay 
(method of Bachmann, Duckert, and Roller, 1958 j appendix IV, 18)
Plasma
dilution
Factor X 
percentage
Clotting times (seconds)
Expt. 1 Expt. 2 Expt. 3
Human control plasma
1/10 100 f 23 25 26
1/20 50 f> 29 33 32i
1/40 25 f> 39 38£ 4l£
1/80 12.5fo 49 4 6 i 46
1/160 6 .2 $ 54i 55 63
1/320 3.1fo 66 66 76
1/640 1.5fo 8li 86 87
1/1280 O .lfo 91* 93 101
0 fo 106 117 130
Horse Test Plasma
1/10 25.8 25 31
1/20 31 29 40
1/40 39 38 44
1/80 — — 54
Calculated factor X cone, 86 $ 106 fo 64.7 $
The average factor X concentration in horse plasma equals 
85*5 fo of human plasma factor X content.
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Table 71. Horse plasma prothrombin assay
(Two-stage area method of Biggs and Douglas, 1953a; appendix IT, 12, C)
Incubation Incubation time (minutes) Weight of area
mixture Expt
1» 4 12 24 1 2 3 4 5 under curve &
Clottin,£ times (seconds) its percentage
Hum.pl. + Hum.Br. 1A - 15 18 25 59 180+ 180+
Hse.pl. + Hum.Br. IB - — 13 14 31 80 180+
Hum.pl. + Hse.Br. 1C - 35 — 22 48 112 180+
Hse.pl. + Hse.Br. ID - 9 9i Hi 45 101 180+
Hum.pl. + Hum.Br. 2A - 13 20 26 78 180+
Hse.pl. + Hum.Br. 2B 16 _ 14 15 30 75 125 180-
Ihim.pl. + Hse.Br. 2C 79 28 — 19 45 119 180+
Hse.pl. + Hse.Br. 2D — 9 11 15i 65 175 180+
Hum.pl. + Hum.Br. 3A __ 15 17 25 48 154 180+
Hse.pl. + Hum.Br. 3B 18 — 16 21 46 111 147 180hh
Hum.pl. + Hse.Br. 3C — 25 ITi 29 98 180+
Hse.pl. + Hse.Br. 3D — 10 13i 16 51 134 175 180+
Thrombin units / ml. mg *
1A — 10.2 8.2 5.6 2 0 156.5
IB — — 12.2 11.2 4.6 1.4 0 269.0 171.8 f
1C — 3.7 — 6.5 2.6 0.9 0 138.8
ID — 19 17.5 14.5 2.7 1.6 0 344.0 247.8 fo
2A _ 12.2 7.2 5.3 1.4 0 147.2
2B 9.6 — 11.2 10.2 4.5 1.5 0.8 0 284.2 193.0 fo
2C 1.4 4.9 — 7.8 2.7 0.8 0 156.5
2D — 19 15 10 1.8 0.5 0 262.4 167.6 fo
3A — 10.2 8.8 5.6 2.6 0.6 0 175.0
3B 8.2 — 9.6 6.9 2.7 0.9 0.6 0 205.5 117.4 fo
3C _ _ 5.6 — 8.5 4.7 1.1 0 203.4
3D — 16.8 11.5 9.6 2.4 0.7 0.5 0 254.0 124.8 fo
Percentages of horse plasma prothrombin are related to the prothrombin 
content of human plasma tested with the same species of brain extract 
on the same day. Vith human brain, the average horse plasma prothrombin 
equals 160 fo of the human, while with horse brain it averages 180 fo of 
the human plasma prothrombin content.
Experiment 2 is illustrated in figure 40.
- 215 - (Appendix V, C)
Curve
Curve
Curve
Curve
MEASUREMENT OF PROTHROMBIN.
2 0 -
18-
16- • ------- •  C
o------- o D
14-
c/>
E 10-
8 -
6 -
4 -
2 -
10 2 3 4
Tim e in Minutes
Figure 40. Measurement of horse plasma prothrombin.
A : obtained for human plasma using human brain. Weight of
area under curve is 147.2 mg which is designated the 100$ 
value.
B : obtained for horse plasma using human brain. Weight of
area under curve is 284.2 mg which is equivalent to 193 $ 
of human plasma prothrombin.
C : obtained for human plasma using horse brain. Weight of
enclosed area is 156.5 mg, which reads 106.3$ of human 
plasma prothrombin when estimated with human brain.
D : obtained for horse plasma using horse brain. Weight of
enclosed area is 262.4 mg which gives a value of 167.6 $
of the human plasma prothrombin when the latter was tested 
with horse brain.
(All data are from the results of experiment 2, table 71).
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Table 72. Horse plasma prothrombin assay 
(globulin fraction method of Douglas and Biggs, 1953; appendix IV, 12,
j--------------------------
Human brain Horse brain
Hum.pl. Hse.pl. Hum.pl. Hse.pl.
Clotting time of the 
substrate (seconds) 21 52 32 92
Thrombin units/ml. 7 2.3 4,1. 1.2
Prothrombin concentration 100 fo 32.8 fo 100 f 29.2 fo
Table 73* Horse prothrombin consumption index
A. Method of Biggs and Macfarlane, 1957, (appendix IV, 13,A) using 
horse brain extract.
Expt. 1 Expt. 2 Expt. 3
Horse plasma time (seconds) 13i 13 14
Horse serum time (seconds) 180+ 180+ 180+
Prothrombin consumption index - 7.5 f - 7.2 fo - 7.7 f
B. Globulin fraction method of Douglas and Biggs, 1953, (appendix IV,
13, B), using human and horse brain extracts.
Human brain Horse brain
Hse.pl. Hse.ser. Hse.pl. Hse.ser.
30 minute clotting time(sec] 52 180+ 92 180+
Thrombin units/ml. 2.3 0.1 1.2 0.1
Prothrombin consumption I. 4.3 fo 8.3 f
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Table 74. Horse blood platelets1 count
(method described in appendix IV, 1, A)
Total count / c.mm. whole blood*
Experiment 1 120,000
Experiment 2 97,000
Experiment 3 114,000
Experiment 4 105,000
Experiment 5 126,000
Experiment 6 133,000
Average 117,000
* Mean of duplicate estimations.
Table 75. Horse whole blood clotting time
(method of Lee and White, 1913; appendix IV, 3)
Clotting times*
Ordinary glass Siliconed glass
Experiment 1 7' 48" 11' 41"
Experiment 2 3' 40" 8' 10"
Experiment 3 9* 7" 20' 7"
Experiment 4 7* 30" 14' 34"
Experiment 5 91 23" 17' 40"
Experiment 6 10' 5" 20' 46"
Average 7* 55" 15' 29"
* Mean of two tubes' readings.
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Table 76. Recalcification time of plasma
(method described in appendix IV, 5)
I Clotting times (seconds)
1 Human plasma Horse plasma
Experiment 1 167 337
Experiment 2 132 392
Experiment 3 141 375
Average 147 368
Table 77. Horse plasma Hageman factor assay 
(method described in appendix IV, 24, II)
Plasma dilution in 
Hageman factor 
deficient plasma
Concentration
of
Hageman factor
Clotting times 
(seconds)
Human plasma
1/5 100 % 142
1/15 3 3 . 3 % 182
1/45 11.1 %> 257
1/135 3 . 7 % 364
1/405 1.2?6 540
Horse plasma
1/15 180
1/45 241
Calculated Hagegtan factor concentration 118.5 %
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Figure 41. Horse plasma Hageman factor assay.
The above human plasma dilution curve -was drawn from the results 
obtained in the experiment presented in table 77.
The dotted lines show how the clotting times obtained with the 
two dilutions of horse plasma tested, were converted into percentage 
values which when multiplied by the dilution factor give the final 
Hageman factor concentration in horse plasma in percentage of human 
plasma Hageman factor activity, since the human plasma dilution 1/5 
was designated the 100 fa value.
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Table 78. Thromboplastin generation test
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixture s 0.3 ml. adsorbed plasma, variable, diluted 1/5,
0.3 ml. serum, variable, diluted l/lO,
0.3 ml. human platelets,
0.3 ml. M/40 CaCl^ solution.
Substrate s human high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 30 9 8 9 10 9!
116 Human plasma 2 49 13! 9 9 9 9
Human serum Avg. 39! Iii 8! 9 9! 9i
f 5.6 78 145 128 110 120 fo
1 15! 9 9! 9 10 9
117
Human plasma 2 31 13 10 10 10 10
Horse serum Avg. 23i 11 9i 9! 10 9!
fo 17 84 104 110 100 110 fo
1 38 16^ 16! 15 15 18
118 Horse plasma 2 52 24 14 14 13 12!
Human serum Avg. 45 201 15i 14! 14 15!
fo 4.2 23 42 47 50 42 fo
1 20 14 13 13 13 13!
119 Horse plasma 2 36! 19
12 12 13 13
Horse serum Avg. 28! 16! 12! 12! 13 13!
fo 11 36 64 64 59 56 fo
Percentage active thromboplastin values were read from the human 
thromboplastin dilution curve A in figure 2.
Each of the two experiments was made with a different set of reagents.
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Table 79. Thromboplastin generation test
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixture: 0.3 ml adsorbed plasma, variable, diluted 1/5,
0.3 ml serum, variable, diluted 1/10,
0.3 ml horse platelets,
0.3 ml M/40 CaCl^ solution.
Substrate : human high-spun plasma.
Incubation
Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 127 105 68 25 11 12
120
Human plasma 2 65 55 38 16i 9 8
Human serum Avg. 96 80 53 201 10 10
# 0.8 1.2 3 22 100 100 #
1 48 13 H i 12 lli 12
121 Human plasma 2 55 43 28 15 10 11
Horse serum Avg. 5li 28 19* 131 ioi lli |
fo 3.2 11.‘ 25 55 88 76 fo
1 137 127 111 60 37 29
122
Horse plasma 2 72 67 56 48 35 23
Human serum Avg. 104-2- 97 83i 54 36 26
# 0.7 0.8 1.1 2.9 6.8 13.5#
1 96 60 48 30 24 21
123 Horse plasma 2 62 50
41 24 20 19
Horse serum Avg. 79 55 44i 27 22 20
f 1.3 2.7 4.3 12.'5 19.!5 23.5#
Percentage active thromboplastin values were read from the human 
thromboplastin dilution curve A in figure 2.
Experiment 2 was made with the same reagents used for experiment 2 
in table 78 except for the different platelet preparation, and can 
therefore be directly compared with each other as to the thromboplastic
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Figure 42. Horse plasma activity in the T.G-.T. 
Figure A (with human platelets)
Curve a s human ads.pl. + human serum (Mixture 116, table 78)
Curve b : horse ads.pl. + human serum (Mixture 118, table 78)
Figure B (with horse platelets)
Curve a : human ads.pl. + human serum (Mixture 120, table 79)
Curve b : horse ads.pl. + human serum (Mixture 122, table 79)
- 223 - (Appendix V, C)
Table 80. A.H.G. assay in horse plasma
(method of Pitney, 1956; appendix IV, 21)
Plasma Concentration Clotting times (seconds)
dilution of A.H.G. Expt. 1 Expt. 2>• Expt. 3
Human control plasma
1/20 100 fo 16 19 20
1/40 50 fo 19 22 23i
1/80 25 f 23 28 30
1/160 12.5 fo 27 35 36
1/320 6.2 fo 33 39 46
1/640 3.1 fo 39 49 54
1/1280 1.5 fo 56 —
Horse test plasma
1/20 16 17i 18
1/40 18 18i
OCM
1/80 20 19 24^
1/160 — — 31
i Calculated A.H.G. concentration 137 f 310 fo 180 fo
The average A.H.G. concentration of the three horse plasma 
pools tested equals 209 f> of the human control plasma A.H.G, content, 
with a range from 137 to 310 f>.
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Figure 43. A.H.G. assay in horse plasma.
A diagrammatic presentation of experiment 3 from table 80.
Qyj v  A Q
Dilution 1/40 reads 94 f  thus horse pi. contains — ~ ---   188 $
4 7 x 80Dilution 1/80 reads 47 f  thus horse pi. contains — ---- = 188 f
Dilution 1/160 reads 20.7$ thus horse pi. contains^*20^^ = ^
The average A.H.G. concentration therefore in this horse plasma 
pool equals 180.6 f  of the human control plasma A.H.G. content.
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Figure 44. Horse serum activity in the T.G.T.
Figure A (using human platelets)
Curve a : human plasma + human serum
Curve b : human plasma + horse serum
Figure B (using horse platelets)
Curve a : human plasma + human serum
Curve b : human plasma + horse serum
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Table 81. Christmas factor assay in horse serum
(based on method of Pitney, 1956; appendix IV, 22)
Serum
dilution
X-mas factor 
concentration
Clotting times (seconds)
Expt. 1 Expt. 2 Expt. 3 Expt. 4
Human control serum
1/20 100 $ 10 12 13i 13
1/40 50 $ 11 13i 16 15
1/80 25 $ 13 17 18 19
1/160 12*5$ 15 26i 25 29
1/320 6.2$ 18^ 45 40 43
1/640 3.1$ 24-g- 72 69 77
1/1280 1.5$ 27 97 83 90
0 $ 32 118 142 152
Horse test serum
1/20 10 11 12i 12i
1/40 ioi 12 14 13
1/80 H i 13i 16i 14i
1/160 13i 15 19 18^
Calculated P IX concentration 168 $ 240 $ 183 $ 221 $
The average of the four horse serum pools tested is 203 $ of the
human serum factor IX concentration.
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Figure 45. Christmas factor assay in horse serum.
A diagrammatic illustration of experiment 4 (table 81) showing the 
human serum dilution curve obtained by correction of X-mas disease serum.
Dilution l/40 reads 100$ thus hse.ser. contains ^ ^ 20~ "^~ = ^
60 x 80
Dilution l/80 reads 60$ thus hse.ser. contains -- — —  = 240$
28 x 160
Dilution 1/160 reads 28$ thus hse.ser. contains ---— --- = 224$
The average Christmas factor concentration for this serum pool is 
therefore 221.3 $ of human serum Christmas factor activity.
- 228 - (Appendix V, C)
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Figure 46. Thromboplastic activity of horse platelets in T.G.T.
Figure A (human ads.pl. and serum are constant)
Curve a s with human platelets (Mixture 116, table 78)
Curve b : with horse platelets (Mixture 120, table 79)
Figure B (horse ads.pl. and serum are constant)
Curve a s with human platelets (Mixture 119, table 78)
Curve b s with horse platelets (Mixture 123, table 79)
It is noted that the horse platelets' suspension used is weaker 
than the human preparation prepared from equal volumes of plasma.
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Table 82. Clot retraction of horse blood
(method of Macfarlane, 1938; appendix IV, 4)
Hematocrit value 
of
sequestrene blood
Percentage of 
clot retraction 
in one hour*
Expt. 1 50 fo 38 f
Expt. 2 39 fo 34 fo
Expt. 3 44 fo 36 fo
Expt. 4 40 fo 36 f
Expt. 5 40 fo 44 f>
Average 37.6 f
* Average of two tubes* readings.
- 230 - (Appendix V, C)
Table 83. Horse plasma substrate reactivity in the T.G-.T.
Incubation mixture: 0.3 ml adsorbed plasma, diluted l/5, variable,
0.3 ml serum, diluted l/lO, variable,
0.3 ml human platelets,
0.3 ml M/40 CaC^ solution.
Substrate : horse high-spun plasma.
—
Incubation Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 1 37 12 124 14 13 13
124
Human ads.pl. 2 51 17 104 11 12 12
Human serum Avg. 44 144 H i 124 124 124
fo 4.4 47 76 64 64 64 f
1 17 11 124 12 13 13
125
Human ads.pl. 2 35 17 13 13 14 16
Horse serum Avg. 26 14 12| 124 134 144
fo 13.5 50 62 64 55 47 f
1 56 21 22 22 24 22
126
Horse ads,pi. 2 70 32 23 24 224 20
Human serum Avg. 63 26| 224 23 23i 21
fo 2 13 18.5 17.5 17 21 f
1 20 15 15 15 16 16
127
Horse ads.pl. 2 40 224 15 15 15 17
Horse serum Avg. ; 30 18f 15 15 154 164
f  | 10 27 43.5 43.5 41 36 %
Percentage active thromboplastin values were read from the human
thromboplastin dilution curve A, figure 2.
Incubation mixtures 124, 125 j 126, and 127 contained identical 
reagents as were used in mixtures 116, 117, 118, and 119 of table 78, 
respectively, and are directly comparable to each other as regards the 
effect of using horse high—spun plasma as substrate instead of human 
high-spun plasma.
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Table 84. Horse plasma substrate reactivity in the T.G.T.
Incubation mixtures 0,3 ml adsorbed plasma, diluted 1/5, variable,
0.3 ml serum, diluted 1/10, variable,
0.3 ml horse platelets,
0.3 ml M/40 CaCl^ solution.
Substrate s horse high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt. 1 2 3 | 4 5 6
No. Clotting times (seconds)
1 140 127 110 70 27 17
128
Human ads.pl. 2 80 82 46 19 14 14
Human serum Avg. 110 104i 78 4 4% 2 0% 15%
f> 0.6 0.7 1.3 4.3 22.5 4 1  fo
1 6 6% 22 17 17 21 20
129
Human ads.pl. 2 64 53 35 19 14i 15
Horse serum Avg. 6 5% 37i 26 18 1 7 i 17 2
1.9 6.2 13.5 30 31 32 fo
1 150 165 156 67 50 50
130 Horse ads.pl.
2 71 68 58 37 24 21
Human serum Avg. 1 1 0 % 116-2- 107 52 37 35i
* 0.6 0.3 0.6 3.1 6.4 7 f
1 120 101 92 58 43 35
131 Horse ads.pl. 2 62 47
34 23 20 22
Horse serum Avg. 91 74 63 4 0 % 31% 27| .
fo 0.9 1.4 2.1 5.2 9 12 fo  •
Percentage active thromboplastin values were read from the human 
thromboplastin dilution curve A, figure 2.
Mixtures 128, 129, 130, and 131 contained identical reagents as 
were used in mixtures 120, 121, 122, and 123, table 79, respectively; 
and are therefore directly comparable with each other as regards the 
effect of using horse H.S.plasma as substrate, instead of the human.
Furthermore, results of experiments numbered 2 were obtained using 
identical reagents as in the same numbered experiments in tables 78 and 
79 using human H.S.plasma substrate, with human and horse platelets 
respectively.
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SUBSTRATE REACTIVITY IN T.G.T
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Figure 47. Horse plasma substrate reactivity in the T.Gr.T.
Figure A (human ads.pl., serum, and platelets are constant)
Curve a : using human H.S.pl. as substrate (Mixture 116, table 78)
Curve b : using horse H.S.pl. as substrate (Mixture 124, table 83)
Figure B (human ads.pl. and serum, with horse platelets are constant) 
Curve a : using human H.S.pl. as substrate (Mixture 120, table 79)
Curve b : using horse H.S.pl. as substrate (Mixture 128, table 84)
The use of horse plasma as substrate does not reflect the true level 
of active thromboplastin generated as in the control mixtures, but shows 
a delay in its reactivity as compared to the human substrate plasma.
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HORSE BLOOD THROMBOPLASTIN GENERATION.
5 63 41 2
120 -
-2 100 -
6 0 -
o 40-
20-
5 63 41 2
T im e in M inutes
Figure 48. Horse plasma substrate reactivity in the T.G.T.
Figure A (horse ads.pl. and serum, with human platelets are constant)
Curve a : using human H.S.pl. as substrate (Mixture 119, table 78)
Curve b : using horse H.S.pl. as substrate (Mixture 127, table 83)
Figure B (horse ads.pl., serum, and platelets are constant)
Curve a : using human H.S.pl. as substrate (Mixture 123, table 79)
Curve b : using horse H.S.pl. as substrate (Mixture 131, table 84)
These curves again show the same effect of delayed horse plasma 
reactivity to active thromboplastin.
Attention is drawn to curve b, figure B, which represents a completely 
homologous horse thromboplastin generation system. It shows much weaker 
thromboplastin generation when compared to a normal human system.
- 234 - (Appendix V, C)
Table 85. Investigation of inhibitors against human intrinsic
thromboplastin in horse plasma and serum in the T.Gr.T.
(method described in appendix IV, 23)
Incubation mixture: 0.3 ml adsorbed plasma, diluted 1/5, variable,
0.3 ml serum, diluted l/lO, variable,
0.3 ml human platelets,
0.3 ml M/40 CaCl^ solution.
Substrate : human U.S.plasma.
A- Before incubation
Incubation
mixture Expt.
Incubation time (minutes)
1 2 3 4 5 6
No. (ml) Clotting times (seconds)
132
0.3 human ads.pl.
0.3 human serum
1
2
90 44 lli 12 lli lli 
60 20 11 10 10i 10
Avg.
f °
75 32 lli 11 11 lof
1.4 3.6 30 84 84 83 fo
133
0.15 human ads.pl. 
0.15 horse ads.pl. 
0.3 human serum
1
2
106 81 40 16 16 16 
92 69 23 13 13 13i
Avg.
/o
! 99 75 31i 14i 14i 14* 
0.7 1.4 9 47 47 46 f
134
0.3 human ads.pi. 
0.15 human serum 
0.15 horse serum
1
2
30 13 12 13 13 15 
73 21 14 13 12 12
Avg.
f>
5li 17 13 13 12i 13i 
3 33 59 59 65 55 fo
135
0.15 human ads.pl. 
0.15 heated Hse.pl.* 
0.30 human serum
1
2
7 B  ' T5 33 16 12 12i 
83 42 21 12 10i lli
Avg.
fo
80i 48i 29 i 14 lli 12 
1.2 3.6 10.5 50 80 70 fo
* Heated horse plasma was prepared by heating the adsorbed plasma 
for 15 minutes at 56°C. , centrifuging, and using the supernatant.
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Table 85* continued
B- After incubation at 37°C. for 2 hours
Incubation
Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. (ml) Clotting times (seconds)
0.3 human ads.pl.
1 60 31 13 14 14 13
136
2 67 22 12 11 11} 12
0.3 human serum
Avg. 63} 26} 12^ 12} 12} 12}
f 2 13 65 65 62 65 f
0.15 human ads.pl.
1 80 50 22 17 18 1 9
137 0.15 horse ads.pl. 
0*30 human serum
2 76 62 17} 14 14 15
Avg. 78 56 14} 15} 16 17
£ 1.2 2.6 46 41 38 33 fo
0.30 human ads.pl.
1 48 12 14 13 13} 14
138 0.15 human serum 2 80 15 13 13} 13 13
0.15 horse serum
Avg. 64 13} 13} 13} 13} 13}
f 2 55 55 56 56 55 fo
0.15 human ads.pl.
1 76 45 21 15 18 21
139 0.15 heated Hse.pl. 
0.30 human serum
2 69 38} 18 13 15 13}
Avg. -4 to Nil
-
41} 19} 14 16} 17}
fo 1.5 5 25 50 36 32 f
The above incubation mixtures were aliquots from mixtures used in
table 85, A, after incubating the adsorbed plasmas or sera mixtures 
o
separately at 37 C. for 2 hours, then similarly tested.
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PLASMA INHIBITORS OF BLOOD THROMBOPLASTIN.
(M odified T G T )
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Figure 49. Horse plasma inhibitors of human intrinsic thromboplastin.
Figure A Before incubation (human serum constant)
Curve a ; human ads.pl. alone (Mixture 132, table 85, A)
Curve b : human ads.pl. + horse ads.pl. (Mixture 133, table 85, A)
Curve c : human ads.pl. + heated Hse.pl. (Mixture 135, table 85, A)
Figure B After incubation at 37°C. for 2 hours (human serum constant) 
Curve a : human ads.pl. alone (Mixture 136, table 85, B)
Curve b s human ads.pl. + horse ads.pl. (Mixture 137, table 85, B)
Curve c : human ads.pl. + heated Hse.pl. (Mixture 139, table 85, B)
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SERUM INHIBITORS OF BLOOD THROMBOPLASTIN.
(Modified T .G T)
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Figure 50. Horse serum inhibitors of human intrinsic thromboplastin.
Figure A Before incubation (human ads.pl. constant)
Curve a : human serum alone (Mixture 132, table 85, A)
Curve b : human serum + horse serum (Mixture 134, table 85, A)
Figure B After incubation at 37°C. for 2 hours (human ads.pl. constant) 
Curve a : human serum alone (Mixture 136, table 85, B)
Curve b ; human serum + horse serum (Mixture 138, table 85, B)
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R E S U L T S  O P  E X P E R I M E N T S  
O N  R A B B I T  B L O O D
All the following data were obtained 
from experiments carried out on blood samples 
obtained from adult rabbits of the Californian 
strain, using pooled plasma or serum samples 
from at least three animals for each experiment 
to obviate as much as possible any individual 
variations from affecting the final levels of 
the various coagulation factors.
Blood samples were obtained fresh on the 
day of the test concerned as described in 
appendix II, 1, v.
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Table 86. Fibrinogen estimation in rabbit plasma 
(modified Greenberg method, appendix IV, 2, II)
mg fibrinogen per 
100 mis absolute plasma
Experiment 1 260
Experiment 2 190
Experiment 3 216
Experiment 4 195.5
Experiment 5 220
Experiment 6 237
Experiment 7 281.2
Average 228.1
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Table 87. Thrombin-fibrinogen reaction of plasma 
(method described in appendix IV, 8 and 9)
Clotting Thrombin topical (P.D.& Co.) in units / ml
mixture Expt. 50 25 12.5 6.25 3.1 1.55
(ml) Clotting times (seconds)
0,2 Rabbit pi. 
0.2 Saline 
0.2 Thrombin
1
2
3
5
412^
7
6
7
n
7
13i
12
14
22\
22
26£
45
39
47
Avg. 5 6.6 8.6 13.1 23.6 44
0*2 Human pi. 
0.2 Saline 
0.2 Thrombin
1
2
3
e;±->2
5
5
7
6i
6|
10
9
10
16
15
16
26
27
25
51
48
48
Avg. 5.1 6.6 9.6 15.6 26 49
0.2 Rabbit pi. 1 3 4 5i 9 14 30
0.1 Fyrocatechol 2 3 5 8i 14 26
0.1 Saline 3 ■>2 4 5 9 14 24
082 Thrombin Avg. 3.1 4.1 5.1 8.8 14 26.6
0.2 Human pi. 1 3 4±^2 51 9 14 26
0.1 lyrocatechol 2 3 5i 9 15 26
0.1 Saline 3 3 5* 9 14 22
0.2 Thrombin Avg. 3 4.1 5.5 9 14.1 24.6
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THROMBIN — FIBRINOGEN REACTION OF PLASMA.
20 -
1.56.212.550 25
Thrombin in units per ml.
Figure 51. Thrombin-fibrinogen reaction of rabbit plasma.
Curve : human plasma + saline + thrombin.
Curve b^ : rabbit plasma + saline + thrombin.
Curve a^  s human plasma + pyrocatechol + saline + thrombin.
Curve bg : rabbit plasma + pyrocatechol + saline + thrombin.
(Illustration of results presented in table 87).
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Table 88. Species specificity of the thrombin-fibrinogen reaction 
(method described in appendix IV, 10)
Thrombin solution (0.1 ml)
Human Bovine 
50 U/ml Rabbit
Clotting times (seconds)*
0.4 ml human fibrinogen 
0.1 ml saline io£ 5 14
0.4 ml rabbit fibrinogen 
0.1 ml saline H i 9 12i
0.4 ml human fibrinogen 
0.1 ml pyrocatechol 1fo 7 9
0.4 ml rabbit fibrinogen 
0.1 ml pyrocatechol 1fo 7i 7
0.4 ml human fibrinogen (l/2) 9
0.4 ml rabbit fibrinogen(l/2) 9i
* Average of duplicate estimations.
The human fibrinogen solution contained 340 mg/100 mis solution.
The rabbit fibrinogen solution contained 160 mg/100 mis solution.
In the last experiment the fibrinogen solutions were diluted in 
saline in the proportion of 1 : 1, thus the human fibrinogen solution 
(1/2) contained 170 mg fibrinogen /100 mis.
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Table 89» Antithrombin assay in rabbit plasma 
(method of Douglas and Biggs, 1953; appendix IV, 11, A)
Incubation Incubation time (minutes)
mixture 12 1 2 3 4 5 6
0.5 ml rabbit plasma 
0.5 ml thrombin
Clotting times (seconds)
15 22 40 90 146 180+ 180+
0.5 ml human plasma 
0.5 ml thrombin 13i 19 50 100 160 180+ 180+
Units of residual thrombin
Rabbit plasma 10.2 6.5 3.2 1.2 0.6 0 0
Human plasma 11.6 7.£ 2.4 1.0 0.6 0 0
The incubation times at which zero activity of thrombin was 
attained were read from curves a and b in figure 52.
Value for rabbit plasma = 6.5 (curve b at 0.1 thrombin units/ml). 
Value for human plasma = 6.0 (curve a at 0.1 thrombin units/ml). 
Rabbit plasma antithrombin = 6 x 100 +6.5
= 92.3 fo of human plasma anti thrombin.
Re
si
du
al
 
Th
ro
m
bi
n 
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its
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ANTITHROMBIN ASSAY
Method of Douglas & Biggs,1953.
10
8
6
4
2
1
50 1 432
Incubation Time in Minutes
Figure 52. Antithrombin assay in rabbit plasma.
This figure was drawn from the results presented in table 89. 
Curve a : human plasma.
Curve b : rabbit plasma.
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Table 90. Antithrombin assay in rabbit plasma
(modified method of Astrup and Darling, 1942d; appendix IV, 11, B)
Mixture Expt. A B C D E
Saline ml. 0.3 0.25 0.20 0.15 0.10 0.0
Plasma (dil. 1/5) ml. 0.0 0.05 0.10 0.15 0.20 0.3
Thrombin* ml. 1 1 1 1 1 1
1 16 19 22 25 28 32
Clotting times Human 2 11 12* 13* 16 18
T-IP*
CMCM
of 3 13 — 15 18 20 22
fibrinogen 1 16 19 33
(seconds) Rabbit 2 11 12* 15 17 20 22*
3 13 — 16 17* 18* 22
1 1 0.84 0.73 0.64 0.57 0.50
Human 2 1 0.88 0.81 0.68 0.61 0.48
T / t 
o ' n
3 1 — 0.86 0.72 0.65 0.59
1 1 0.84 0.76 0.64 0.61 0.48
Rabbit 2 1 0.88 0.73 0.64 0.55 0.48
3 1 — 0.81 0.74 0.70 0.59
1 1 0.90 0.80 0.70 0.60 0.40
Corrected
Human 2 1 0.90 0.81 0.71 0.62 0.42
3 1 0.84 0.76 0.69 0.54
T / T o n
1 1 0.90 0.80 0.70 0.60 0.40
Rabbit 2 1 0.89 0.77 0.66 0.55 0.34
3 1 — 0.84 0.76 0.69 0.54
1 0 300 300 300 300 300
Calculated Human 2 0 330 313 319 313 319
units of 3 0 — 240 240 231 229.8
antithrombin 1 0 300 300 300 300 300
per ml plasma Rabbit 2 0 363 379 374 371 365
3 0 — 240 240 231 229.8
Thrombin solution used for experiments 1 and 3 contained 30 units/ml. 
while that used for experiment 2 contained 33 units/ml.
Expt. 1 Expt. 2 Expt. 3
Average value for human plasma (units/ml) = 300 315 235.2
Average value for rabbit plasma (units/ml) = 300 370 235.2
Rabbit plasma anti thrombin activity in
percentage of human plasma antithrombin = ioo io 117.4 fo 100 fo
Average rabbit plasma antithrombin = 105.8 fo  of human plasma anti thrombin
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A N TITH R O M B IN  ASSAY.
M odified m ethod of Astrup & Darling, 1942.
0.8-
0.6-
0 .4 -
0.2-
0 0.1 0.20.2 0.3 0.30 0.1
Plasm a Concentration  
Figure 53. Anti thrombin assay in rabbit plasma.
Figures A and B represent experiments 1 and 2 (table 90) respectively.
Curves a : human plasma.
Curves b s rabbit plasma.
The corrected values of T /T in table 90 were derived from theseo n
curves. For experiment 3, a similar curve was drawn to obtain the 
corrected values.
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Table 91. Quick’s one-stage prothrombin time test
Test plasma j
Rabbit brain Human brain
Clotting times (seconds)
Rabbit plasma
15
Jy (16.5) 
18
E*(u .d
n
Human plasma !
22
30 <28> 
32
17
J? (17.7) 
17
Rab.pl. + Hum.pl.
16i
20 (19*6> 
22
17
13|<16a)
14
Rab.pl. + saline
16*
(18.D
21
19
16 <17> 
16
Hum.pl. + saline
26
37 (32.5) 
34
20
20 <21'2) 
20
Figures between brackets are the mean for each group of
four experiments carried out with different batches of 
brain thromboplastins and different plasma pools.
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Table 92. Factor V — brain thromboplastin species specificity
(method described in appendix IV, 16)
Incubation mixture :-
0<>3 ml brain extract, diluted 1/4 in saline, variable, 
0*3 ml purified factor V (appendix III, 9), variable, 
0.3 ml M/40 CaCl_ solution.
Incubation time (minutes)
Variables Substrate 1S. 1 2 3 4 5 6
Clotting times (seconds)
Human brain
Fresh hum.pl. 26 25 24 25 26 26i 29
Human F V Fresh rab.pl. 27 26^ 27 26j 27 28 28
F V-def.pi. 61 59 58 60 59 62 6li
Human brain
Fresh hum.pl. 26 26 24 24 24^ 25 26
Rabbit F V Fresh rab.pl. 28 28 27 27 30 30 28
F V-def.pi. 30 30 30 30 31 32 32
Human brain
Fresh hiim.pl. 30 32 33 33 32 35 36
Saline Fresh rab.pl. 27 31 30 32 32 31 31
F V-def.pi. 92 94 90 88 81 92 80
Rabbit brain
Fresh hum.pl. 36 36i 34-1 36 37i 39 38
Human F V Fresh rab.pl. 27
26 24 24 23^ 22 21
F V-def.pi. 79 77 77 78 77 78 75
Rabbit brain
Fresh hum.pl. 33 32 31 33 33 33 31
Rabbit F V
Fresh rab.pl. 28 26^ 25 24 23i 19i 19
F V-def.pi. 40 40 41 41 4li 44 45
Rabbit brain
Fresh hum.pl. 40 4 0 j 43 40 39 40 40
Saline Fresh rab.pl. 32 31 28 27 26 25
24
F V-def.pi. 98 97 93 95 93 95 97
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Table 93. Rabbit plasma factor V assay
(method described in appendix IV, 14)
Plasma
dilution
Factor V 
percentage
Clotting times (seconds)
Expt. 1 Expt. 2 Expt. 3
Human control plasma
1/10 100 $ 39 24 34
1/20 50 fo 46 32 39
1/40 25 f 53 42 45
1/80 12.5$ 60 48 54
1/160 6.2fo 66 53 60
1/320 l . l f o 69 60 68
1/640 1.5$ 74 62 70
Rabbit test 3>lasma
1/160 25i 12 —
1/320 27 13£ —
1/500 ----- — 25
1/800 38 22 —
1/1000 — — 32
1/1600 41 29 —
1/2000 — — 37i
1/3200 48 40 —
1/4000 — — 43
1/6400 58 44 —
1/8000 — — 51
1/12800 63 50 —
Calculated factor V conc. 9696 $ 10120 $ 11975 $
The average factor V content in rabbit plasma for the three
experiments is 105.58 times that contained in the human control plasma.
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RABBIT FACTOR V ASSAY.
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Figure 54. Rabbit plasma factor V assay.
The dilution curve drawn above for human normal plasma represents 
experiment 2, table 93.
Dilution 1/1600 reads 62$ thus rabbit plasma contains 
Dilution 1/3200 reads 24$ thus rabbit plasma contains
10
62 x 1600
10
24 x 3200
10
18 x 6400
10
= 7680 $
The average of all readings for rabbit plasma factor V content 
therefore equals about 10120 $ of the human control plasma factor V 
content, i.e. about 100 folds more.
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Table 94. Factors VII and X - brain thromboplastin species specificity
(method described in appendix IV, 17)
Incubation mixture
0.3 ml brain extract, diluted 1/4 in saline, variable,
0.3 ml purified F VII and X solution,(appendix III,10), variable,
0.3 ml M/40 CaCl^ solution.
Incubation time (minutes)
Variables Substrate 12 1 2 3 4 5 6
Clotting times (seconds)
Rabbit brain Fresh hum.pl. 39 32 281 29 26 24 25
Rabbit VII &  X Fresh rab.pl. 19 15 13 13 13 13 14
Phenindione pi. 32 27 25 24 23 24 24
Rabbit brain
Fresh hum.pl. 39 32 29 27i 2 7i 26 25
Human VII & X Fresh rab.pl. 18 15 13 13 13 13 12
Phenindione pi. 40 37 31 30 30 26 26
Rabbit brain
Fresh hum.pl. 99 101 105 105 103 110 112
Saline Fresh rab.pl. 70 71 70 70 66 72 65
Phenindione pi. 150 124 100 106 100 101 100
Human brain
Fresh hum.pl. 13 12 12 12 11 11 12
Rabbit VII & X Fresh rab.pl. 6 5 5 5 5 5 5
Phenindione pi. 15 14 14 14 14 13 13
Human brain
Fresh hum.pl. 14 12 13 12| 12 12 12
Human VII & X Fresh rab.pl. 6 5
4±2^ 4±2^ 5 5
Phenindione pi. 16 15 15 15 15 15 15
Human brain
Fresh hum.pl. 32i 33 34 33 29 33 34
Saline
Fresh rab.pl. 24 21 22 2li 2li 22 r^ 22
Phenindione pi. 45 43 44 45 44 43 50
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Table^^. Rabbit plasma factor VII assay 
Method A : by correction of phenindione plasma, (appendix IV, 15, A). 
Method B : by correction of Seitz-filtered bovine plasma, (method of 
Koller et al, 1951; appendix IV, 15, B).
Human brain thromboplastin was used in all experiments.
Plasma Factor VII
Method A Method B
dilution percentage Sxpt.l Expt.2 Expt. 3 Expt.4
Clotting times (seconds)
Human control plasma
1/10 100 fo 25 42 39 40
1/20 50 fo 30 56£ 52 53
1/40 25 f 32 87 81 90
1/80 12.5^ 35 132 124 140
1/160 6.2f 35i 195 200 215
1/320 3.1f 36 311 288 358
1/640 1.5f 36i 440 412 520
0 fo 38i - 742 765
Rabbit test plasma
1/10 20 41 38£ 37
1/20 25 66 56 66
1/40 25 109 94 103
1/80 26 212 179 200
Calculated F VII & X cor
-i
lc. 820 fo 86.6 f 94 f 87 f
The average of the last three experiments gives a value for rabbit 
factors VII and X activities in plasma of 89*2 fo of the human control 
plasma content. It should be noted that the plasma pool tested in 
experiment 3 was the same one tested by method A in experiment 1, in 
which latter case it gave a very high value of factor VII activity, 
most probably due to the excess of factor V present in the test plasma 
relative to that in the substrate; while in method B the substrate 
bovine plasma is rich in factor V.
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RABBIT FACTOR VII ASSAY.1000
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Figure 55. Rabbit plasma factors VII and X activity.
The above dilution curve of the normal human plasma represents 
experiment 3, table 95.
99 x 10Dilution l/lO reads 99 f> thus rabbit plasma contains — ~ --- = 99 fo
51 x 20Dilution 1/20 reads 51 fo thus rabbit plasma contains — \q  ~  &
20 2 x40
Dilution 1/40 reads 20.2$thus rabbit plasma contains — ^ 
The average of the three dilutions = 94 $ of the human plasma.
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Table 96. Rabbit plasma factor X assay
(method of Bachmann, Duckert, and Koller, 1958; appendix IY, 18)
Plasma
dilution
Factor X 
percentage
Clotting times (seconds)
Expt. 1 Expt. 2 1 Expt. 3
Human control plasma
1/10 100 fo 20 23 22
1/20
oir\ 26 29 29
1/40 to VJ1 32-| 39 38
1/80 12.5$ 40 49 48
1/160 6.2% 51 54* 54
1/320 3.1fo 56 66 66
1/640 1.5% 73 8li 85
1/1280 0 . 7 % 82 91* 89
0 fo 101 106 118
Rabbit test plasma
1/10 14 14 15
1/20 16 19 18
1/40 20 24 22
1/80 26 31 27
1/160 32 OJ 00 Ml-
1
32
1/320 41 — 41
Calculated factor X conc. 440.4$ 388 % 479.2$
The average of the three experiments for rabbit plasma factor 
X content is 436.5 fo of the human control plasma factor X content.
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Table 97. Rabbit plasma prothrombin assay
(Two-stage area method of Biggs and Douglas, 1953a; appendix IV, 12, C)
Incubation Incubation time (minutes) Weight of area
mixture Expt,
12 l4 1 2 3 4 5 under curve &
Clotting times (seconds) its percentage
Hrun.pl. + Hum.Br. 1A 12 15 15 26 65 129 180+
Rab.pl. + Hum.Br. IB 12j 16 20 64 108 170 180+
Hum.pl. + Rab.Br. 1C 66 15 14 44 150 180+
Rab.pl. + Rab.Br. ID - 17 40 84 131 180+
Hum.pl. + Hum.Br. 2A 15 16 21 43 143 180+
Rab.pl. + Hum.Br. 2B 16 18 29 96 180+ 180+
Hum.pl. + Rab.Br. 2C 45 17 18 36 112 180+
Rab.pl. + Rab.Br. 2D — 15 24 92 124 173 180+
Hum.pl. + Hum.Br. 3A 12 16 18 70 180+
Rab.pl. + Hum.Br. 3B
r—1 18 27 104 180+
Hum.pl. + Rab.Br. 3C 55 — 10 20 80 180+
Rab.pl. + Rab.Br. 3D — 11 16 125 180+ 180+
Thrombin units / ml. mg fo
1A 13.5 10.2 10.2 5.2 1.8 0.8 0 292.1
IB 13 9.5 7.2 1.8 1 0.5 0 196.1 67.1 fo
1C 1.7 10.2 11 2.8 0.6 0.0 188.3
ID — 8.8 3.2 1.3 0.7 0.0 126.9 67.3 fo
2A 10.2 9.5 6.8 2.9 0.7 0 201.0
2B 9.5 8.2 4.6 1.1 0 134.6 66.9 fo
2C 2.7 8.9 8.2 3.6 0.9 0 185.6
2D — 10.2 5.8 1.2 0.8 0.5 0 157.8 85.0 fo
3A 13.5 9.5 8.2 1.6 0 198.7
3B 11.5 8.2 5 1 0 136.4 68.6 fo
3C 2.2 _ 16.5 7.2 1.4 0 297.8
3D — 15 9.5 0.8 0.0 0 189.7 63.7 fo
Percentage of rabbit plasma prothrombin is related to the prothrombin 
content of the human control plasma tested with the same species of brain 
extract. With human brain the average rabbit plasma prothrombin equals
67.5 fo of the human, while with rabbit brain it averages 72 fo of the 
human plasma prothrombin content.
Experiment 1 is illustrated in figure 56.
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MEASUREMENT OF PROTHROMBIN.
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Figure 56. Measurement of rabbit plasma prothrombin.
Curve A s obtained for human plasma using human brain. Weight of
area under curve is 292.1 mg which is designated the 100 fa value.
Curve B : obtained for rabbit plasma using human brain. Weight of 
area enclosed is 196.1 mg which is equivalent to 67.1 fo of 
human plasma prothrombin activity.
Curve C : obtained for human plasma using rabbit brain. Weight of
enclosed area is 188.3 mg which is equivalent to 64.4 fo of
human plasma prothrombin when estimated with human brain.
Curve D : obtained for rabbit plasma using rabbit brain. Weight of 
enclosed area is 126.9 mg which gives a value of 67.3 fo of 
the human plasma prothrombin when the latter was tested with 
rabbit brain.
(All the above data are from the results of experiment 1, table 97)
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Table 98. Rabbit plasma prothrombin assay
(globulin fraction method of Douglas and Biggs, 1953; appendix IV, 12, B)
Experiment 1 Experiment 2
Human brain Human brain Rabbit brain
Hum.pl. Rab.pl. Hum.pl. Rab.pl. Hum.pl. Rab.pi.
Fibrinogen clotting 
times (seconds)*
Thrombin units/ml.
20
7.2
63
1.9
24i
5.7
69
1.75
25i
5.4
71
1.6
Prothrombin conc. 100 fo 26.2 % 100 fo 30.7 fo 100 fo 29.6 fo
* Average of duplicate estimations.
With human brain as the thromboplastic agent, rabbit plasma was 
found to have an average prothrombin concentration of 28.4 fo  of human 
plasma prothrombin. With rabbit brain, it also contained 29.6 fo  of 
the human plasma prothrombin content.
It is noted that rabbit plasma used in experiment 2, having 30.7 fo  
of the human plasma prothrombin, was also tested on the same day by 
the two—stage area method (experiment 2, table 97) using the same 
human brain extract. By the latter method it had 66.9 f> of the human
plasma prothrombin activity.
With rabbit brain extract, this method yielded a value of 29.6 fo  
of the human, while the two-stage area method gave a value of 85 fo  of 
prothrombin for the same plasma pool against the same control human plasma.
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Table 99. Rabbit plasma prothrombin consumption index 
(method of Biggs and Macfarlane, 1957; appendix IV, 13, A)
Incubation time (seconds)
45 90 45 90 45 90
Expt. 1 Expt. 2 Expt. 3
Rabbit plasma time(sec.) 13 26 17 37 18 37
Rabbit serum time (sec.) 52 90 72 180+ 63 157
P.C.I. 25$ 28.8$ 23.6$ 20.5$ 28.5$ 23.5$
Average P.C.I. 26.9 $ 22 fo 26 fo
The average P.C.I. of the three experiments = 24.9 $
Table 100. Rabbit blood platelets1 count 
(method described in appendix IV, 1, A)
Total count/c.mm. whole blood*
Experiment 1 274,000
Experiment 2 422,000
Experiment 3 258,000
Experiment 4 360,000
Experiment 5 266,000
Experiment 6 335,000
Experiment 7 248,000
Experiment 8 225,000
Average 311,000
* Mean of duplicate counts.
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Table 101. Rabbit •whole blood clotting time
(method of Lee and Tulhite, 1913; appendix IY, 3)
Clotting times*
Ordinary glass Siliconed glass
Experiment 1 6* 30” 12* —
Experiment 2 7' 10” 131 40”
Experiment 3 3* 45” V 58”
Experiment 4 6* 15” V 30”
Experiment 5 5' 52” 12' 2”
Experiment 6 6’ 10” 13' 20”
Experiment 7 7* — 13' 29”
Average 6» 6" 12 * 51”
* Mean of two tubes1 readings.
Table 102. Recalcification time of plasma 
(method described in appendix IY, 5)
Clotting times (seconds)
Human plasma Rabbit plasma
Experiment 1 148 106
Experiment 2 154 120
Experiment 3 143 116
Average 148 114
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Table 103. Babbit plasma Hageman factor assay
(method described in appendix IV, 24, II)
Plasma dilution 
in
Hag.F.~def.pl.
Concentration
of
Hageman factor
Clotting times (seconds)
Expt. 1 Expt. 2
Human control plasma
1/2 250 fo 106 -
1/5 100 f> 127 142
1/10 50 fo 165 -
1/15 33.3f - 182
1/20 25 fo 191 -
1/40 12.5# 236 -
1/45 11.1# - 257
1/80 6.2# 300 -
1/135 3.7# - 364
1/405 1.2# - 540
0 fo 1200+ 1200+
Rabbit test plasma
1/5 65 -
1/10 80 -
1/15 - 87
1/20 98 -
1/45 - 132
Calculated Hagema,n factor conc. 910 # 1140 #
The average of the two experiments equals 1025 #, i.e. rabbit plasma 
contains about tenfolds more of Hageman factor activity as compared to 
the human control plasma.
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HAGEMAN FACTOR ASSAY.
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 - 01/20100
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Figure 57. Hageman factor assay in rabbit plasma.
The above human plasma dilution curve was obtained from the 
results of experiment 1, table 103.
950 x 5
Dilution 1/5 reads 950$ thus rabbit pi. contains  ---  = 950 $
5
4 4 0  x  10
Dilution l/lQ reads 440$ thus rabbit pi. contains ---- = 880 $
225 x 20
Dilution l/20 reads 225$ thus rabbit pi. contains  -----= 900 $
The average Hageman factor concentration in this plasma pool 
equals 910 per cent of human control plasma Hageman factor activity.
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Table 104. Thromboplastin generation test
(method of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixture : 0.3 ml adsorbed plasma, diluted 1/5, variable,
0.3 ml serum, diluted l/lO, variable,
0.3 ml human platelets,
0.3 ml M/40 CaCl2 solution. 
Substrate : human high-spun plasma.
Incubation
Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 52 15 12 11 10i 11
140 Human plasma Human serum
2
3
65
60
15
12
10
10
9
9i
10
9i
ioi
9i
Avg. 59 14 10.6 9.8 10 10.3
fo 2.4 50 90 106 100 94 fo
1 45 14 11 11 11 11
141 Human plasma Rabbit serum
2
3
68
63
22
14
17i
12
13
12
14
lli
15
lli
Avg. 58.6 16.6 13.5 12 12.1 12.5
f 2.4 35 55 70 68 65 f
1 10 9 i 9 8i si si
142
Rabbit plasma 
Rabbit serum
2
3
18
15
H i
11
11
10
ioi
9
11
9
10
9
Avg. 14.2 10.6 10 9.3 9.5 9.1
fo 48 90 100 117 112 122 f
1 17 10 10 10 10 9i
143
Rabbit plasma 
Human serum
2
3
9
11
8
9
8
8i
9
8
9
si
si
si
Avg. 12.5 9 9.5 9 9.1 8.8
fo 66 125 112 125 122 132 f
Percentage active thromboplastin values were read from the human 
thromboplastin dilution curve A, figure 2.
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Table 105. Thromboplastin generation test
(method of Biggs and Douglas, 1953b; appendix IY, 20)
Incubation mixture s 0,3 ml adsorbed plasma, diluted 1/5, variable,
0.3 ml serum, diluted l/lO, variable,
0.3 ml rabbit platelets,
0.3 ml M/40 CaCl^ solution.
Substrate s human high-spun plasma.
Incubation time (minutes)
mixture Expt. 1 2 3 4 1 5 6
No. Clotting times (seconds)
1 64 30 14 lli 12 n i
144 Human ads.pl. Human serum
2
3
117
60
90
25
15
11
H i
ioi
12
ioi
12
10
Avg. 80.3 48.3 13.3 11.1 11.5 11.1
f 1.1 3.6 56 82 76 82 °/o
1 12 10 10 9 10 9
145 Human ads.pl. Rabbit serum
2
3
70
44
40
15
20
15
16
12
14
12
13
11
Avg.
*
42
4.9
31.6 15 12.3 
9 43.5 66
12
70
11
84 fo
1 8 si 7 7i 7 7
146 Rabbit ads.pl. Rabbit serum
2
3
19
14
si
9
9
8
9
8
9
8
9
8
Avg. 13.6
54
8.6
138
8
160
8.1
158
8
160
8
160 f
147
Rabbit ads.pl. 
Human serum
1
2
3
58
60
41
15
n
9i
U i
7i
7i
11
6i
6i
10
6i
7
10
7i
7
Avg.
fo
53
3
10.6
90
8.7 8 
135 160
7.8 8.1 
170 158 fo
Percentage active thromboplastin values were read from the human 
thromboplastin dilution curve A, figure 2. All the above experiments 
were conducted on the same batches of rabbit and human reagents as 
those used for experiments cited in table 104, and are therefore 
directly comparable with each other as regards the effect of using 
rabbit platelets’ suspension instead of the human preparation.
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PLASMA ACTIVITY IN TG.T
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Figure 58. Rabbit plasma activity in the T.G.T.
Figure A (using human platelets)
Curve a : human ads.pl. + human serum (Mixture 140, table 104)
Curve b : rabbit ads.pi.+ human serum (Mixture 143, table 104)
Figure B (using rabbit platelets)
Curve a : human ads.pl. + human serum (Mixture 144, table 105)
Curve b : rabbit ads.pl. + human serum (Mixture 147, table 105)
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Table 106, A.H.G. assay in rabbit plasma
(method of Pitney, 1956; appendix IV, 21)
Plasma Cone entrati on Clotting times (seconds)
dilution of A.H.G. Expt. 1 Expt. 2 Expt. 3
Human control plasma
1/20 100 fo 20 20 19i
1/40 50 fo 25^ 25 24
1/80 25 fo 33 33 33%
1/160 12.5 fo 39 45 3 7
1/320 6.2 fo 43 52 43
1/640 3.1 fo 49 63 53
1/1280 1.5 f 50 67 63
Rabbit test plasma
1/20 15% 13 12^
1/100 27 26 22
1/200 32 37 33
1/400 36 43 36
1/800 — — 41
Calculated A.H.G. conc. 295 f> 246.6 fo 324 fo
The average A.H.G. concentration in the three rabbit plasma 
pools equals 288.5 fo  of the human control plasma content, vith a range
from 246.6 to 324 per cent.
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A .H .G . ASSAY.
Method of Pitney, 1956.
5 0 -
 01/400
4 0 -
—  -01/200</)
~ocou0)
y  30 -
0)
E
F
 o  1 /1 0 0
i* 20-
_o
U
0 20 40 60 80
A.H .G . Percentage
Figure 59. A.H.G. assay in rabbit plasma.
A diagrammatic presentation of experiment 2, table 106.
48 x 100Dilution l/lOO reads 48.0$ thus rabbit pi. contains--— --- = 240 $
21 x 2f¥l
Dilution 1/200 reads 21.0$ thus rabbit pi. contains--— --- = 210 $
14.5 x400
Dilution 1/400 reads 14.5$ thus rabbit pi. contains— ---= 290 $
The average A.H.G. for this plasma pool therefore equals 246.6 $
of the human control plasma A.H.G. content.
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SERUM A C TIV ITY  IN TG .T
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Figure 60. Rabbit serum activity in the T.G.T.
Figure A (using human platelets)
Curve a s hum.ads.pl. + human serum (Mixture 140, table 104)
Curve b : hum.ads.pl. + rabbit serum (Mixture 141, table 104)
Figure B (using rabbit platelets)
Curve a : hum.ads.pl. + human serum (Mixture 144, table 105)
Curve b j hum.ads.pl. + rabbit serum (Mixture 145, table 105)
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Table 107. Christmas factor assay in rabbit serum
(based on method of Pitney, 1956; appendix IV, 22)
Serum
dilution
X-mas factor 
concentration
Clotting times (seconds)
Expt. 1 Expt. 2 Expt. 3
Human control serum
1/20 100 $ 10 15 15
1/40 50 fo 11 20 I82
1/80 25 fo 13 . 25 24
1/160 12.5$ 15 34 28i
1/320 6.2$ 00 w|-
“
44 39
1/640 3.1$ 24^ 56 49
1/1280 1.5$ 27 60 62
0 $ 32 65 74
Rabbit test serum
1/10 — 20 16
1/20 iH 26 18j
1/40 15 42 25
1/80 17 51 39i
Calculated X-mas factor 27.5 $ 20.4 $ 4 0 $
The average for the three rabbit serum pools equals 29*3 $
of the human control serum Christmas factor activity.
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CHRISTM AS FACTOR ASSAY. 
Modified method of Pitney, 1956.
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Figure 61.Christmas factor assay in rabbit serum.
Illustration of experiment 2, table 107, showing the human
serum dilution curve by correction of Christmas disease serum.
50 x 10Dilution l/lO reads 50 fo thus rabbit serum contains ----— —  = 25 fo
231 x 20
Dilution 1/20 reads 23^ thus rabbit serum contains —
7I x  40
Dilution 1/40 reads fo thus rabbit serum contains ,2---—  =15 fo
Dilution l/80 reads 4 j fo thus rabbit serum contains 20~" = 18 #
The average of Christmas factor content in this rabbit serum pool,
therefore equals 20.4 fo of the human control serum activity.
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PLATELET ACTIVITY IN T.G.T
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Figure 62. Thromboplastic activity of rabbit platelets in the T.G.T.
Figure A (human ads.pl. and serum are constants)
Curve a : using human platelets (Mixture 140, table 104)
Curve b : using rabbit platelets (Mixture 144, table 105)
Figure B (rabbit ads.pl. and serum are constants)
Curve a : using human platelets (Mixture 142, table 104)
Curve b : using rabbit platelets (Mixture 146, table 105)
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Table 108. Clot retraction of rabbit blood 
(method of Macfarlane, 1938; appendix IV, 4)
Hematocrit value 
of
sequestrene blood
Percentage of 
clot retraction 
in one hour*
Expt. 1 56 fo 46 fo
Expt. 2 49 f 58 f>
Expt. 3 50 f 56 f>
Expt. 4 52 fo 56 f>
Expt. 5 54 fo 56 fo
Expt. 6 55 fo 56 fo
Average 54.6 fo
* Average of two tubes'readings.
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Table 109. Rabbit plasma substrate reactivity in the T.G-.T.
Incubation mixture s 0.3 ml adsorbed plasma, diluted l/5, variable,
0.3 ml serum, diluted 1/10, variable,
0.3 ml human platelets,
0.3 ml M/40 CaCl^ solution. 
Substrate : rabbit high-spun plasma.
Incubation
Incubation time (minutes)
mixture Expt. 1 2 3 4 5 6
No. Clotting times (seconds)
1 35 12 10 10 10 10
148 Human ads.pl. Human serum
2
3
43
42
11
11
9
9
9
9
9i
9
9
9
Avg. 40 11.2 9.: 9.2 9.= 9.3
5.4 79 117 117 112 117 f
1 30 11 ioi 10 ioi ioi
149
Human ads.pl. 
Rabbit serum
2
3
42
39
23
lli
12
11
Hi
11
lli
11
11
11
Avg. 37 15.1 11.1 10.8 11 10.8
fo 6.4 42 82 87 84 87 f
1 20 10 9i 9 9 9i
150 Rabbit ads.pl. Rabbit serum
2
3
22
25
10
10
10
9
10
9
9i
9i
10
9
Avg. 22.3 10 9.5 9.3 9.3 9.5
fo 19 100 112 117 117 112 io
1 12 8i 8i 8i 8i 8
151
Rabbit ads.pl. 
Human serum
2
3
9
10
7i
9
8
8
8
8
9
8
8i
8
Avg. 10.3 8.3 8.1 8.1 8.5 8.1
f 94 150 158 158 140 158 fo
Incubation mixtures 148, 149, 150, and 151 were made with the same
solutions used for mixtures 140, 141, 142, and 143 respectively, and are 
therefore directly comparable with each other as regards the effect of 
using rabbit high-spun plasma as substrate instead of the human high-spun 
plasma.
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Table 110. Rabbit plasma substrate reactivity in the T.G.T.
Incubation mixture : 0*3 ml adsorbed plasma, diluted 1/5, variable,
0*3 ml serum, diluted l/lO, variable,
0*3 ml rabbit platelets,
0*3 ml M/40 CaOl^ solution.
Substrate : rabbit high-spun plasma.
Incubation Incubation time (minutes)
mixture Expt, 1 2 3 4 5 6
No. Clotting times (seconds)
1 38 19 11 10 9 9
152 Human ads.pl* Human serum
2
3
54
32
33
21
124
94
10
9
9
9
8
9
Avg. 41.3 24.3 11 9.6 9 8.6
f 5 15.7 84 110 125 138 ic
1 84 74 64 7 7 64
153 Human ads.pl* Rabbit serum
2
3
42
25
25
13
12
104
9
10
9
9
9
9
Avg. 25.1 15.1 9.6 8.6 8.3 8.1
1° 14.4 42 110 138 150 158 <$>
1 64 6 64 6 6 6
154 Rabbit ads.pl. Rabbit serum
2
3
12±
13
54
74
6
6
6
6
6
64
6
6
Avg. 10.6 6.3 6 6 6.1 6
i° 90 270 300 300 290 300 #
i 324 10 9 7 7 8
155
Rabbit ads.pl. 
Human serum
2
3
22
30
6
64
64
64
64
64
7
64
7
64
Avg. 28.1 7.5 7.2 6.6 6.8 7.1
f 11.2 185 200 245 230 210 io
Incubation mixtures 152, 153, 154, and 155 were made with the same 
reagents used for mixtures 144, 145, 146, and 147 respectively, with 
which they are therefore directly comparable as regards the effect of 
substituting rabbit high-spun plasma substrate instead of the human plasma 
substrate.
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SUBSTRATE REACTIVITY IN T.G.T
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Figure 63. Rabbit plasma substrate reactivity in the T.G.T.
Figure A (human ads.pl., serum, and platelets are constants)
Curve a : on human H.S.plasma substrate (Mixture 140, table 104)
Curve b : on rabbit II.S.plasma substrate (Mixture 148, table 109)
Figure B (human ads.pl. and serum, with rabbit platelets are constants) 
Curve a : on human H.S.plasma substrate (Mixture 144, table 105)
Curve b s on rabbit H.S.plasma substrate (Mixture 152, table 110)
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SUBSTRATE REACTIVITY IN TG.T
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Figure 64. Rabbit plasma substrate reactivity in the T.G.T.
Figure A (rabbit ads.pl. and serum, with human platelets are constant) 
Curve a : on human H.S.plasma substrate (Mixture 142, table 104)
Curve b : on rabbit H.S.plasma substrate (Mixture 150, table 109)
Figure B (rabbit ads.pl., serum, and platelets are constant)
Curve a : on human H.S.plasma substrate (Mixture 146, table 105)
Curve b : on rabbit H.S.plasma substrate (Mixture 154, table 110)
Curve b, figure B, represents a completely homologous rabbit 
thromboplastin generation system.
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Table 111, Investigation of inhibitors against human intrinsic
thromboplastin in rabbit plasma and serum in the T.G.T.
(method described in appendix IV, 23)
Incubation mixture : 0.3 ml adsorbed plasma, diluted l/5, variable,
0.3 ml serum, diluted 1/10, variable,
0.3 ml human platelets,
0.3 ml M/40 CaCl2 solution. 
Substrate s human high-spun plasma.
Incubation
TTP TctUT*fi
Incubation time (minutes)
Expt. 1 2 | 3 4 5 6
No. (ml) Clotting times (seconds)
A - BEFORE INCUBATION
1 58 26 12 10 10 10
156 0.30 Human ads.pl.
2 60 25 15 11 11 10
0.30 Human serum Avg. 59 25* 13i 10* 10* 10
f 2.4 14 55 92 92 100 fo
157
0.15 Human ads.pl. 
0.15 Rabbit ads.pl. 
0.30 Human serum
1
2
42
32
10
12
10
10
9
10
9
10
9
9*
Avg.
ft
37
6.4
11
84
10
100
9i
112
9i
112
9* 
119 f
158
0.30 Human ads.pl. 
0.15 Human serum 
0.15 Rabbit serum
1
2
26
23
12*
12
12
11
12
11
12
11
13
11
Avg.
f°
24* 12* 
15.5 67
lli
76
lli
76
H i
76
12
70 fo
B - AFTER INCUBATION AT 37°C. FOR 2 HOURS
1 67 35 12* H i lli 12*
159
0.30 Human ads.pl. 2 87 36 14 H i H i lU-
0.30 Human serum Avg. 77 35* 13i H i 11* 12
fo 1.3 7 56 76 76 70 fo
160
0.15 Human ads.pl. 
0.15 Rabbit ads.pl. 
0.30 Human serum
1
2
63
46
14
20
11
12
11
11
H i
H i
11
11
Avg.
#
54*
2.7
17
33
H i
76
11
84
lli
76
11
84 fo
161
0.30 Human ads.pl. 
0.15 Human serum 
0.15 Rabbit serum
1
2
40
21
12
11
12
10*
12*
10*
13*
11
12*
10*
Avg.
*
30*
9.6
H i
76
lli
80
lli
76
12*
67
11* 
76 fo
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PLASMA INHIBITORS OF BLOOD THROMBOPLASTIN.
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Figure 65. Rabbit plasma inhibitors of human intrinsic thromboplastin.
(Human serum and platelets are constant)
Figure A Before incubation
Curve a : human ads.pl. alone (Mixture 156, table 111)
Curve b : human ads.pl. + rabbit ads.pl. (Mixture 157, table 111)
Figure B After incubation at 37°C. for 2 hours
Curve a : human ads.pl. alone (Mixture 159, table 111)
Curve b : human ads.pl. + rabbit ads.pl. (Mixture 160, table 111)
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SERUM INHIBITORS OF BLOOD THROMBOPLASTIN.
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Figure 66. Rabbit serum inhibitors of human intrinsic thromboplastin.
(Human ads.pl. and platelets are constant)
Figure A Before incubation
Curve a : human serum alone (Mixture 156, table 111)
Curve b : human serum + rabbit serum (Mixture 158, table 111)
Figure B After incubation at 37°C. for 2 hours
Curve a : human serum alone (Mixture 159, table 111)
Curve b : human serum + rabbit serum (Mixture 161, table 111)
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R E S U L T S  O F  E X P E R I M E N T S
O N  L O B S T E R  B L O O D
All the following data were obtained 
from experiments carried out on blood samples 
obtained from live lobsters of the Nephrops 
norvegicus strain, using pooled plasma or serum 
samples from at least three animals for each 
experiment to obviate as much as possible any 
individual variations from affecting the final 
levels of the various coagulation factors.
Blood samples were obtained fresh on the 
day of the test concerned as described in 
appendix II, 1, iii.
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Table 112. Activity of lobster muscle extract
Clotting mixture Expt. 1 Expt. 2 Expt. 3*
Clotting times
0.2 ml Lob.plasma
0.1 ml Lob.muscle extract
0.1 ml J fo CaCl2
31 13« 5' — 10*+
0.2 ml Lob.plasma 
0.1 ml Saline 
0.1 ml J fo CaCl2
more t]lan 10 mi]lutes
0.2 ml Lob.plasma 
0.1 ml Lob.cell extract 
0.1 ml J fo CaCl2
- 5” - 6” 6”
0.5 ml Lob.plasma
0.1 ml Lob.muscle extract
0.1 ml J fo CaCl2
2' 15” 3* — 10*+
0.5 ml Lob.plasma 
0.1 ml Saline 
0.1 ml Jfo CaCl2
more ttlan 10 millutes
0.2 ml Lob.fibrinogen 
0.1 ml Lob.muscle extract 
0.1 ml J fo CaCl2
1« 19" 10’+
0.2 ml Lob.fibrinogen 
0.1 ml Saline 
0.1 ml J fo CaCl2
10*+ 10*+
0.2 ml Lob.fibrinogen 
0.1 ml Lob.muscle extract 
diluted 1 in 2 
0.1 ml J fo CaCl2
1* 23" 10’+
The test was performed at 37°C. in a similar manner to Quick’s 
one-stage test, except for using the above specified reagents, and 
recording the mean clotting time of duplicate estimations.
* The lobster muscle extract used in experiment 2 was kept frozen 
at -20°C. for 72 hours and used fro experiment 3.
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Table 113. Species specificity of lobster muscle extract
Etyual volumes of plasma, tissue extract, and calcium chloride 
solution were tested by Quick's one-stage test (Appendix IV, 6).
M/40 CaCl^ solution was used for the human plasma and human brain 
mixture only. For all the other mixtures, different concentrations 
of CaCl^ solution (M/40, 3%, and molar or IVfo) were used and gave 
fairly similar clotting times.
Human brain Lob. muscle extract
Clotting times
10'+ 4* 42"
Lobster plasma 10'+ 5* —
10'+ 3* 55"
15“ 4' 20"
Human plasma 14£" 2' 36"
15" 31 x4"
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Table 114. Factor Y activity in lobster plasma 
(by correction of factor V-deficient human plasma; appendix IV, 14)
Clotting mixture
0*1 ml test or control plasma l/lO in factor V-deficient plasma, 
0.1 ml human brain extract,
0.1 ml M/40 CaCl^ solution.
Test substance (l/lO) Expt. 1
Expt. 2 Expt. 3
Clotting times (seconds)
Human plasma 19 20 22
Lobster plasma 80 78 91
Saline 67 63 82
Table 115. Factor VII activity in lobster serum 
(by correction of phenindione human plasma; appendix IV, 15, A)
Clotting mixture
0.1 ml test or control serum l/lO in phenindione plasma,
0.1 ml human brain extract,
0.1 ml ^40 CaCl^ solution.
Test substance (l/lO) Expt. 1 Expt. 2
Expt. 3
Clotting times (seconds)
Human serum 21 20 19-jf
Lobster serum 50 52 49
Saline 48 53 47
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Table 116. Factor X assay in lobster plasma
(method of Bachmann, Duckert, and Koller, 1958; appendix IV, 18)
Plasma Factor X Experiment 1 Experiment 2
dilution percentage Clotting times (seconds)
Human control plasma
1/10 100 <?c 27 23
1/20 50 io 32 29
1/40 25 1o 42 39
1/80 12.59$ 47 49
1/160 6.29$ 60 54£
1/320 3.19$ 70 66
1/640 1.59$ 90 8l£
1/1280 0.79$ 100 91*
Buffer 0 9$ 114 106
Lobster test plasma
1/5 130 122
1/10 130 120
1/20 114 115
1/40 116 113
1/80 115 —
Calculated factor X conc. 0 9$ 0 9$
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Table 117» R.V.V.—cephalin clotting time of lobster plasma 
(method described in appendix IV, 19)
Various concentrations of calcium chloride solution were used 
as shown. The different mixtures were also tested with lobster 
blood cell extract (last column) to prove suitability of the plasma.
Clotting
mixture
Concentration of R.V.V.-cephalin Lobster
1/10,000 - 0.06% 1/40,000 - 0.06% cell extract
Clotting times (seconds)
Lobster plasma 
M/40 CaCl2 180+ 180+ 104
Lobster plasma 
3 % CaCl2 180+ 180+ 6
Lobster plasma 
115& CaCl2 (molar) 180+ 180+ n
Lob. fibrinogen 
11 % CaCl2 (molar) 180+ 180+ 5
Similar results were obtained on using R.V.V. reagent alone
without cephalin.
Table 118. Thrombin clotting time of lobster plasma
Clotting mixture: 0.1 ml lobster plasma,
0.1 ml bovine thrombin, 100 units/ml.
Thrombin clotting times (sec.)
Expt. 1 180+
Expt. 2 180+
Expt. 3 180+
These prolonged clotting times were not improved by the addition 
of a molar calcium chloride solution to the mixture.
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Table 119. Antithrombin assay in lobster plasma
(modified method of Astrup and Darling, 1942d; appendix IV, 11, B)
Incubation mixture A B C D
Saline ml. 
Plasma (diluted l/5) ml. 
Thrombin (30 U/ml) ml.
0.3 0.2 0.15 0.1 0.0 
0.0 0.1 0.15 0.2 0.3 
1 1 1 1 1
Clotting times 
of
fibrinogen
(seconds)
Hum.pl.
Lob.pl.
15 17 18 22 25 
15 15 15 15 15
T / T o ' n
Hum.pl.
Lob.pl.
1 0.88 0.83 0.68 0.60 
1 1 1 1 1
Corrected
T / T o n
Hum.pl.
Lob.pl.
1 0.87 0.80 0.73 0.60 
1 1 1 1 1
Calculated units 
of antithrombin 
per ml. plasma
Hum.pl.
Lob.pl.
0 195 200 202 200 
0 0 0 0 0
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Table 120. Lobster whole blood clotting times 
(method of Lee and Ihite, 1913; appendix IV, 3)
Clotting times*
Ordinary glass Siliconed glass
Expt. 1 at 37°C. 151 12" 28' 30"
Expt. 2 at 37°C. t—* vO to o 25’ —
Expt. 3 at 15°C. 4' 16" 6' 33"
Expt. 4 at 15°C. 2' 50" 6' 20"
Expt. 5 at 15°C. 4* 42" 12’ 30"
Expt. 6 at 15°C. 5f — 9‘ 10"
Expt. 7 at 15°C. 22* 40"
Expt. 8 at 15°C. 20' 36"
Expt. 9 at 15°C. 29 * 10"
Expt.10 at 15°C. ii
vDCM
|
* Average of two tubes' readings.
The slightest shaking of any tube resulted in instantaneous 
cellular agglutination and clotting of the blood, whether in 
ordinary glass or in siliconed tubes, at 37°C. or at 15°C. This 
necessitated very gentle and slow inversion of the tubes for the 
observation of the development of a firm clot.
Experiments 7, 8, 9, and 10 were made on lobster blood from the 
same animals used in experiments 3, 4, 5, and 6 respectively, after 
keeping them in captivity in the sea-water tank until they showed 
signs of devitalisation, which usually occured within 24 to 48 hours.
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Table 121. Hageman factor and plasma thromboplastin antecedent 
activity in lobster plasma 
(method of Ratnoff and Rosenblum, 1958; appendix IV, 23, I)
Test plasma 
preparation
Clotting times (minutes) of human intact 
citrated platelet-deficient substrate plasma
Experiment 1 Experiment 2
Human, intact 90 110
Lobster, intact 150 120+
Saline 120+ 120+
Human, glass activated 11 10
Lobster, glass activated 110 100
Table 122. Hageman factor assay in lobster plasma
(by correction of human Hageman-deficient plasma; appendix IV, 23, II)
Plasma dilution 
in
Hag.-def.plasma
Concentration
r\-P
Clotting times (seconds)
O X
Hageman factor Human control plasma
1/5 100 / 142 107
1/15 33.3/o 182 140
1/45 11.1/ 257 186
1/135 3.7% 364 254
1/405 1.2fo 540 320
0 / 1200+ 1200+
Lobster test plasma
1/5 2100+ 1200+
1/15 1800+ 1200+
Calculated Hageman factor conc. 0 °/o 0 /
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Figure 67. Phase contrast photomicrograph of lobster blood, one 
minute after withdrawal, showing the process of cell explosion. 
Magnification xl70, enlargement x3.6, total x612.
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Figure 68. Phase contrast photomicrograph of the same field as 
above, two minutes later, showing the dense coagulation islands 
around the explosive cells. Magnification as above.
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Figure 69. Phase contrast photomicrograph of lobster blood several 
minutes after withdrawal, showing two well developed coagulation 
islands. Magnification on film xl70, enlargement x3.6, total x612.
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Table 123. Lobster blood cells1 count
(method described in appendix IV, 1, C)
Total cell 
count/c.mm.
Percentage of the 
explosive cells
Experiment 1 30,400 23 $
Experiment 2 14,800 19 fo
Experiment 3 22,800 20 $
Experiment 4 13,400 18 f
Experiment 5 15,000 24 $
Experiment 6 17,500 20 $
10,800 * 15 fo
Experiment 7 13,200 13 f
Experiment 8** 49,000 26 f
Experiment 9** 56,000 24 f
Experiment 10 27,000 20 f
Average 25,910 20.7$
* This count was made on blood of the same lobster 
after 24 hours in captivity, when it was found to be 
nearly dead.
** The two lobsters used for these two experiments 
were of unusually big size compared to the other several 
hundred specimens obtained.
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a. Lob. Plasma b. Lob Serum
I I
Figure 70. Electrophoresis pattern and its densitometric 
scanning of lobster plasma and serum.
(method described in appendix II, 7)
h : haemocyanin, a blue oxygen carrying 
pigment present free in the plasma, 
f : fibrinogen.
x : unidentified protein component.
The lobster serum was separated after spontaneous clotting of 
lobster whole blood by centrifugation.
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a. Lob. Plasma b. Lob. Serum
1 I
Figure 71. Electrophoresis pattern and its densitometric 
scanning of lobster plasma and serum.
(method described in appendix II, 7)
h s haemocyanin.
f : fibrinogen.
x : unidentified protein.
This is the more usual pattern obtained with most of the 
lobster plasma and serum samples.
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I
H. Fibrinogen
II
H. Plasm*
m
H. Serum
1 I
Figure 72. Electrophoresis patterns and their densitometric scannings 
for human plasma, serum, and purified fibrinogen.
(method described in appendix II, 7)
A : albumin.
: alpha-l-globulin.
: alpha-2-gl obulin.
|3 : betar-globulin.
Y : garama-globulin.
F : fibrinogen.
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a) Lobster Cel Extract.
1
b) Lobster Plasma.
cell extract.
I I
Figure 73. Electrophoresis pattern and densitometric scannings of 
lobster blood cells' extract, lobster plasma, and 
lobster plasma defibrinated with lobster cell extract, 
(method described in appendix II, 7)
The fibrinogen band f present in the plasma has been removed 
by the action of the cell extract in the form of fibrin which was
separated by centrifugation.
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Table 124. Fibrinogen assay in lobster plasma 
(methods described in appendix IV, 2, I and II)
mg fibrinogen per 
100 mis absolute plasma
micro-Kjeldahl method
Expt. 1 301
Expt. 2 202.2
Average 251.6
modified Greenberg method
Expt. 3 138.8
Expt. 4 169.9
Expt. 5 186.6
Expt. 6 * 30
Expt. 7 330
Average 213.2
* Experiment 6 was made on blood from the same lobster 
used for experiment 5, after keeping it for a further 48 
hours1 period in captivity when it was found to be devitalised 
as judged by its sluggish movements and lack of fight on 
handling it.
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II III
I
i
Figure 74. Electrophoresis patterns and their densitoraetric
scannings of purified lobster fibrinogen preparations, 
(method described in appendix II, 7)
h : haemocyanin
f : fibrinogen
I : precipitate 1 preparation, containing both haemocyanin and 
fibrinogen.
II : precipitate 2 preparation, consisting mainly of fibrinogen.
Ill : precipitate 3 preparation, containing a residual amount of 
haemocyanin and a trace of fibrinogen.
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Table 125. Activity of lobster blood cells* extract
Clotting mixtures consisted of 0.1 ml amounts of the different 
reagents shown in the table, all tests were carried out at 37°C. 
The lobster blood cells' extract was prepared as described in 
appendix III, 16. The lobster fibrinogen preparations (ppt. 1, 2, 
and 3) were prepared as described in appendix III, 6, B.
Clotting M/40 CaCl2 3fo CaCl2 11 fo CaCl2 Saline
mixture Clotting times (seconds)
1 Lobster plasma Cell extract
! 26 
36 
104
7
5
6
8i
6i
7i
180+
180+
180+
2 Lobster plasma Saline
180+
180+
180+
180+
180+
180+
180+
180+
180+ 180+ 180+ 180+
3
Cell extract 
Saline j
180+
180+
180+
180+
180+
180+
180+
180+
180+ 180+ 180+ 180+
4 Human plasma Cell extract
180
155
190
180+
180+
180+
180+
180+
180+
180+
180+
180+
5
Human plasma 170120
180+
180+
180+
180+
180+
180+
Saline
165 180+ 180+ 180+
6 Lobster serum i Cell extract
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
7
Ads.lob.plasma i 
Cell extract
180+
110
134
6
6
17
8
9
180+
180+
180+
* Oxalated lobster plasma adsorbed with BaSO^.
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Table 123* continued
Clotting N/40 CaCl2 yfo CaCl2 llfo CaCl2 Saline
No, mixture Clotting times (seconds)
8 Undialysed ppt. 1 Cell extract
180+
180+
180+
72 
7 Si 
80
180+
180+
180+
180+
180+
180+
9 Dialysed ppt. Cell extract
1
160
28
31
7
8
7i
Si
7
7
180+
180+
180+
10 Dialysed ppt. Cell extract
2 17023
28^
6
7i
6
6
5
6
180+
180+
180+
11 Dialysed ppt. Cell extract
3 180+180+
180+
120**
123**
160**
135**
134**
180+
180+
180+
180+
12 Human fibrinogen Cell extract
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
13
Dialysed ppt. 
Saline
1 180+180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
14 Dialysed ppt. Saline
2 180+180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
180+
** Formation of a small weak gel.
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Table 126. Measurement of the esteratic activity 
of the lobster blood cells1 extract 
(method of Sherry and Troll, 1954; appendix IV, 24)
Expt. 1 Expt. 2 Expt. 3 Expt. 4
Bovine
Thrombin* Lobster cell esctract
mis. alkali consumed 
by 0.2 ml test solution 1.42 1.00 1.09 1.09
mis. alkali consumed 
by the blank 0.97 1.00 1.06 1.10
net mis. alkali 
consumed in test 0.45 0 0.03 0
TAMe units in 0.2 ml 
of test solution 7.55 0 0.50 0
* Bovine thrombin (P.D. & Co.) containing nominal 50 N.I.H. units/ipl.
Table 127. Storage lability of lobster blood cells* extract
Clotting mixture: 0.2 ml fresh lobster plasma,
0.1 ml lobster blood cells' extract, as specified, 
0.1 ml 3$ CaCl^ solution.
Expt. 1 Expt. 2 Expt. 3
Clotting times (seconds)
Eresh cell extract
Cell extract stored 3 hours at 18°C.
Cell extract stored 3 hours at -20°C,
4
240 + 
240 +
6
240 + 
240 +
240 + 
240 +
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Table 128« Effect of heparin on lobster blood cells1 extract activity
Lobster clotting mixtures
0.1 ml lobster plasma,
Ool ml heparin solution, various concentrations,
0.1 ml saline or heparin antagonist, as shown, 
incubate above mixture for 3 minutes at 37°C. then add:- 
0.1 ml lobster blood cells* extract,
0.1 ml Jfo CaGl^ solution.
Human clotting mixtures
0.1 ml human plasma,
0.1 ml heparin solution, various concentrations,
0.1 ml saline or heparin antagonist, as shown, 
incubate above mixture for 3 minutes at 37°C. then add:- 
0.1 ml bovine thrombin, 50 units/ml.
Incubation
mixture
Total heparin units present in each mixture
500 250 125 62.5 31.2 15.6 0
No, Clotting times (seconds)
t 1 Lobster plasma Saline 360 150 120 69 42 28 27
2 Human plasma Saline 240+ 240+ 240+ 240+ 240+ 240+ W
3
Lobster plasma 
Toluidine blue 25 mg$
250 100 90 61 44 39 35
4
Human plasma 
Toluidine blue 25 mg?& 240+ 240+ 240+
240+ 240+ 240+ 15
5
Lobster plasma 
Toluidine blue 50 mg/o
64 54 49 44 45 48 46
■ 6 Human plasma Toluidine blue 50 mg$
240+ 240+ 240+ 240+ 240+ 240+ 25
7
Lobster plasma 
Polybrene (1 mg/0.1 ml)
192 51 52 52 53 48 56
8 Human plasma Polybrene (l mg/0.1 ml)
240+ 240+ 22^ 22^ 22 2li 22
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Table 129■ Lobster blood cells* extract — fibrinogen reaction
(method described in appendix IV, 8 and 9)
Clotting mixture : 0.2 ml lobster plasma or fibrinogen preparation (ppt.2), 
0*1 ml lobster blood cells’ extract,
0.1 ml 3^ CaCl^ solution.
Clotting times (seconds)
Dilution of variable in saline |
1 1/2 1/4 1/8 1/16 1/32 1
Lobster plasma
Lobster blood cells’ extract *
5
5
8
23
250
240
560
600
1200+
1200+
n 18 51 113 300 900
Lobster fibrinogen 10 18 42 74 150 300 1
Lobster fibrinogen |
Lob. cell extract ** 11 22j 77 189 360+
Lobsi>er oxalated plasma
Lob. cell extract ** 5 7 10 27 118 190
* Two different batches of fresh lobster blood cells’ extract were 
used, the first experiments in each case was made with one preparation, 
while the second two experiments were made using the second batch.
** The same batch of this cell extract was used in clotting the 
•various dilutions of lobster plasma or purified fibrinogen (ppt. 2).
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Table 130. Antihaemophilic globulin activity in lobster plasma
(T.Gr.T. of Biggs and Douglas, 1953b; appendix IV, 20)
Incubation mixture
0.2 ml BaSO^-adsorbed oxalated plasma, diluted 1/5, variable, 
0.2 ml human serum, diluted l/lO,
0.2 ml human platelets,
0.2 ml M/40 CaCl^ solution.
Substrate : human high-spun plasma.
Mixt.
No.
Adsorbed test
plasma mixture 
(ml)
Incubation time (minutes)
1 2 3 4 5 6
Clotting times (seconds)
162 0.2 ads.hum.pl. 24 13£ 12 12 11 10 
43 15 12i H i  11 10i
163 0.2 ads.lob.pl. 180+ 180+ 180+ 180+ 180+ 180+ 
180+ 180+ 180+ 180+ 180+ 180+
164 0.1 ads.hum.pl. 
0.1 ads.lob.pl.
180+ 180 70 22 18 18 
180+ 162 57 23 20 19
165
0.1 ads.hum.pl. 
0.1 saline
163 97 19 14 14 17 
180+ 102 44 30 19 16
The adsorbed lobster plasma used was clottable with lobster 
blood cells* extract and calcium chloride solution within 7 seconds.
From the above table it is obvious that lobster adsorbed plasma 
lacks completely any antihaemophilic globulin activity, nor does it 
possess any inhibitory activity on human plasma antihaemophilic 
globulin activity.
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Table 131. Christmas factor activity in lobster serum
(T.G,T. of Biggs and Douglas, 1953b; appendix XV, 20)
Incubation mixture
0<>2 ml adsorbed human normal plasma, diluted 1/5,
0*2 ml serum mixture, variable,
0*2 ml human platelets,
0*2 ml M/40 CaCl^ solution.
Substrate : human high-spun plasma.
Mixt.
No.
Serum
mixture
(ml)
Incubation time (minutes)
1 2 3 4 5 6
Clotting times (seconds)
166 0.2 hum.ser. l/lO 75 25 12i 12 11 11 
62 20 12 11 11 10
. 167 0.2 lob.ser. l/lO
180+ 142 112 120 125 119 
180+ 167 136 142 129 131
168 0.2 lob.ser. 1/5 115 126 104 147 145 147 
168 145 138 118 140 142
169
0.1 hum.ser. l/lO 
0.1 lob.ser. l/lO
66 25 12i 13 14 15 
59 24^ 12 12% 12 13
170 0.1 hum.ser. l/lO 0.1 saline
145 30 12 H i  13 14 
132 26 14 14 13i 15
171 0.2 Christmas ser.
103 91 109 98 59 45 
121 101 97% 86 56 48
Lobster serum had no Christmas factor activity at all in a 
human thromboplastin generation mixture. Also, it did not contain 
any inhibitor against human serum Christmas factor activity.
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Table 132. Development of clotting activity 
in native lobster whole blood 
A technique essentially similar to the thrombin generation 
test of Maefarlane and Biggs (1953) was used. Immediately after 
withdrawal of 2 mis. lobster whole blood by a siliconed syringe, 
the blood is placed in a tube and a stop watch started. At one 
minute intervals 0.1 ml volumes are removed and added together with 
0.1 ml volumes of 3°/o CaCl^ solution to 0.2 ml amounts of purified 
lobster fibrinogen previously distributed in clotting tubes placed 
in the water bath at 37°C. The clotting times are recorded and 
are a measure of the rate and amount of clotting activity produced 
in the native lobster blood. When the native blood itself clots, 
the clot is removed by winding it on an applicator wooden stick 
and the test continued.
Incubation time (minutes)
12 1 2 3 4 5 6 7 8 9 10
Clotting times of lobster fibrinogen (seconds)
Expt. 1 at 37°C. 42 27 34 49 57 50 57 65 78 74 92
Expt. 2 at 37°C. 30 23 27 35 42 57 55 75 70 76 74
Expt. 3 at 37°C. 37 13 18 30 36 42 38 50 57 64 68
Expt. 4 at 20°C. 37 27 32 32 35 30 33 54 52 58 73
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Table 133. Clot retraction of lobster whole blood
(method of Macfarlane, 1938; appendix IV, 4)
Percentage of retraction
in one hour in 24 hours
Experiment 1 4 f> 6 f>
Experiment 2 2  °/o 2  f<>
Experiment 3 0 fo 3 f>
Due to the negligible retraction observed after 
one hour, identical aliquots of lobster whole blood 
were incubated at 37°C. for 24 hours before estimating 
the degree of retraction which was still very negligible.
Lobster blood clots are not firm, being in the 
form of clear gels that break easily on handling.
- 308 -
Table 134. General comparison of the levels of the blood 
coagulation factors of the investigated species
The average levels of the blood coagulation factors shown below 
were compiled from the findings presented previously. Except in 
the case of platelets and fibrinogen, the levels were expressed in 
terms of percentage as compared to the reference control human plasma 
or serum.
S P E C I E S
Lobster Fowl Cattle Horse Rabbit
Blood platelets 
/c,mm.whole blood 5,200* 19,650** 312,350 117,000 311,000
Fibrinogen in mgms. 
per 100 mis plasma 230 264 697 436 228
Prothrombin Nil 13-23 fo 100-300 f 160 f 70 fo
Factor V Nil Present(sp.sp.) 268 % 643 fo 10558 fo
Factor VII Nil Present(sp.sp.)
Present
(sp.sp.)
80 fo
(sp.sp.) 89 f
Factor VIII Nil
Present
(sp.sp.) 816 fo 209 f 288 fo
Factor IX Nil Nil 20 fo 203 fo 29 f
Factor X Nil Present(sp.sp.)
101 f  
(sp.sp.)
85 f  
(sp.sp.) 436 f
Factor XI Nil Nil 100 fo — —
Factor XII Nil Nil 100 f 118 f 1025 f
* Explosive cells.
** Thrombocytes.
(sp.sp.) : species specific.
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